被験者番号 [redacted] (Investigator [redacted])

Reason for Narrative

Adverse Event Preferred Term(s)	Serious Adverse Event	Adverse Event Leading to Discontinuation of Study Drug	Death	Event of Interest
帯状疱疹	X			X

Treatment Group	Age at Study Start	Sex	Race
ABT-494 30 mg QD	5[redacted]	FEMALE	ASIAN

Medical History	Onset Year
HYPERLIPIDEMIA: HYPERCHOLESTEROLEMIA	NOT REPORTED
HYPERTENSION	NOT REPORTED
OTHER: OVARIAN CYSTS	19[redacted]
OTHER: APPENDICTIS	19[redacted]
OTHER: MAXILLARY SINUSITIS	20[redacted]
OTHER: PSORIASIS VULGARIS	20[redacted]
OTHER: MENOPAUSE	20[redacted]
OTHER: HYPERURICEMIA	20[redacted]

Prior Procedures	Procedure Year
SURGERY: APPENDECTOMY	19[redacted]

Tobacco Use	Status	Number/Day	Number of Years	Year Stopped
CHEWING TOBACCO	NEVER			
CIGARETTES	CURRENT	1 PACK	32	
CIGARS	NEVER			
E-CIGARETTES	CURRENT	0.3 SESSIONS	2	
PIPES	NEVER			

Alcohol Use	Status	Number/Day
ALCOHOL	NEVER	

Study Drug Administration

Study Drug	Dose/Units	Route	Frequency	First Dose Date/Day	Last Dose Date/Day	Duration (Days)
ABT-494	30MG	ORAL	QD	[redacted]20[redacted] / 1	[redacted]20[redacted] / 168	168
ABT-494	30MG	ORAL	QD	[redacted]20[redacted] / 169	[redacted]20[redacted] / 392	224
ABT-494	30MG	ORAL	QD	[redacted]20[redacted] / 393	/	

Previous Therapy - Prior to baseline/enrollment

Medication Name (WHO Drug)	Dose/Units	Frequency	Start Year-Month / RX Day
ROSUVASTATIN	2.5 mg	QD	Y-M: 20[redacted]
BETAMETHASONE	1 OTHER: APPLICATION	OTHER: UNK	Y-M: 20[redacted]
EPINASTINE	1 OTHER: TABLET	OTHER: UNK	Y-M: 20[redacted]
CLOBETASOL	1 OTHER: APPLICATION	QD	Y-M: 20[redacted]
PREDNISOLONE	15 mg	BID	Y-M: 20[redacted]
TIGASON	20 mg	TID	Y-M: 20[redacted]
BETAMETHASONE	1.5 mg	BID	Y-M: 20[redacted]
HYDROCORTISONE	1 OTHER: APPLICATION	BID	Y-M: 20[redacted]
METHOTREXATE	6 mg	EVERY WEEK	Y-M: 20[redacted]
BETAMETHASONE	1 OTHER: APPLICATION	BID	Y-M: 20[redacted]
DAIVOBET	1 OTHER: APPLICATION	QD	Y-M: 20[redacted]
HEPARINOID	1 OTHER: APPLICATION	QD	Y-M: 20[redacted]
WHITE SOFT PARAFFIN	1 OTHER: APPLICATION	BID	Y-M: 20[redacted]
UNSPECIFIED HERBAL	20 mg	QD	Y-M: 20[redacted]
CICLOSPORIN	100 mg	BID	Y-M: 20[redacted]
FAMOTIDINE	20 mg	BID	Y-M: 20[redacted]
LOXOPROFEN	60 mg	TID	Y-M: 20[redacted]
METHOTREXATE	8 mg	EVERY WEEK	Y-M: 20[redacted]
HEPARINOID	1 OTHER: APPLICATION	BID	Y-M: 20[redacted]
LEVOCETIRIZINE	5 mg	QD	Y-M: 20[redacted]
BACTRIM	1 OTHER: TABLET	OTHER: TWICE A WEEK	Y-M: 20[redacted]
BEPOTASTINE	100 mg	QD	Y-M: 20[redacted]
ADALIMUMAB	80 mg	EVERY 2 WEEKS	Y-M: 20[redacted]
DAIVOBET	1 OTHER: APPLICATION	QD	Y-M: 20[redacted] / -359
HEPARINOID	1 OTHER: APPLICATION	BID	Y-M: 20[redacted] / -359
HYDROCORTISONE	1 OTHER: APPLICATION	BID	Y-M: 20[redacted] / -359
CLOBETASOL	1 OTHER: APPLICATION	BID	Y-M: 20[redacted] / -331
BETAMETHASONE	2 mg	QD	Y-M: 20[redacted] / -296
TIGASON	20 mg	TID	Y-M: 20[redacted]

			/ -296
DEPRODONE	1 OTHER: APPLICATION	BID	Y-M: 20[redacted] / -289
BILASTINE	20 mg	QD	Y-M: 20[redacted] / -282
BETAMETHASONE	1 OTHER: APPLICATION	BID	Y-M: 20[redacted] / -275
HEPARINOID	1 OTHER: APPLICATION	BID	Y-M: 20[redacted] / -275
INFLIXIMAB	350 mg	EVERY 2 WEEKS	Y-M: 20[redacted] / -275
BETAMETHASONE	1 OTHER: APPLICATION	BID	Y-M: 20[redacted] / -261
CROTAMITON	1 OTHER: APPLICATION	PRN	Y-M: 20[redacted] / -261
OLOPATADINE	5 mg	BID	Y-M: 20[redacted] / -254
DEPRODONE	1 OTHER: APPLICATION	BID	Y-M: 20[redacted] / -177
IXEKIZUMAB	80 mg	EVERY 2 WEEKS	Y-M: 20[redacted] / -170
DAIVOBET	1 OTHER: APPLICATION	QD	Y-M: 20[redacted] / -142
APREMILAST	30 mg	BID	Y-M: 20[redacted] / -127
GENTAMICIN	1 OTHER: APPLICATION	PRN	Y-M: 20[redacted] / -127
WHITE SOFT PARAFFIN	1 OTHER: APPLICATION	PRN	Y-M: 20[redacted] / -127
WHITE SOFT PARAFFIN	1 OTHER: APPLICATION	PRN	Y-M: 20[redacted] / -114
HYDROCORTISONE	1 OTHER: APPLICATION	BID	Y-M: 20[redacted] / -103
CELECOXIB	200 mg	BID	Y-M: 20[redacted] / -65
BETAMETHASONE BUTYRATE PROPIONATE W/MAXACALCI	1 OTHER: APPLICATION	QD	Y-M: 20[redacted] / -44

Other Medications - Medications taken within 30 days prior to each narrative event until AE stopped or end of study

Medication Name (WHO Drug)	Dose/Units	Frequency	Start Year-Month / RX Day	Stop Year-Month / RX Day
ROSUVASTATIN	2.5 mg	QD	Y-M: 20[redacted]	Not reported.
FAMOTIDINE	20 mg	BID	Y-M: 20[redacted]	Y-M: 20[redacted] / 82
BACTRIM	1 OTHER: TABLET	OTHER: TWICE A	Y-M: 20[redacted]	Y-M: 20[redacted] / -1

		WEEK		
HEPARINOID	1 OTHER: APPLICATION	BID	Y-M: 20[redacted]- / -359	Y-M: 20[redacted]- / -16
OLOPATADINE	5 mg	BID	Y-M: 20[redacted]- / -254	Y-M: 20[redacted]- / 465
DAIVOBET	1 OTHER: APPLICATION	QD	Y-M: 20[redacted]- / -142	Y-M: 20[redacted]- / -16
GENTAMICIN	1 OTHER: APPLICATION	PRN	Y-M: 20[redacted]- / -127	Not reported.
APREMILAST	30 mg	BID	Y-M: 20[redacted]- / -127	Y-M: 20[redacted]- / 462
WHITE SOFT PARAFFIN	1 OTHER: APPLICATION	PRN	Y-M: 20[redacted]- / -114	Not reported.
HYDROCORTISONE	1 OTHER: APPLICATION	BID	Y-M: 20[redacted]- / -103	Y-M: 20[redacted]- / -16
CELECOXIB	200 mg	BID	Y-M: 20[redacted]- / -65	Y-M: 20[redacted]- / 483
BETAMETHASONE BUTYRATE PROPIONATE W/MAXACALCI	1 OTHER: APPLICATION	QD	Y-M: 20[redacted]- / -44	Y-M: 20[redacted]- / -16
BACTRIM	1 OTHER: TABLET	QD	Y-M: 20[redacted]- / 1	Not reported.
HYZAAR	50/12.5 mg	QD	Y-M: 20[redacted]- / 86	Y-M: 20[redacted]- / 464
CARBOCISTEINE	1500 mg	TID	Y-M: 20[redacted]- / 225	Y-M: 20[redacted]- / 231
ACICLOVIR	250 mg	BID	Y-M: 20[redacted]- / 463	Y-M: 20[redacted]- / 463
LIDOCAINE	150 mg	QD	Y-M: 20[redacted]- / 463	Y-M: 20[redacted]- / 463
PARACETAMOL	400 mg	QID	Y-M: 20[redacted]- / 463	Y-M: 20[redacted]- / 463
HEPARIN	10 mL	BID	Y-M: 20[redacted]- / 463	Y-M: 20[redacted]- / 464
LOXOPROFEN	60 mg	QD	Y-M: 20[redacted]- / 464	Y-M: 20[redacted]- / 464
PARACETAMOL	400 mg	QD	Y-M: 20[redacted]- / 464	Y-M: 20[redacted]- / 464
REBAMIPIDE	100 mg	QD	Y-M: 20[redacted]- / 464	Y-M: 20[redacted]- / 464
TRAMADOL	25 mg	BID	Y-M: 20[redacted]- / 464	Y-M: 20[redacted]- / 464
ACICLOVIR	250 mg	BID	Y-M: 20[redacted]- / 464	Y-M: 20[redacted]- / 465
ACICLOVIR	500 mg	QD	Y-M: 20[redacted]- / 464	Y-M: 20[redacted]- / 465
PROCHLORPERAZINE	5 mg	BID	Y-M: 20[redacted]- / 464	Y-M: 20[redacted]- / 465
LIDOCAINE	150 mg	BID	Y-M: 20[redacted]-	Y-M: 20[redacted]- /

			/ 464	466
GUALENIC ACID	1 OTHER: APPLICATION	QID	Y-M: 20[redacted] / 464	Y-M: 20[redacted] / 477
LIDOCAINE	1 OTHER: APPLICATION	QID	Y-M: 20[redacted] / 464	Y-M: 20[redacted] / 477
TRAMADOL	25 mg	QID	Y-M: 20[redacted] / 465	Y-M: 20[redacted] / 465
HEPARIN	10 mL	TID	Y-M: 20[redacted] / 465	Y-M: 20[redacted] / 466
OLOPATADINE	10 mg	BID	Y-M: 20[redacted] / 466	Y-M: 20[redacted] / 466
PROCHLORPERAZINE	5 mg	QD	Y-M: 20[redacted] / 466	Y-M: 20[redacted] / 466
TRAMADOL	25 mg	QD	Y-M: 20[redacted] / 466	Y-M: 20[redacted] / 466
ACICLOVIR	250 mg	TID	Y-M: 20[redacted] / 466	Y-M: 20[redacted] / 467
PARACETAMOL	400 mg	QID	Y-M: 20[redacted] / 466	Y-M: 20[redacted] / 467
CELESTAMINE	1 OTHER: TABLET	BID	Y-M: 20[redacted] / 466	Y-M: 20[redacted] / 468
CLOBETASOL	1 OTHER: APPLICATION	BID	Y-M: 20[redacted] / 466	Y-M: 20[redacted] / 472
OLOPATADINE	5 mg	BID	Y-M: 20[redacted] / 467	Not reported.
HEPARIN	10 mL	BID	Y-M: 20[redacted] / 467	Y-M: 20[redacted] / 467
HYZAAR	50/12.5 mg	QD	Y-M: 20[redacted] / 467	Y-M: 20[redacted] / 470
DEXCHLORPHENIRAMINE	6 mg	BID	Y-M: 20[redacted] / 467	Y-M: 20[redacted] / 472
LIDOCAINE	150 mg	TID	Y-M: 20[redacted] / 467	Y-M: 20[redacted] / 478
ACICLOVIR	250 mg	BID	Y-M: 20[redacted] / 468	Y-M: 20[redacted] / 468
DICLOFENAC	37.5 mg	QD	Y-M: 20[redacted] / 468	Y-M: 20[redacted] / 468
HEPARIN	10 mL	QD	Y-M: 20[redacted] / 468	Y-M: 20[redacted] / 468
PARACETAMOL	400 mg	BID	Y-M: 20[redacted] / 468	Y-M: 20[redacted] / 468
RABEPRAZOLE	10 mg	QD	Y-M: 20[redacted] / 469	Not reported.
ACICLOVIR	250 mg	QD	Y-M: 20[redacted] / 469	Y-M: 20[redacted] / 469
LIDOCAINE	100 mg	QD	Y-M: 20[redacted] / 469	Y-M: 20[redacted] / 469
GUAIAZULENE	1 OTHER:	QD	Y-M: 20[redacted]	Y-M: 20[redacted] /

	APPLICATION		/ 469	475
DICLOFENAC	37.5 mg	BID	Y-M: 20[redacted]	Y-M: 20[redacted] / 478
CODEINE	2 g	BID	Y-M: 20[redacted] / 470	Y-M: 20[redacted] / 470
BETAMETHASONE	1 OTHER: APPLICATION	BID	Y-M: 20[redacted] / 473	Not reported.
APREMILAST	10 mg	QD	Y-M: 20[redacted] / 473	Y-M: 20[redacted] / 473
APREMILAST	10 mg	BID	Y-M: 20[redacted] / 474	Y-M: 20[redacted] / 474
TIGASON	20 mg	BID	Y-M: 20[redacted] / 474	Y-M: 20[redacted] / 490
APREMILAST	10 mg	QD	Y-M: 20[redacted] / 475	Y-M: 20[redacted] / 475
APREMILAST	20 mg	QD	Y-M: 20[redacted] / 475	Y-M: 20[redacted] / 475
PREGABALIN	25 mg	TID	Y-M: 20[redacted] / 475	Y-M: 20[redacted] / 475
HYZAAR	50/12.5 mg	QD	Y-M: 20[redacted] / 476	Not reported.
APREMILAST	20 mg	BID	Y-M: 20[redacted] / 476	Y-M: 20[redacted] / 476
PREGABALIN	25 mg	QID	Y-M: 20[redacted] / 476	Y-M: 20[redacted] / 477
APREMILAST	20 mg	QD	Y-M: 20[redacted] / 477	Y-M: 20[redacted] / 477
APREMILAST	30 mg	QD	Y-M: 20[redacted] / 477	Y-M: 20[redacted] / 477
APREMILAST	30 mg	BID	Y-M: 20[redacted] / 478	Not reported.
PREGABALIN	75 mg	BID	Y-M: 20[redacted] / 478	Y-M: 20[redacted] / 490
HEPARINOID	1 OTHER: APPLICATION	BID	Y-M: 20[redacted] / 479	Not reported.
LIDOCAINE	150 mg	BID	Y-M: 20[redacted] / 479	Y-M: 20[redacted] / 480
OLEA EUROPAEA	1 OTHER: APPLICATION	QD	Y-M: 20[redacted] / 480	Y-M: 20[redacted] / 487
LIDOCAINE	150 mg	QD	Y-M: 20[redacted] / 481	Y-M: 20[redacted] / 482
PREGABALIN	25 mg	PRN	Y-M: 20[redacted] / 484	Y-M: 20[redacted] / 490
DICLOFENAC	25 mg	PRN	Y-M: 20[redacted] / 484	Y-M: 20[redacted] / 491
CELECOXIB	200 mg	QD	Y-M: 20[redacted] / 484	Y-M: 20[redacted] / 644
SENNOSIDE A+B	12 mg	PRN	Y-M: 20[redacted]	Y-M: 20[redacted] /

			/ 491	504
TIGASON	10 mg	BID	Y-M: 20[redacted] / 491	Y-M: 20[redacted] / 504
AMITRIPTYLINE	10 mg	QD	Y-M: 20[redacted] / 491	Y-M: 20[redacted] / 525
PREGABALIN	75 mg	TID	Y-M: 20[redacted] / 491	Y-M: 20[redacted] / 560
MAGNESIUM OXIDE	500 mg	QD	Y-M: 20[redacted] / 505	Not reported.
DEPRODONE	1 OTHER: APPLICATION	PRN	Y-M: 20[redacted] / 519	Y-M: 20[redacted] / 525
LULICONAZOLE	1 OTHER: APPLICATION	QD	Y-M: 20[redacted] / 526	Not reported.
PREGABALIN	25 mg	PRN	Y-M: 20[redacted] / 561	Y-M: 20[redacted] / 602
PREGABALIN	75 mg	BID	Y-M: 20[redacted] / 561	Y-M: 20[redacted] / 602
PREGABALIN	25 mg	QD	Y-M: 20[redacted] / 603	Y-M: 20[redacted] / 644
PREGABALIN	75 mg	QD	Y-M: 20[redacted] / 603	Y-M: 20[redacted] / 644
PREGABALIN	75 mg	BID	Y-M: 20[redacted] / 644	Not reported.

Event #3: Serious Adverse Event, Study Specific Adverse Events of Interest

Event Description	HERPES ZOSTER
Preferred term	帯状疱疹
AE Onset Date / Rx Day	[redacted]20[redacted] / 456
Age at AE Onset	5[redacted]
Laboratory Testing	
NOT REPORTED	
Microbiology	
NOT REPORTED	
SAE Supplemental Procedure	
NOT REPORTED	
AE Stopped Rx Day	NOT REPORTED
Duration of AE	NOT REPORTED
Relation to Study Drug by Investigator	REASONABLE POSSIBILITY
Investigator Alternative Etiology	NOT REPORTED
Discontinued Study Drug Due to the Event	NO
SAE Criteria	REQUIRES OR PROLONGS HOSPITALIZATION

Generated: [redacted]
Program Source Code: [redacted]

Investigator No.: [redacted]

Subject Number: [redacted]

Protocol Number: M15-554

治験責任医師からの報告。本被験者は日本の 5[redacted] 歳女性であり，ABT-494（ウパダシチニブ）の治験で盲検化された治験薬が投与され，帯状疱疹の事象を発現した。

Event 3 の臨床経過：

関連する病歴は尋常性乾癬，閉経，乾癬性関節炎，現喫煙者（1 日 1 箱を 32 年間），現電子タバコ使用者（1 日 0.3 回を 2 年間）及び非飲酒者であった。

試験の盲検を解除。

20[redacted] 年 [redacted] 月 [redacted] 日，被験者は帯状疱疹を発現した。

20[redacted] 年 [redacted] 月 [redacted] 日，被験者は頭部に有痛性皮疹を見つけた。20[redacted] 年 [redacted] 月 [redacted] 日，皮疹は顔面，首及び肩に広がった。20[redacted] 年 [redacted] 月 [redacted] 日，被験者は，38.2°C の発熱を伴う顔面・首・肩の小水疱のため入院した。被験者は 1 つの皮膚分節の帯状疱疹と診断された。疼痛に対し，アシクロビル及びリドカインの静脈内投与が行われた。20[redacted] 年 [redacted] 月 [redacted] 日，頭痛があったため，アシクロビルが増量された。20[redacted] 年 [redacted] 月 [redacted] 日，薬剤性と思われる紅斑が出現した。帯状疱疹の治療が継続された。20[redacted] 年 [redacted] 月 [redacted] 日，水疱は痂皮化し，薬疹はわずかに軽快した。アシクロビルの投与は中止された。リドカインの投与は継続された。20[redacted] 年 [redacted] 月 [redacted] 日，帯状疱疹は悪化していなかったが，乾癬性発疹が出現した。20[redacted] 年 [redacted] 月 [redacted] 日，治験薬の投与が再開された。20[redacted] 年 [redacted] 月 [redacted] 日，症状は悪化することなく安定しており，リドカインの投与は中止された。20[redacted] 年 [redacted] 月 [redacted] 日，被験者は退院した。

被験者に水疱瘡及び帯状疱疹の既往歴はなく，帯状疱疹のワクチンの接種歴もなかった。

投与された薬剤は，アズノール，トラマドール塩酸塩，リリカ，ロキソプロフェン，ボルタレン，トリプタノール，リン酸コデイン，オリブ油，カロナール，キシロカイン，アセトアミノフェン，アシクロビル及びオテズラであった。

The patient's past medications include:

HUMIRA for PSORIATIC ARTHRITIS ([redacted])

REMICADE for PSORIATIC ARTHRITIS ([redacted])

TALTZ for PSORIATIC ARTHRITIS ([redacted])

Causality for UPADACITINIB (Blinded)

---

1) Herpes zoster (10019974) (Herpes zoster (10019974)) [v.22.1] [10019974]

Causality as per reporter (Drug/Vaccine): Reasonable possibility

Causality as per Mfr. (Drug/Vaccine): Reasonable possibility

Dechallenge: No

Alternative Etiology for UPADACITINIB (Blinded)

Event of HERPES ZOSTER

- Investigator: Not applicable.

- AbbVie: Not applicable

Relevant Laboratory & Other Diagnostic Tests

[redacted] **BODY TEMPERATURE:** 38.2 Degrees C

被験者番号 [redacted] (Investigator [redacted])

Reason for Narrative

Adverse Event Preferred Term(s)	Serious Adverse Event	Adverse Event Leading to Discontinuation of Study Drug	Death	Event of Interest
腱断裂	X			

Treatment Group	Age at Study Start	Sex	Race
ABT-494 15 mg QD	7[redacted]	FEMALE	ASIAN

Medical History	Onset Year
HEPATITIS: HEPATITIS C	NOT REPORTED
OTHER: PLAQUE PSORIASIS	19[redacted]
OTHER: POSTMENOPAUSE	19[redacted]
OSTEOPOROSIS	20[redacted]
CHOLELITHIASIS	20[redacted]
OTHER: HEPATIC CYST	20[redacted]
OTHER: DRY EYE	20[redacted]

Prior Procedures	Procedure Year
SURGERY: APPENDECTOMY	19[redacted]
SURGERY: TONSILLAR HYPERTROPHY	19[redacted]
SURGERY: RIGHT TOTAL HIP REPLACEMENT	20[redacted]

Tobacco Use	Status	Number/Day	Number of Years	Year Stopped
CHEWING TOBACCO	NEVER			
CIGARETTES	FORMER	0.5 PACK	36	20[redacted]
CIGARS	NEVER			
E-CIGARETTES	NEVER			
PIPES	NEVER			

Alcohol Use	Status	Number/Day
ALCOHOL	FORMER	Less than 2

Study Drug Administration

Study Drug	Dose/Units	Route	Frequency	First Dose Date/Day	Last Dose Date/Day	Duration (Days)
ABT-494	15MG	ORAL	QD	[redacted]20[redacted] / 1	[redacted]20[redacted] / 168	168
ABT-494	15MG	ORAL	QD	[redacted]20[redacted] / 169	[redacted]20[redacted] / 391	223
ABT-494	15MG	ORAL	QD	[redacted]20[redacted] / 392	/	

Previous Therapy - Prior to baseline/enrollment

Medication Name (WHO Drug)	Dose/Units	Frequency	Start Year-Month / RX Day
INFLIXIMAB	200 mg	OTHER: UNKNOWN	Y-M: 20[redacted]
SODIUM AUROTHIOMALATE	10 mg	OTHER: MONTHLY	Y-M: 20[redacted]
MELOXICAM	10 mg	QD	Y-M: 20[redacted]
ALENDRONIC ACID	35 mg	EVERY WEEK	Y-M: 20[redacted]
ETANERCEPT	50 mg	EVERY WEEK	Y-M: 20[redacted]
BUCILLAMINE	100 mg	QD	Y-M: 20[redacted]
PREGABALIN	75 mg	QD	Y-M: 20[redacted]
KETOPROFEN	1 OTHER: APPLICATION	QD	Y-M: 20[redacted]
METHOTREXATE	8 mg	EVERY WEEK	Y-M: 20[redacted]
ADALIMUMAB	40 mg	EVERY 2 WEEKS	Y-M: 20[redacted]
USTEKINUMAB	45 mg	OTHER: EVERY 4 WEEKS	Y-M: 20[redacted]
VONOPRAZAN	10 mg	QD	Y-M: 20[redacted]
FOLIC ACID	1.25 mg	QD	Y-M: 20[redacted]
IGURATIMOD	25 mg	BID	Y-M: 20[redacted]
LOXOPROFEN	60 mg	BID	Y-M: 20[redacted]
METHOTREXATE	10 mg	EVERY WEEK	Y-M: 20[redacted]
GOLIMUMAB	100 mg	OTHER: EVERY 4 WEEKS	Y-M: 20[redacted]
DIQUAFOSOL	1 OTHER: APPLICATION	PRN	Y-M: 20[redacted]
ABATACEPT	500 mg	OTHER: EVERY 4 WEEKS	Y-M: 20[redacted] / -114
BETAMETHASONE	1 OTHER: APPLICATION	QD	Y-M: 20[redacted] / -32

Other Medications - Medications taken within 30 days prior to each narrative event until AE stopped or end of study

Medication Name (WHO Drug)	Dose/Units	Frequency	Start Year-Month / RX Day	Stop Year-Month / RX Day
ALENDRONIC ACID	35 mg	EVERY WEEK	Y-M: 20[redacted]	Not reported.
KETOPROFEN	1 OTHER: APPLICATION	QD	Y-M: 20[redacted]	Not reported.
FOLIC ACID	1.25 mg	QD	Y-M: 20[redacted]	Not reported.
IGURATIMOD	25 mg	BID	Y-M: 20[redacted]	Y-M: 20[redacted] / 410
METHOTREXATE	10 mg	EVERY WEEK	Y-M: 20[redacted]	Not reported.
DIQUAFOSOL	1 OTHER: APPLICATION	PRN	Y-M: 20[redacted]	Not reported.
ESOMEPRAZOLE	20 mg	QD	Y-M: 20[redacted] / 245	Not reported.

POVIDONE-IODINE	1 OTHER: APPLICATION	BID	Y-M: 20[redacted]-[redacted] / 252 Y-M: 20[redacted]-[redacted] / 259
POVIDONE-IODINE	1 OTHER: APPLICATION	QD	Y-M: 20[redacted]-[redacted] / 252 Y-M: 20[redacted]-[redacted] / 259
BROMHEXINE	4 mg	TID	Y-M: 20[redacted]-[redacted] / 281 Y-M: 20[redacted]-[redacted] / 283
CARBOCISTEINE	500 mg	TID	Y-M: 20[redacted]-[redacted] / 281 Y-M: 20[redacted]-[redacted] / 283
DEQUALINIUM	0.25 mg	TID	Y-M: 20[redacted]-[redacted] / 281 Y-M: 20[redacted]-[redacted] / 283
DEXTROMETHORPHAN	15 mg	TID	Y-M: 20[redacted]-[redacted] / 281 Y-M: 20[redacted]-[redacted] / 283
GARENOXACIN	400 mg	QD	Y-M: 20[redacted]-[redacted] / 281 Y-M: 20[redacted]-[redacted] / 283
POVIDONE-IODINE	1 OTHER: APPLICATION	QD	Y-M: 20[redacted]-[redacted] / 331 Y-M: 20[redacted]-[redacted] / 343
BILE THERAPY	10 mg	PRN	Y-M: 20[redacted]-[redacted] / 370 Y-M: 20[redacted]-[redacted] / 375
CEFAZOLIN	3 g	QD	Y-M: 20[redacted]-[redacted] / 412 Y-M: 20[redacted]-[redacted] / 412
EPINEPHRINE	UNKNOWN OTHER: UNKNOWN	OTHER: ONCE	Y-M: 20[redacted]-[redacted] / 412 Y-M: 20[redacted]-[redacted] / 412
FAMOTIDINE	UNKNOWN OTHER: UNKNOWN	OTHER: ONCE	Y-M: 20[redacted]-[redacted] / 412 Y-M: 20[redacted]-[redacted] / 412
FLURBIPROFEN	UNKNOWN OTHER: UNKNOWN	OTHER: ONCE	Y-M: 20[redacted]-[redacted] / 412 Y-M: 20[redacted]-[redacted] / 412
HYDROCORTISONE	UNKNOWN OTHER: UNKNOWN	OTHER: ONCE	Y-M: 20[redacted]-[redacted] / 412 Y-M: 20[redacted]-[redacted] / 412
LIDOCAINE	UNKNOWN OTHER: UNKNOWN	OTHER: ONCE	Y-M: 20[redacted]-[redacted] / 412 Y-M: 20[redacted]-[redacted] / 412
MEPIVACAINE	UNKNOWN OTHER: UNKNOWN	OTHER: ONCE	Y-M: 20[redacted]-[redacted] / 412 Y-M: 20[redacted]-[redacted] / 412
ROPIVACAINE	UNKNOWN OTHER: UNKNOWN	OTHER: ONCE	Y-M: 20[redacted]-[redacted] / 412 Y-M: 20[redacted]-[redacted] / 412
CARBAZOCHROME	UNKNOWN OTHER: UNKNOWN	QD	Y-M: 20[redacted]-[redacted] / 412 Y-M: 20[redacted]-[redacted] / 413
PHYSIO 140	UNKNOWN OTHER: UNKNOWN	QD	Y-M: 20[redacted]-[redacted] / 412 Y-M: 20[redacted]-[redacted] / 413
SOLACET F	UNKNOWN OTHER: UNKNOWN	QD	Y-M: 20[redacted]-[redacted] / 412 Y-M: 20[redacted]-[redacted] / 413
TRANEXAMIC ACID	UNKNOWN OTHER: UNKNOWN	QD	Y-M: 20[redacted]-[redacted] / 412 Y-M: 20[redacted]-[redacted] / 413
CEFAZOLIN	2 g	QD	Y-M: 20[redacted]-[redacted] / 413 Y-M: 20[redacted]-[redacted] / 413
ESZOPICLONE	1 mg	QD	Y-M: 20[redacted]-[redacted] / 413 Y-M: 20[redacted]-[redacted] / 431
SENNOSIDE A+B	12 mg	QD	Y-M: 20[redacted]-[redacted] / 413 Y-M: 20[redacted]-[redacted] / 443

NEW LECICARBON	1 OTHER: PIECE	OTHER: ONCE	Y-M: 20[redacted] / Y-M: 20[redacted] / 415 415
PREDNISOLONE	2.5 mg	QD	Y-M: 20[redacted] / Y-M: 20[redacted] / 420 427
IGURATIMOD	25 mg	BID	Y-M: 20[redacted] / Not reported. 426
PREDNISOLONE	1 mg	QD	Y-M: 20[redacted] / Y-M: 20[redacted] / 428 432

Event #1: Serious Adverse Event

Event Description	TENDON RUPTURE (RIGHT HAND EXTENSOR TENDON)
Preferred term	腱断裂
AE Onset Date / Rx Day	[redacted]20[redacted] / 281
Age at AE Onset	7[redacted]
Laboratory Testing	
NOT REPORTED	
Microbiology	
NOT REPORTED	
SAE Supplemental Procedure	
[redacted]20[redacted] (RX DAY 412): HAND ARTHROPLASTY: ALL SUTURE REMOVAL, NO SURGICAL SITE INFECTION; JOINT PROSTHESIS REPLACEMENT (RIGHT METACARPOPHALANGEAL 5): ALL SUTURE REMOVAL, NO SURGICAL SITE INFECTION	
AE Stopped Rx Day	432
Duration of AE	152 DAYS
Relation to Study Drug by Investigator	NO REASONABLE POSSIBILITY
Investigator Alternative Etiology	PSORIATIC ARTHRITIS
Discontinued Study Drug Due to the Event	NO
SAE Criteria	REQUIRES OR PROLONGS HOSPITALIZATION

Generated: [redacted]
Program Source Code: [redacted]

Investigator No.: [redacted]

Subject Number: [redacted]

Protocol Number: M15-554

治験責任医師からの報告。本被験者は日本の7[redacted]歳女性であり，ABT-494（ウパダシチニブ）の治験で盲検化された治験薬が投与され，腱断裂（右手伸筋腱）の事象を発現した。

Event 1 の臨床経過：

関連する病歴は乾癬性関節炎，閉経後，元喫煙者（1 日 0.5 箱を 36 年間），骨粗鬆症及び元飲酒者（1 日 2 杯未満）であった。

20[redacted] 年 [redacted] 月 [redacted] 日，被験者は腱断裂（右手伸筋腱）を発現した。20[redacted] 年 [redacted] 月 [redacted] 日，腱断裂（右手伸筋腱）は消失した。

20[redacted] 年 [redacted] 月 [redacted] 日の規定来院にて，治験責任医師は右手伸筋腱断裂を確認した。手術が必要と判断された。20[redacted] 年 [redacted] 月 [redacted] 日，被験者から手術の予約が完了したとの電話があった（手術予定日の報告なし）。20[redacted] 年 [redacted] 月 [redacted] 日，被験者は入院した。20[redacted] 年 [redacted] 月 [redacted] 日，腱断裂の手術として，手関節形成術及び人工関節置換（右第 5 中手指節関節）が行われた。20[redacted] 年 [redacted] 月 [redacted] 日，リハビリテーションが開始された。抜糸が行われた。手術部位感染は見られなかった。20[redacted] 年 [redacted] 月 [redacted] 日，被験者は退院した。

The patient's past medications include:

REMICADE for PSORIATIC ARTHRITIS ([redacted] 20[redacted] - [redacted] 20[redacted])

SHIOSOL for PSORIATIC ARTHRITIS ([redacted] 20[redacted] - [redacted] 20[redacted])

MOBIC for PSORIATIC ARTHRITIS ([redacted] 20[redacted] - [redacted] 20[redacted])

ENBREL for PSORIATIC ARTHRITIS ([redacted] 20[redacted] - [redacted] 20[redacted])

RIMATIL for PSORIATIC ARTHRITIS ([redacted] 20[redacted] - [redacted] 20[redacted])

LYRICA for PSORIATIC ARTHRITIS ([redacted] 20[redacted] - [redacted] 20[redacted])

METOLATE for PSORIATIC ARTHRITIS ([redacted] 20[redacted] - [redacted] 20[redacted])

HUMIRA for PSORIATIC ARTHRITIS ([redacted] 20[redacted] - [redacted] 20[redacted])

STELARA for PSORIATIC ARTHRITIS ([redacted] 20[redacted] - [redacted] 20[redacted])

TAKECAB for PREVENTION GASTRITIS ([redacted] 20[redacted] - [redacted] 20[redacted])

LOXONIN for PSORIATIC ARTHRITIS ([redacted] 20[redacted] - [redacted] 20[redacted])

SIMPONI for PSORIATIC ARTHRITIS ([redacted] 20[redacted] - [redacted] 20[redacted])

ORENCIA for PSORIATIC ARTHRITIS ([redacted] 20[redacted] - [redacted] 20[redacted])

ANTEBATE for PSORIASIS ([redacted] 20[redacted] - [redacted] 20[redacted])

Causality for UPADACITINIB (Blinded)

---

1) Tendon rupture (10043248) (Tendon rupture (10043248)) [v.22.1] [10043248]

Causality as per reporter (Drug/Vaccine): No reasonable possibility

Causality as per Mfr. (Drug/Vaccine): No reasonable possibility

Dechallenge: Yes

Rechallenge: rechallenge was done, reaction did not recur

Alternative Etiology for UPADACITINIB (Blinded)

Event of TENDON RUPTURE (RIGHT HAND EXTENSOR TENDON)

- Investigator: PSORIATIC ARTHRITIS

- AbbVie: Etiology of the event is inconsistent with the study drug's mechanism of action. Advanced age and pre-existing psoriatic arthritis are additional risk factors.

被験者番号 [redacted] (Investigator [redacted])

Reason for Narrative

Adverse Event Preferred Term(s)	Serious Adverse Event	Adverse Event Leading to Discontinuation of Study Drug	Death	Event of Interest
乾癬性関節症	X	X		

Treatment Group	Age at Study Start	Sex	Race
ABT-494 15 mg QD	4[redacted]	MALE	ASIAN

Medical History	Onset Year
OTHER: HYPERURICEMIA	NOT REPORTED
OTHER: PSORIASIS VULGARIS	19[redacted]
HYPERLIPIDEMIA: HYPERLIPIDEMIA	20[redacted]
HYPERTENSION	20[redacted]
OTHER: PYOGENIC GRANULOMA OF LEFT LEG	20[redacted]

Prior Procedures	Procedure Year
SURGERY: CRYOTHERAPY	20[redacted]

Tobacco Use	Status	Number/Day	Number of Years	Year Stopped
CHEWING TOBACCO	NEVER			
CIGARETTES	FORMER	1 PACK	15	20[redacted]
CIGARS	NEVER			
E-CIGARETTES	NEVER			
PIPES	NEVER			

Alcohol Use	Status	Number/Day
ALCOHOL	CURRENT	Less than 2

Study Drug Administration

Study Drug	Dose/Units	Route	Frequency	First Dose Date/Day	Last Dose Date/Day	Duration (Days)
ABT-494	15MG	ORAL	QD	[redacted]20[redacted] / 1	[redacted]20[redacted] / 28	28

Previous Therapy - Prior to baseline/enrollment

Medication Name (WHO Drug)	Dose/Units	Frequency	Start Year-Month / RX Day
DIFLUCORTOLONE	1 OTHER: APPLICATION	PRN	Y-M: 19[redacted]
DIFLUPREDNATE	1 OTHER: APPLICATION	PRN	Y-M: 19[redacted]
MAXACALCITOL	1 OTHER: APPLICATION	PRN	Y-M: 19[redacted]
ADALIMUMAB	40 mg	EVERY 2 WEEKS	Y-M: 20[redacted]
ETANERCEPT	0.5 mL	EVERY WEEK	Y-M: 20[redacted]
AMLODIPINE	5 mg	QD	Y-M: 20[redacted]
BEZAFIBRATE	200 mg	BID	Y-M: 20[redacted]
BETAMETHASONE	1 OTHER: APPLICATION	BID	Y-M: 20[redacted] / -280
CELECOXIB	100 mg	BID	Y-M: 20[redacted] / -272
FEBUXOSTAT	20 mg	QD	Y-M: 20[redacted] / -272
IXEKIZUMAB	160 mg	OTHER: ONCE	Y-M: 20[redacted] / -272
REBAMIPIDE	100 mg	BID	Y-M: 20[redacted] / -272
IXEKIZUMAB	80 mg	EVERY 2 WEEKS	Y-M: 20[redacted] / -251
IXEKIZUMAB	80 mg	OTHER: EVERY 4 WEEKS	Y-M: 20[redacted] / -167
LOXOPROFEN	100 mg	QD	Y-M: 20[redacted] / -28
WHITE SOFT PARAFFIN	1 OTHER: APPLICATION	PRN	Y-M: 20[redacted] / -28

Other Medications - Medications taken within 30 days prior to each narrative event until AE stopped or end of study

Medication Name (WHO Drug)	Dose/Units	Frequency	Start Year-Month / RX Day	Stop Year-Month / RX Day
AMLODIPINE	5 mg	QD	Y-M: 20[redacted]	ONGOING
BEZAFIBRATE	200 mg	BID	Y-M: 20[redacted]	ONGOING
CELECOXIB	100 mg	BID	Y-M: 20[redacted] / -272	ONGOING
FEBUXOSTAT	20 mg	QD	Y-M: 20[redacted] / -272	ONGOING
REBAMIPIDE	100 mg	BID	Y-M: 20[redacted] / -272	ONGOING
WHITE SOFT PARAFFIN	1 OTHER: APPLICATION	PRN	Y-M: 20[redacted] / -28	ONGOING

LOXOPROFEN	100 mg	QD	Y-M: 20[redacted] / -28	Y-M: 20[redacted] / 57
IXEKIZUMAB	80 mg	OTHER: EVERY 4WEEKS	Y-M: 20[redacted] / 31	ONGOING
DAIVOBET	1 OTHER: APPLICATION	PRN	Y-M: 20[redacted] / 57	ONGOING
KETOPROFEN	20 mg	QD	Y-M: 20[redacted] / 58	ONGOING

Event #1: Serious Adverse Event, AE Leading to Discontinuation of Study Drug

Event Description	EXACERBATION OF PSORIATIC ARTHRITIS
Preferred term	乾癬性関節症
AE Onset Date / Rx Day	[redacted]20[redacted] / 23
Age at AE Onset	4[redacted]

Laboratory Testing

[redacted]20[redacted] (RX DAY 27): NPTST197-T-CHOLESTEROL: 305 [0 - 219] mg/dL; Triglycerides: 3.04 [0 - 1.68] mmol/L

Microbiology

NOT REPORTED

SAE Supplemental Procedure

[redacted]20[redacted] (RX DAY 24): X-RAY(FOOT): SPUR FORMATION AT THE EDGE OF THE PLANTAR FASCIA.; [redacted]20[redacted] (RX DAY 29): MRI: SYNOVITIS AT TARSAL JOINT

AE Stopped Rx Day	ONGOING
Duration of AE	ONGOING
Relation to Study Drug by Investigator	REASONABLE POSSIBILITY
Investigator Alternative Etiology	NOT REPORTED
Discontinued Study Drug Due to the Event	YES
SAE Criteria	REQUIRES OR PROLONGS HOSPITALIZATION

Generated: [redacted]
Program Source Code: [redacted]

Investigator No.: [redacted]

Subject Number: [redacted]

Protocol Number: M15-554

治験責任医師からの報告。本被験者は日本の 4[redacted] 歳男性であり，ABT-494（ウパダシチニブ）の治験で盲検化された治験薬が投与され，乾癬性関節炎の悪化の事象を発現した。

Event 1 の臨床経過：

関連する病歴は乾癬性関節炎，高脂血症，元喫煙者（1 日 1 箱を 15 年間），化膿性肉芽腫（左脚）の手術，高尿酸血症及び現飲酒者（2 杯未満）であった。

20[redacted] 年 [redacted] 月 [redacted] 日，被験者は乾癬性関節炎の悪化を発現した。

20[redacted] 年 [redacted] 月 [redacted] 日より，被験者は左足の痛みを訴えていた。20[redacted] 年 [redacted] 月 [redacted] 日，被験者はクリニックを受診し，整形外科医の診察を受けた。整形外科医は左足底の圧痛を確認した。炎症の徴候はなく，左足の骨折も認められなかった。X 線検査により足底筋膜縁に棘突起形成が認められた。投薬は行われず，被験者は帰宅した。痛みが持続し，被験者は 20[redacted] 年 [redacted] 月 [redacted] 日にクリニックを再度受診した。同日，被験者は，動作に伴う痛みを訴えて入院した。被験者は安静下に置かれた。20[redacted] 年 [redacted] 月 [redacted] 日，被験者は退院した。

本事象により治験薬の投与が完全に中止された。

投与された薬剤はトルツであった。

The patient's past medications include:

MYSER for PSORIASIS VULGARIS (19[redacted] - [redacted] [redacted] 20[redacted])

NERISONA for PSV (19[redacted] - [redacted] [redacted] 20[redacted])

OXAROL for PSV (19[redacted] - [redacted] [redacted] 20[redacted])

HUMIRA for PSORIATIC ARTHRITIS ([redacted] [redacted] 20[redacted] - [redacted] [redacted] 20[redacted])

ENBREL for PSORIATIC ARTHRITIS (20[redacted] - [redacted] [redacted] 20[redacted])

RINDERON-V for PSORIASIS VULGARIS ([redacted] [redacted] 20[redacted] - [redacted] [redacted] 20[redacted])

TALTZ for PSORIATIC ARTHRITIS ([redacted] [redacted] 20[redacted] - [redacted] 20[redacted], [redacted] [redacted] 20[redacted] - [redacted] [redacted] 20[redacted], [redacted] [redacted] 20[redacted] - [redacted] [redacted] 20[redacted])

Causality for UPADACITINIB (Blinded)

---

1) Psoriatic arthritis aggravated (10037161) (Psoriatic arthropathy (10037162)) [v.22.0] [10037161]

Causality as per reporter (Drug/Vaccine): Reasonable possibility

Causality as per Mfr. (Drug/Vaccine): No reasonable possibility

Dechallenge: No

Alternative Etiology for UPADACITINIB (Blinded)

Event of EXACERBATION OF PSORIATIC ARTHRITIS

- Investigator: Not applicable.

- AbbVie: Event more likely related to pre-existing psoriatic arthritis.

Relevant Laboratory & Other Diagnostic Tests

[redacted] **20[redacted] MRI:** Synovitis at tarsal joint

[redacted] **20[redacted] T-CHOLESTEROL:** 305 mg/dL (normal 0 to 219)

[redacted] **20[redacted] TRIGLYCERIDES:** 269 mg/dL (normal 0 to 149)

[redacted] **20[redacted] X-RAY (FOOT):** Spur formation at the edge of the plantar fascia.

被験者番号 [redacted] (Investigator [redacted])

Reason for Narrative

Adverse Event Preferred Term(s)	Serious Adverse Event	Adverse Event Leading to Discontinuation of Study Drug	Death	Event of Interest
肛門膿瘍	X			X

Treatment Group	Age at Study Start	Sex	Race
ABT-494 30 mg QD	4[redacted]	MALE	ASIAN

Medical History	Onset Year
LIVER DISEASE (EXCLUDING HEPATITIS): FATTY LIVER	NOT REPORTED
MIGRAINE HEADACHE	NOT REPORTED
OTHER: COITAL CEPHALALGIA	NOT REPORTED
OTHER: COLON HYPERPLASTIC POLYP	NOT REPORTED
OTHER: HAY FEVER	NOT REPORTED
OTHER: TINEA PEDIS	NOT REPORTED
SLEEP APNEA	NOT REPORTED
OTHER: PSORIASIS VULGARIS	20[redacted]
LIVER DISEASE (EXCLUDING HEPATITIS): INCREASE OF TRANSAMINASES	20[redacted]
DIABETES MELLITUS	20[redacted]
HYPERLIPIDEMIA: HYPER LDL CHOLESTEROLEMIA	20[redacted]
ANGINA	20[redacted]
OTHER: INTERNAL HEMORRHOIDS	20[redacted]
OTHER: PERIANAL DERMATITIS	20[redacted]
HYPERTENSION	20[redacted]
OTHER: GINGIVAL NECROSIS	20[redacted]
OTHER: HYPERURICEMIA	20[redacted]

Prior Procedures	Procedure Year
Not reported.	

Tobacco Use	Status	Number/Day	Number of Years	Year Stopped
CHEWING TOBACCO	NEVER			
CIGARETTES	FORMER	3 PACK	22	20[redacted]
CIGARS	NEVER			
E-CIGARETTES	NEVER			
PIPES	NEVER			

Alcohol Use	Status	Number/Day
ALCOHOL	CURRENT	Less than 2

Study Drug Administration

Study Drug	Dose/Units	Route	Frequency	First Dose Date/Day	Last Dose Date/Day	Duration (Days)
ABT-494	30MG	ORAL	QD	[redacted]20[redacted] / 1	[redacted]20[redacted] / 168	168
ABT-494	30MG	ORAL	QD	[redacted]20[redacted] / 169	[redacted]20[redacted] / 392	224
ABT-494	30MG	ORAL	QD	[redacted]20[redacted] / 393	/	

Previous Therapy - Prior to baseline/enrollment

Medication Name (WHO Drug)	Dose/Units	Frequency	Start Year-Month / RX Day
CELECOXIB	100 mg	BID	Y-M: 20[redacted]
SULFASALAZINE	250 mg	BID	Y-M: 20[redacted]
BETAMETHASONE	1 OTHER: APPLICATION	PRN	Y-M: 20[redacted]
DIFLUCORTOLONE	1 OTHER: APPLICATION	PRN	Y-M: 20[redacted]
METHOTREXATE	6 mg	EVERY WEEK	Y-M: 20[redacted]
METHOTREXATE	8 mg	EVERY WEEK	Y-M: 20[redacted]
CELECOXIB	200 mg	BID	Y-M: 20[redacted]
INFLIXIMAB	600 mg	OTHER: EVERY 2 MONTHS	Y-M: 20[redacted]
METHOTREXATE	6 mg	EVERY WEEK	Y-M: 20[redacted]
DICLOFENAC	50 mg	QD	Y-M: 20[redacted]
LOXOPROFEN	60 mg	TID	Y-M: 20[redacted]
INFLIXIMAB	600 mg	OTHER: EVERY 8WEEKS	Y-M: 20[redacted]
INFLIXIMAB	500 mg	OTHER: EVERY 8WEEKS	Y-M: 20[redacted]
INFLIXIMAB	600 mg	OTHER: EVERY 8WEEKS	Y-M: 20[redacted]
ETANERCEPT	50 mg	EVERY WEEK	Y-M: 20[redacted]
KETOPROFEN	1 OTHER: APPLICATION	QD	Y-M: 20[redacted]
ADALIMUMAB	40 mg	OTHER: ONCE	Y-M: 20[redacted]
ADALIMUMAB	80 mg	EVERY 2 WEEKS	Y-M: 20[redacted]
LOXOPROFEN	60 mg	TID	Y-M: 20[redacted]
REBAMIPIDE	100 mg	TID	Y-M: 20[redacted]
ADALIMUMAB	80 mg	EVERY 2 WEEKS	Y-M: 20[redacted]
FEBUXOSTAT	20 mg	QD	Y-M: 20[redacted]
AMLODIPINE	5 mg	QD	Y-M: 20[redacted] / -90
DIFLUPREDNATE	1 OTHER: APPLICATION	PRN	Y-M: 20[redacted] / -56

TERBINAFINE	1 OTHER: APPLICATION	PRN	Y-M: 20[redacted] / -56
FEXOFENADINE	60 mg	BID	Y-M: 20[redacted] / -30
NARON ACE	2 OTHER: TBLETS	PRN	Y-M: 20[redacted] / -8

Other Medications - Medications taken within 30 days prior to each narrative event until AE stopped or end of study

Medication Name (WHO Drug)	Dose/Units	Frequency	Start Year-Month / RX Day	Stop Year-Month / RX Day
FEBUXOSTAT	20 mg	QD	Y-M: 20[redacted]	Not reported.
TERBINAFINE	1 OTHER: APPLICATION	PRN	Y-M: 20[redacted] / -56	Not reported.
NARON ACE	2 OTHER: TBLETS	PRN	Y-M: 20[redacted] / -8	Not reported.
IBUPROFEN	100 mg	BID	Y-M: 20[redacted] / 86	Not reported.
REBAMIPIDE	100 mg	BID	Y-M: 20[redacted] / 86	Not reported.
RIZATRIPTAN	10 mg	PRN	Y-M: 20[redacted] / 86	Not reported.
CLINDAMYCIN	1 OTHER: APPLICATION	PRN	Y-M: 20[redacted] / 92	Not reported.
CANDESAR A	1 OTHER: TABLET	QD	Y-M: 20[redacted] / 365	Not reported.
RABEPRAZOLE	10 mg	QD	Y-M: 20[redacted] / 365	Not reported.
ZINC PRODUCTS	1 OTHER: APPLICATION	QD	Y-M: 20[redacted] / 393	Not reported.
IMIQUIMOD	1 OTHER: APPLICATION	PRN	Y-M: 20[redacted] / 420	Not reported.
GUAIAZULENE	1 OTHER: APPLICATION	PRN	Y-M: 20[redacted] / 744	Not reported.
PARACETAMOL	500 mg	PRN	Y-M: 20[redacted] / 744	Not reported.
PENCICLOVIR	500 mg	TID	Y-M: 20[redacted] / 744	Y-M: 20[redacted] / 749
LEVOFLOXACIN			Y-M: 20[redacted] / 762	Not reported.

Event #2: Serious Adverse Event, Study Specific Adverse Events of Interest

Event Description	PERIANAL ABCESS
Preferred term	肛門膿瘍
AE Onset Date / Rx Day	[redacted]20[redacted] / 762
Age at AE Onset	4[redacted]

Laboratory Testing
NOT REPORTED
Microbiology
NOT REPORTED
SAE Supplemental Procedure
[redacted] 20[redacted] (RX DAY 766): DISSECTION OF PERIANAL ABCESS: RESOLVED;
[redacted] 20[redacted] (RX DAY 770): DISSECTION OF PERIANAL ABCESS: RESOLVED

AE Stopped Rx Day	NOT REPORTED
Duration of AE	NOT REPORTED
Relation to Study Drug by Investigator	REASONABLE POSSIBILITY
Investigator Alternative Etiology	NOT REPORTED
Discontinued Study Drug Due to the Event	NO
SAE Criteria	REQUIRES OR PROLONGS HOSPITALIZATION

Generated: [redacted]
Program Source Code: [redacted]

Investigator No.: [redacted]

Subject Number: [redacted]

Protocol Number: M15-554

治験責任医師からの報告。本被験者は日本の 4[redacted] 歳男性であり，ABT-494（ウパダシチニブ）の治験で盲検化された治験薬が投与され，肛門周囲膿瘍の事象を発現した。

Event 2 の臨床経過：
関連する病歴は乾癬性関節炎，糖尿病，内痔核，肛門周囲皮膚炎，元喫煙者（1 日 3 箱を 22 年間），高血圧，結腸の過形成ポリープ，現飲酒者（1 日 2 杯未満）及び痔瘻であった。

被験者は，最初の 24 週間，本治験の盲検プラセボ対照期に組み入れられていた。20[redacted] 年 [redacted] 月 [redacted] 日，ウパダシチニブの盲検投与が開始された。

20[redacted] 年 [redacted] 月 [redacted] 日，被験者は肛門周囲膿瘍を発現した。

20[redacted] 年 [redacted] 月 [redacted] 日，被験者は肛門周囲膿瘍と診断され，外来でレボフロキサシンを投与された。

20[redacted] 年 [redacted] 月 [redacted] 日，被験者は肛門周囲膿瘍が悪化したため入院した。20[redacted] 年 [redacted] 月 [redacted] 日と 20[redacted] 年 5 月 [redacted] 日，被験者は肛門周囲膿瘍の切開術を受けた。20[redacted] 年 [redacted] 月 [redacted] 日，被験者は退院した。

投与された薬剤は，レボフロキサシン水和物であった。

The patient's past medications include:

AZULFIDINE EN for PSORIATIC ARTHRITIS ([redacted] [redacted] 20[redacted] - [redacted] [redacted] 20[redacted])

CELECOX for PSORIATIC ARTHRITIS ([redacted])

RHEUMATREX for PSORIATIC ARTHRITIS ([redacted])

REMICADE for PSORIATIC ARTHRITIS ([redacted])

DICLOFENAC SODIUM for PSORIATIC ARTHRITIS ([redacted])

LOXOPROFEN for PSORIATIC ARTHRITIS ([redacted])

ENBREL for PSORIATIC ARTHRITIS ([redacted])

MOHRUS for PSORIATIC ARTHRITIS ([redacted])

HUMIRA for PSORIATIC ARTHRITIS ([redacted])

Causality for UPADACITINIB (Blinded)

---

1) Perianal abscess (10034447) (Anal abscess (10048946)) [v.23.0] [10034447]

Causality as per reporter (Drug/Vaccine): Reasonable possibility

Causality as per Mfr. (Drug/Vaccine): No reasonable possibility

Dechallenge: No

Alternative Etiology for UPADACITINIB (Blinded)

Event of PERIANAL ABSCESS

- Investigator: Not Applicable

- AbbVie: Risk factors include past history of anal fistula (as noted by PI), pre-existing diabetes, pre-existing perianal dermatitis, and obesity.

Relevant Laboratory & Other Diagnostic Tests

[redacted] **BMI:** 50.2 kg/m2

[redacted] **BODY WEIGHT:** 141.7 KG

被験者番号 [redacted] (Investigator [redacted])

Reason for Narrative

Adverse Event Preferred Term(s)	Serious Adverse Event	Adverse Event Leading to Discontinuation of Study Drug	Death	Event of Interest
薬物性肝障害	X			

Treatment Group	Age at Study Start	Sex	Race
ABT-494 30 mg QD	4[redacted]	FEMALE	ASIAN

Medical History	Onset Year
OTHER: ALLERGIC RHINITIS	19[redacted]
OTHER: URTICARIA	20[redacted]
OTHER: TINEA PEDIS	20[redacted]
HYPERLIPIDEMIA	20[redacted]
OTHER: PSORIASIS VULGARIS	20[redacted]
ASTHMA	20[redacted]
HYPERTENSION	20[redacted]
LIVER DISEASE (EXCLUDING HEPATITIS): FATTY LIVER	20[redacted]
OTHER: ADRENAL ADENOMA	20[redacted]
OTHER: FLOZEN SHOULDER	20[redacted]

Prior Procedures	Procedure Year
Not reported.	

Tobacco Use	Status	Number/Day	Number of Years	Year Stopped
CHEWING TOBACCO	NEVER			
CIGARETTES	FORMER	1 PACK	28	20[redacted]
CIGARS	NEVER			
E-CIGARETTES	CURRENT	0.5 SESSIONS	1	
PIPES	NEVER			

Alcohol Use	Status	Number/Day
ALCOHOL	CURRENT	Less than 2

Study Drug Administration

Study Drug	Dose/Units	Route	Frequency	First Dose Date/Day	Last Dose Date/Day	Duration (Days)
ABT-494	30MG	ORAL	QD	[redacted]20[redacted]/ 1	[redacted]20[redacted] / 168	168
ABT-494	30MG	ORAL	QD	[redacted]20[redacted] / 169	[redacted]20[redacted] / 392	224
ABT-494	30MG	ORAL	QD	[redacted]20[redacted] / 393	[redacted]20[redacted] /497	105

Previous Therapy - Prior to baseline/enrollment

Medication Name (WHO Drug)	Dose/Units	Frequency	Start Year-Month / RX Day
BETAMETHASONE	1 OTHER: APPLICATION	PRN	Y-M: 20[redacted]
BIOTIN	1.5 mg	TID	Y-M: 20[redacted]
CLOBETASOL	1 OTHER: APPLICATION	PRN	Y-M: 20[redacted]
DIFLORASONE	1 OTHER: APPLICATION	PRN	Y-M: 20[redacted]
MAXACALCITOL	1 OTHER: APPLICATION	PRN	Y-M: 20[redacted]
PREDNISOLONE	1 OTHER: APPLICATION	PRN	Y-M: 20[redacted]
TACALCITOL	1 OTHER: APPLICATION	PRN	Y-M: 20[redacted]
DIFLUCORTOLONE	1 OTHER: APPLICATION	PRN	Y-M: 20[redacted]
FLUOCINONIDE	1 OTHER: APPLICATION	PRN	Y-M: 20[redacted]
MAXACALCITOL	1 OTHER: APPLICATION	PRN	Y-M: 20[redacted]
MAXACALCITOL	1 OTHER: APPLICATION	PRN	Y-M: 20[redacted]
WHITE SOFT PARAFFIN	1 OTHER: APPLICATION	PRN	Y-M: 20[redacted]
BETAMETHASONE	1 OTHER: APPLICATION	PRN	Y-M: 20[redacted]
BETAMETHASONE	1 OTHER: APPLICATION	PRN	Y-M: 20[redacted]
DAIVOBET	1 OTHER: APPLICATION	PRN	Y-M: 20[redacted]
BETAMETHASONE BUTYRATE PROPIONATE W/MAXACALCI	1 OTHER: APPLICATION	PRN	Y-M: 20[redacted]
CELECOXIB	100 mg	BID	Y-M: 20[redacted]
METHOTREXATE	8 mg	OTHER:	Y-M: 20[redacted]

BLINDED THERAPY	400 mg	ONCE/WEEK EVERY 2 WEEKS	Y-M: 20[redacted]
FEXOFENADINE	60 mg	QD	Y-M: 20[redacted]
AMLODIPINE	5 mg	QD	Y-M: 20[redacted]
FEXOFENADINE	60 mg	BID	Y-M: 20[redacted] / -329
DAIVOBET	1 OTHER: APPLICATION	PRN	Y-M: 20[redacted] / -49
CELECOXIB	100 mg	BID	Y-M: 20[redacted] / -27
REBAMIPIDE	100 mg	BID	Y-M: 20[redacted] / -27

Other Medications - Medications taken within 30 days prior to each narrative event until AE stopped or end of study

Medication Name (WHO Drug)	Dose/Units	Frequency	Start Year-Month / RX Day	Stop Year-Month / RX Day
WHITE SOFT PARAFFIN	1 OTHER: APPLICATION	PRN	Y-M: 20[redacted]	Not reported.
AMLODIPINE	5 mg	QD	Y-M: 20[redacted]	Not reported.
FEXOFENADINE	60 mg	BID	Y-M: 20[redacted] / -329	Not reported.
CELECOXIB	100 mg	BID	Y-M: 20[redacted] / -27	Not reported.
REBAMIPIDE	100 mg	BID	Y-M: 20[redacted] / -27	Not reported.
LOXOPROFEN	100 mg	PRN	Y-M: 20[redacted] / 309	Not reported.
FEXOFENADINE	60 mg	QD	Y-M: 20[redacted] / 393	Not reported.
PREDNISOLONE	30 mg	BID	Y-M: 20[redacted] / 520	Y-M: 20[redacted] / 531
PREDNISOLONE	25 mg	BID	Y-M: 20[redacted] / 532	Y-M: 20[redacted] / 537
PREDNISOLONE	20 mg	BID	Y-M: 20[redacted] / 538	Y-M: 20[redacted] / 544
PREDNISOLONE	15 mg	BID	Y-M: 20[redacted] / 545	Y-M: 20[redacted] / 551
PREDNISOLONE	10 mg	BID	Y-M: 20[redacted] / 552	Y-M: 20[redacted] / 562
PREDNISOLONE	15 mg	QD	Y-M: 20[redacted] / 563	Not reported.

Event #2: Serious Adverse Event, Study Specific Adverse Events of Interest

Event Description	DRUG-INDUCED HEPATITIS
Preferred term	薬物性肝障害
AE Onset Date / Rx Day	[redacted]20[redacted] / 520 (23 DAYS AFTER LAST TREATMENT)
Age at AE Onset	5[redacted]

Laboratory Testing

[redacted]20[redacted] (RX DAY 497): Alanine Aminotransferase: 151 [7 - 23] U/L; Aspartate Aminotransferase: 115 [13 - 30] U/L; [redacted]20[redacted] (RX DAY 512): Alanine Aminotransferase: 206 [7 - 23] U/L; Aspartate Aminotransferase: 104 [13 - 30] U/L; [redacted]20[redacted] (RX DAY 519): Alanine Aminotransferase: 257 [7 - 23] U/L; Aspartate Aminotransferase: 212 [13 - 30] U/L; Bilirubin: 10.26 [6.84 - 25.66] umol/L; NPTST091-G-GTP: 118 [9 - 32] U/L; NPTST119- INR: 0.95 [NOT REPORTED - 1.15] UNIT NOT REPORTED; NPTST176-PT: 110.8 [80 - 127] %; Platelets: 247 [158 - 348] 10^9/L; [redacted]20[redacted] (RX DAY 524): Alanine Aminotransferase: 167 [7 - 23] U/L; Aspartate Aminotransferase: 85 [13 - 30] U/L; [redacted]20[redacted] (RX DAY 527): Alanine Aminotransferase: 188 [7 - 23] U/L; Aspartate Aminotransferase: 71 [13 - 30] U/L; [redacted]20[redacted] (RX DAY 531): Alanine Aminotransferase: 123 [7 - 23] U/L; Aspartate Aminotransferase: 35 [13 - 30] U/L; [redacted]20[redacted] (RX DAY 535): Alanine Aminotransferase: 102 [7 - 23] U/L; Aspartate Aminotransferase: 35 [13 - 30] U/L; [redacted]20[redacted] (RX DAY 538): Alanine Aminotransferase: 103 [7 - 23] U/L; Aspartate Aminotransferase: 32 [13 - 30] U/L; [redacted]20[redacted] (RX DAY 542): Alanine Aminotransferase: 92 [13 - 30] U/L; Aspartate Aminotransferase: 36 [13 - 30] U/L; [redacted]20[redacted] (RX DAY 545): Alanine Aminotransferase: 109 [7 - 23] U/L; Aspartate Aminotransferase: 36 [13 - 30] U/L; [redacted]20[redacted] (RX DAY 549): Alanine Aminotransferase: 99 [7 - 23] U/L; Aspartate Aminotransferase: 32 [13 - 30] U/L; NPTST091-G-GTP: 113 [9 - 32] U/L; NPTST119

Microbiology

NOT REPORTED

SAE Supplemental Procedure

[redacted]20[redacted] (RX DAY 510): ABDOMINAL ULTRASOUND FINDING: FATTY LIVER

AE Stopped Rx Day	NOT REPORTED
Duration of AE	NOT REPORTED
Relation to Study Drug by Investigator	REASONABLE POSSIBILITY
Investigator Alternative Etiology	NOT REPORTED
Discontinued Study Drug Due to the Event	NO
SAE Criteria	REQUIRES OR PROLONGS HOSPITALIZATION

Generated: [redacted]
Program Source Code: [redacted]

Investigator No.: [redacted]

Subject Number: [redacted]

Protocol Number: M15-554

治験責任医師からの報告。本被験者は日本の5[redacted]歳女性であり，ABT-494（ウパダシチニブ）の治験で盲検化された治験薬が投与され，薬剤誘発性肝炎の事象を発現した。

Event 2 の臨床経過：
関連する病歴は高脂血症，尋常性乾癬，高血圧，脂肪肝，乾癬性関節炎，元喫煙者（1 日 1 箱を 28 年間），現電子タバコ使用者（1 日 0.5 回を 1 年間）及び現飲酒者（1 日 2 杯未満）であった。

被験者は，最初の 24 週間，本治験の盲検プラセボ対照期に組み入れられていた。20[redacted] 年 [redacted] 月 [redacted] 日，ウパダシチニブの盲検投与が開始された。

20[redacted] 年 [redacted] 月 [redacted] 日，被験者は薬剤誘発性肝炎を発現した。

入院前，20[redacted] 年 [redacted] 月 [redacted] 日に被験者は薬剤誘発性肝炎（非重篤）を発現した。20[redacted] 年 [redacted] 月 [redacted] 日，被験者の ALT 及び AST は，それぞれ 126 U/L 及び 99 U/L に上昇した。20[redacted] 年 [redacted] 月 [redacted] 日，薬剤誘発性肝炎（非重篤）により治験薬の投与が中止された。20[redacted] 年 [redacted] 月 [redacted] 日，ALT 及び AST は，それぞれ 248 U/L 及び 280 U/L に上昇した。

20[redacted] 年 [redacted] 月 [redacted] 日，被験者は薬剤誘発性肝炎の治療のため入院した。20[redacted] 年 [redacted] 月 [redacted] 日，AST 及び ALT は，それぞれ 32 U/L 及び 99 U/L に低下した。同日，被験者は退院した。

投与された薬剤は，プレドニゾロンであった。

The patient's past medications include:

ANTEBATE OINTMENT for PSORIASIS ([redacted] 20[redacted] - [redacted] 20[redacted], [redacted] 20[redacted] - [redacted] 20[redacted])

BIOTIN for PSORIASIS ([redacted] 20[redacted] - [redacted] 20[redacted])

BONALFAHIGH for PSORIASIS ([redacted] 20[redacted] - [redacted] 20[redacted])

DERMOVATE OINTMENT for PSORIASIS ([redacted] 20[redacted] - [redacted] 20[redacted])

DERMOVATE SCALP LOTION for PSORIASIS ([redacted] 20[redacted] - [redacted] 20[redacted])

DIFLAL for PSORIASIS ([redacted] 20[redacted] - [redacted] 20[redacted])

LIDOMEX KOWA for PSORIASIS ([redacted] 20[redacted] - [redacted] 20[redacted])

OXAROL LOTION for PSORIASIS ([redacted] 20[redacted] - [redacted] 20[redacted], [redacted] 20[redacted] - [redacted] 20[redacted])

OXAROL OINTMENT for PSORIASIS ([redacted] 20[redacted] - [redacted] 20[redacted], [redacted] 20[redacted] - [redacted] 20[redacted])

NERISONA for PSORIASIS ([redacted] 20[redacted] - [redacted] 20[redacted]) TOPSYM for PSORIASIS ([redacted] 20[redacted] - [redacted] 20[redacted])

ANTEBATE LOTION for PSORIASIS ([redacted] 20[redacted] - [redacted] 20[redacted])

DOVOBET OINTMENT for PSORIASIS ([redacted] 20[redacted] - [redacted] 20[redacted], [redacted] 20[redacted] - [redacted] 20[redacted])

MARDUOX for PSORIASIS ([redacted] 20[redacted] - [redacted] 20[redacted])

RHEUMATREX for PSORIATIC ARTHRITIS (■■ 20■ - ■■ 20■)

CERTOLIZUMAB PEGOL for PSORIASIS (■■ 20■ - ■■ 20■)

Causality for UPADACITINIB (Blinded)

---

1) Drug-induced hepatitis (10013762) (Drug-induced liver injury (10072268))[v.23.0] [10013762]

Causality as per reporter (Drug/Vaccine): Reasonable possibility

Causality as per Mfr. (Drug/Vaccine): Reasonable possibility

Dechallenge: Not Applicable

Alternative Etiology for UPADACITINIB (Blinded)

Event of DRUG-INDUCED HEPATITIS

- Investigator: Not applicable.

- AbbVie: Not applicable.

Relevant Laboratory & Other Diagnostic Tests

■■■ **20■ ABDOMINAL ULTRASOUND:** Fatty liver.

■■■ **20■ ALANINE AMINO TRANSFERASE:** 35 U/L (normal 6 to 34)

■■■ **20■ ALANINE AMINO TRANSFERASE:** 25 U/L (normal 6 to 34)

■■■ **20■ ALANINE AMINO TRANSFERASE:** 24 U/L (normal 6 to 34)

■■■ **20■ ALANINE AMINO TRANSFERASE:** 36 U/L (normal 6 to 34)

■■■ **20■ ALANINE AMINO TRANSFERASE:** 34 U/L (normal 6 to 34)

■■■ **20■ ALANINE AMINO TRANSFERASE:** 38 U/L (normal 6 to 34)

■■■ **20■ ALANINE AMINO TRANSFERASE:** 48 U/L (normal 6 to 34)

■■■ **20■ ALANINE AMINO TRANSFERASE:** 68 U/L (normal 6 to 34)

[redacted] **20[redacted] ALANINE AMINO TRANSFERASE:** 68 U/L (normal 6 to 34)

[redacted] **20[redacted] ALANINE AMINO TRANSFERASE:** 93 U/L (normal 6 to 34)

[redacted] **20[redacted] ALANINE AMINO TRANSFERASE:** 92 U/L (normal 6 to 34)

[redacted] **20[redacted] ALANINE AMINO TRANSFERASE:** 75 U/L (normal 6 to 34)

[redacted] **20[redacted] ALANINE AMINO TRANSFERASE:** 108 U/L (normal 6 to 34)

[redacted] **20[redacted] ALANINE AMINO TRANSFERASE:** 126 U/L (normal 6 to 34)

[redacted] **20[redacted] ALANINE AMINO TRANSFERASE:** 180 U/L (normal 6 to 34)

[redacted] **20[redacted] ALANINE AMINO TRANSFERASE:** 151 U/L (normal 7 to 23)

[redacted] **20[redacted] ALANINE AMINO TRANSFERASE:** 248 U/L (normal 6 to 34)

[redacted] **20[redacted] ALANINE AMINO TRANSFERASE:** 206 U/L (normal 13 to 30)

[redacted] **20[redacted] ALANINE AMINO TRANSFERASE:** 257 U/L (normal 6 to 34)

[redacted] **20[redacted] ALANINE AMINO TRANSFERASE:** 255 U/L (normal 6 to 34)

[redacted] **20[redacted] ALANINE AMINO TRANSFERASE:** 167 U/L (normal 7 to 23)

[redacted] **20[redacted] ALANINE AMINO TRANSFERASE:** 188 U/L (normal 7 to 23)

[redacted] **20[redacted] ALANINE AMINO TRANSFERASE:** 102 U/L (normal 7 to 23)

[redacted] **20[redacted] ALANINE AMINO TRANSFERASE:** 92 U/L (normal 7 to 23)

[redacted] **20[redacted] ALANINE AMINO TRANSFERASE:** 99 U/L (normal 7 to 23)

[redacted] **20[redacted] ALANINE AMINO TRANSFERASE:** 84 U/L (normal 6 to 34)

[redacted] **20[redacted] ALANINE AMINO TRANSFERASE:** 85 U/L (normal 7 to 23)

[redacted] **20[redacted] ALKALINE PHOSPHATASE:** 79 U/L (normal 31 to 106)

[redacted] **20[redacted] ALKALINE PHOSPHATASE:** 78 U/L (normal 31 to 106)

[redacted] **20[redacted] ALKALINE PHOSPHATASE:** 78 U/L (normal 31 to 106)

[redacted] **20[redacted] ALKALINE PHOSPHATASE:** 67 U/L (normal 31 to 106)

[redacted] **20[redacted] ALKALINE PHOSPHATASE:** 58 U/L (normal 31 to 106)

[redacted] **20[redacted] ALKALINE PHOSPHATASE:** 59 U/L (normal 31 to 106)

[redacted] **20[redacted] ALKALINE PHOSPHATASE:** 65 U/L (normal 31 to 106)

[redacted] **20[redacted] ALKALINE PHOSPHATASE:** 62 U/L (normal 31 to 106)

[redacted] **20[redacted] ALKALINE PHOSPHATASE:** 57 U/L (normal 31 to 106)

[redacted] **20[redacted] ALKALINE PHOSPHATASE:** 65 U/L (normal 31 to 106)

[redacted] **20[redacted] ALKALINE PHOSPHATASE:** 60 U/L (normal 31 to 106)

[redacted] **20[redacted] ALKALINE PHOSPHATASE:** 62 U/L (normal 31 to 106)

[redacted] **20[redacted] ALKALINE PHOSPHATASE:** 64 U/L (normal 31 to 106)

[redacted] **20[redacted] ALKALINE PHOSPHATASE:** 68 U/L (normal 31 to 106)

[redacted] **20[redacted] ASPARTATE AMINO TRANSFERASE:** 24 U/L (normal 9 to 34)

[redacted] **20[redacted] ASPARTATE AMINO TRANSFERASE:** 22 U/L (normal 9 to 34)

[redacted] **20[redacted] ASPARTATE AMINO TRANSFERASE:** 64 U/L (normal 9 to 34)

[redacted] **20[redacted] ASPARTATE AMINO TRANSFERASE:** 29 U/L (normal 9 to 34)

[redacted] **20[redacted] ASPARTATE AMINO TRANSFERASE:** 32 U/L (normal 9 to 34)

[redacted] **20[redacted] ASPARTATE AMINO TRANSFERASE:** 33 U/L (normal 9 to 34)

[redacted] **20[redacted] ASPARTATE AMINO TRANSFERASE:** 40 U/L (normal 9 to 34)

[redacted] **20[redacted] ASPARTATE AMINO TRANSFERASE:** 57 U/L (normal 9 to 34)

[redacted] **20[redacted] ASPARTATE AMINO TRANSFERASE:** 50 U/L (normal 9 to 34)

[redacted] **20[redacted] ASPARTATE AMINO TRANSFERASE:** 80 U/L (normal 9 to 34)

[redacted] **20[redacted] ASPARTATE AMINO TRANSFERASE:** 73 U/L (normal 9 to 34)

[redacted] **20[redacted] ASPARTATE AMINO TRANSFERASE:** 58 U/L (normal 9 to 34)

[redacted] **20[redacted] ASPARTATE AMINO TRANSFERASE:** 77 U/L (normal 9 to 34)

[redacted] **20[redacted] ASPARTATE AMINO TRANSFERASE:** 99 U/L (normal 9 to 34)

[redacted] **20[redacted] ASPARTATE AMINO TRANSFERASE:** 118 U/L (normal 9 to 34)

[redacted] **20[redacted] ASPARTATE AMINO TRANSFERASE:** 115 U/L (normal 13 to 30)

[redacted] **20[redacted] ASPARTATE AMINO TRANSFERASE:** 280 U/L (normal 9 to 34)

[redacted] **20[redacted] ASPARTATE AMINO TRANSFERASE:** 104 U/L (normal 9 to 34)

[redacted] **20[redacted] ASPARTATE AMINO TRANSFERASE:** 212 U/L (normal 9 to 34)

[redacted] **20[redacted] ASPARTATE AMINO TRANSFERASE:** 227 U/L (normal 9 to 34)

[redacted] **20[redacted] ASPARTATE AMINO TRANSFERASE:** 85 U/L (normal 9 to 34)

[redacted] **20[redacted] ASPARTATE AMINO TRANSFERASE:** 71 U/L (normal 9 to 34)

[redacted] **20[redacted] ASPARTATE AMINO TRANSFERASE:** 35 U/L (normal 9 to 34)

[redacted] **20[redacted] ASPARTATE AMINO TRANSFERASE:** 36 U/L (normal 9 to 34)

[redacted] **20[redacted] ASPARTATE AMINO TRANSFERASE:** 32 U/L (normal 13 to 30)

[redacted] **20[redacted] ASPARTATE AMINO TRANSFERASE:** 39 U/L (normal 9 to 34)

[redacted] **20[redacted] BMI:** 36 kg/m^2

[redacted] **20[redacted] G-GTP:** 118 U/L (normal 9 to 32)

[redacted] **20[redacted] G-GTP:** 113 U/L (normal 9 to 32)

[redacted] **20[redacted] INR:** 1.0 U/L (normal 0.8 to 1.2)

[redacted] **20[redacted] INR:** 1.1 U/L (normal 0.8 to 1.2)

[redacted] **20[redacted] INR:** 0.95 U/L (normal 0.8 to 1.2)

[redacted] **20[redacted] INR:** 0.98 U/L (normal <1.15)

[redacted] **20[redacted] PLATELET COUNT:** 247 10^3/uL (normal 158 to 348)

[redacted] **20[redacted] PLATELET COUNT:** 207 10^3/uL (normal 158 to 348)

[redacted] **20[redacted] PLATELETS:** 220 No units (normal 140 to 400)

[redacted] **20[redacted] PLATELETS:** 226 No units (normal 140 to 400)

[redacted] **20[redacted] PLATELETS:** 260 No units (normal 140 to 400)

[redacted] **20[redacted] PLATELETS:** 267 No units (normal 140 to 400)

[redacted] **20[redacted] PLATELETS:** 318 No units (normal 140 to 400)

[redacted] **20[redacted] PLATELETS:** 296 No units (normal 140 to 400)

[redacted] **20[redacted] PLATELETS:** 260 No units (normal 140 to 400)

[redacted] **20[redacted] PLATELETS:** 339 No units (normal 140 to 400)

[redacted] **20[redacted] PT:** 110.8 % (normal 80 to 127)

[redacted] **20[redacted] PT:** 105.3 % (normal 80 to 127)

[redacted] **20[redacted] TOTAL BILIRUBIN:** 0.7 mg/dL (normal 0.2 to 1.2)

[redacted] **20[redacted] TOTAL BILIRUBIN:** 0.2 mg/dL (normal 0.2 to 1.2)

[redacted] **20[redacted] TOTAL BILIRUBIN:** 0.7 mg/dL (normal 0.2 to 1.2)

[redacted] **20[redacted] TOTAL BILIRUBIN:** 0.8 mg/dL (normal 0.2 to 1.2)

[redacted] **20[redacted] TOTAL BILIRUBIN:** 0.6 mg/dL (normal 0.2 to 1.2)

[redacted] **20[redacted] TOTAL BILIRUBIN:** 0.6 mg/dL (normal 0.2 to 1.2)

[redacted] **20[redacted] TOTAL BILIRUBIN:** 0.6 mg/dL (normal 0.4 to 1.5)

被験者番号 [redacted] (Investigator [redacted])

Reason for Narrative

Adverse Event Preferred Term(s)	Serious Adverse Event	Adverse Event Leading to Discontinuation of Study Drug	Death	Event of Interest
咽頭炎	X			X

Treatment Group	Age at Study Start	Sex	Race
Placebo/ABT-494 30 mg QD	5[redacted]	FEMALE	ASIAN

Medical History	Onset Year
ASTHMA	NOT REPORTED
OTHER: LOW BACK PAIN	NOT REPORTED
OTHER: PSORIASIS VULGARIS	19[redacted]
CANCER: CERVICAL CANCER	20[redacted]
DIABETES MELLITUS	20[redacted]

Prior Procedures	Procedure Year
SURGERY: HYSTERECTOMY	20[redacted]

Tobacco Use	Status	Number/Day	Number of Years	Year Stopped
CHEWING TOBACCO	NEVER			
CIGARETTES	CURRENT	1 PACK	36	
CIGARS	NEVER			
E-CIGARETTES	NEVER			
PIPES	NEVER			

Alcohol Use	Status	Number/Day
ALCOHOL	CURRENT	Less than 2

Study Drug Administration

Study Drug	Dose/Units	Route	Frequency	First Dose Date/Day	Last Dose Date/Day	Duration (Days)
PLACEBO		ORAL	QD	[redacted]20[redacted] / 1	[redacted]20[redacted] / 168	168
ABT-494	30MG	ORAL	QD	[redacted]20[redacted] / 169	[redacted]20[redacted] / 391	223
ABT-494	30MG	ORAL	QD	[redacted]20[redacted] / 392	/	

Previous Therapy - Prior to baseline/enrollment

Medication Name (WHO Drug)	Dose/Units	Frequency	Start Year-Month / RX Day
BCG Vaccine	NOT REPORTED	NOT REPORTED	Y-M: 19[redacted]
LOXOPROFEN	60 mg	QD	Y-M: 20[redacted]
DIFLUCORTOLONE	1 OTHER: APPLICATION	BID	Y-M: 20[redacted]
MAXACALCITOL	1 OTHER: APPLICATION	BID	Y-M: 20[redacted]
KETOPROFEN	20 mg	QD	Y-M: 20[redacted]
DICLOFENAC	25 mg	TID	Y-M: 20[redacted]
REBAMIPIDE	100 mg	TID	Y-M: 20[redacted]
BEPOTASTINE	10 mg	BID	Y-M: 20[redacted]
GUSELKUMAB	100 mg	OTHER: Q8WK	Y-M: 20[redacted]
TRAMADOL	50 mg	TID	Y-M: 20[redacted]
METHOTREXATE	6 mg	EVERY WEEK	Y-M: 20[redacted]
PREDNISOLONE	5 mg	BID	Y-M: 20[redacted]
METHOTREXATE	8 mg	EVERY WEEK	Y-M: 20[redacted]
ESOMEPRAZOLE	20 mg	QD	Y-M: 20[redacted]
METHOTREXATE	10 mg	EVERY WEEK	Y-M: 20[redacted]
RISEDRONIC ACID	75 mg	OTHER: ONCE PER MONTH	Y-M: 20[redacted]
TENELIGLIPTIN	20 mg	BID	Y-M: 20[redacted]
METFORMIN	250 mg	BID	Y-M: 20[redacted] / - 224

Other Medications - Medications taken within 30 days prior to each narrative event until AE stopped or end of study

Medication Name (WHO Drug)	Dose/Units	Frequency	Start Year-Month / RX Day	Stop Year-Month / RX Day
DICLOFENAC	25 mg	TID	Y-M: 20[redacted]	Not reported.
REBAMIPIDE	100 mg	TID	Y-M: 20[redacted]	Not reported.
BEPOTASTINE	10 mg	BID	Y-M: 20[redacted]	Not reported.
TRAMADOL	50 mg	TID	Y-M: 20[redacted]	Not reported.
PREDNISOLONE	5 mg	BID	Y-M: 20[redacted]	Not reported.
ESOMEPRAZOLE	20 mg	QD	Y-M: 20[redacted]	Not reported.
METHOTREXATE	10 mg	EVERY WEEK	Y-M: 20[redacted]	Not reported.
RISEDRONIC ACID	75 mg	OTHER: ONCE PER MONTH	Y-M: 20[redacted]	Not reported.
TENELIGLIPTIN	20 mg	BID	Y-M: 20[redacted]	Not reported.
METFORMIN	250 mg	BID	Y-M: 20[redacted] / - 224	Not reported.
DAIVOBET	1 OTHER:	QD	Y-M: 20[redacted] /	Not reported.

	APPLICATION		113	
KETOCONAZOLE	1 OTHER: APPLICATION	QD	Y-M: 20[redacted] / 567	Not reported
CEFTRIAXONE	2 g	BID	Y-M: 20[redacted] / 625	Y-M: 20[redacted] / 629
DEXAMETHASONE	2 mL	TID	Y-M: 20[redacted] / 625	Y-M: 20[redacted] / 629
GARENOXACIN	400 mg	QD	Y-M: 20[redacted] / 625	Y-M: 20[redacted] / 629
HYDROCORTISONE	100 mg	QD	Y-M: 20[redacted] / 625	Y-M: 20[redacted] / 629
SODIUM CHLORIDE	100 mL	BID	Y-M: 20[redacted] / 625	Y-M: 20[redacted] / 629
SODIUM CHLORIDE	100 mL	QD	Y-M: 20[redacted] / 625	Y-M: 20[redacted] / 629

Event #1: Serious Adverse Event, Study Specific Adverse Events of Interest

Event Description	ACUTE PHARYNGITIS
Preferred term	咽頭炎
AE Onset Date / Rx Day	[redacted]20[redacted] / 625
Age at AE Onset	5[redacted]

Laboratory Testing

NOT REPORTED

Microbiology

NOT REPORTED

SAE Supplemental Procedure

[redacted]20[redacted] (RX DAY 607): LARYNGOSCOPY: WHITE MOSS AT MUCOSA OF THE RIGHT PIRIFORM FOSSA OF THE HYPOPHARYNX WAS FOUND BY FOLLOW UP LARYNGOSCOPY. THESE FINDING WERE THOUGHT TO BE CAUSED BY FISH BONE INJURY. THE PATIENT WAS DISCHARGED.; [redacted]20[redacted] (RX DAY 625): LARYNGOSCOPY: [redacted]-[redacted]-20[redacted]: SWELLING OF THE RIGHT CLEFT WAS FOUND BY LARYNGOSCOPY. WHITE MOSS AT MUCOSA OF THE RIGHT PIRIFORM FOSSA OF THE HYPOPHARYNX WAS FOUND BY FOLLOW UP LARYNGOSCOPY (PERFORM DATE IS UNKNOWN). T

AE Stopped Rx Day	629
Duration of AE	5 DAYS
Relation to Study Drug by Investigator	NO REASONABLE POSSIBILITY
Investigator Alternative Etiology	INJURY WITH FISH BORN, BACTERIAL INFECTION.
Discontinued Study Drug Due to the Event	NO
SAE Criteria	REQUIRES OR PROLONGS HOSPITALIZATION

Generated: [redacted]
Program Source Code: [redacted]

Investigator No.: [redacted]

Subject Number: [redacted]

Protocol Number: M15-554

治験責任医師からの報告。本被験者は日本の 5[redacted] 歳女性であり，ABT-494（ウパダシチニブ）の治験で盲検化された治験薬が投与され，急性咽頭炎の事象を発現した。

Event 1 の臨床経過：
関連する病歴は尋常性乾癬，乾癬性関節炎，糖尿病，現喫煙者（1 日 1 箱を 36 年間）及び現飲酒者（2 杯未満）であった。

被験者は，最初の 24 週間，本治験の盲検プラセボ対照期に組み入れられていた。20[redacted] 年 [redacted] 月 [redacted] 日，ウパダシチニブの盲検投与が開始された。

20[redacted] 年 [redacted] 月 [redacted] 日，被験者は急性咽頭炎を発現した。20[redacted] 年 [redacted] 月 [redacted] 日，急性咽頭炎は消失した。

20[redacted] 年 [redacted] 月 [redacted] 日，被験者は魚の小骨で受傷した。被験者は咽喉痛があり，クリニックを受診し，病院を紹介された。

20[redacted] 年 [redacted] 月 [redacted] 日，被験者は入院し，20[redacted] 年 [redacted] 月 [redacted] 日～23 日に抗生物質（経口と点滴）及びステロイド（点滴と吸入）が投与された。症状は改善し，20[redacted] 年 [redacted] 月 [redacted] 日，被験者は退院した。

投与された薬剤は，デカドロン，ソル・コーテフ，ジェニナック及びセフトリアキソンナトリウム水和物であった。

The patient's past medications include:

LOXOPROFEN SODIUM HYDRATE for PSORIATIC ARTHRITIS ([redacted] 20[redacted] - [redacted] 20[redacted])

NERISONA for PSORIASIS ([redacted] 20[redacted] - [redacted] 20[redacted])

OXAROL for PSORIASIS ([redacted] 20[redacted] - [redacted] 20[redacted])

MOHRUS for PSORIATIC ARTHRITIS ([redacted] 20[redacted] - [redacted] 20[redacted])

GUSELKUMAB for PSORIATIC ARTHRITIS ([redacted] 20[redacted] - [redacted] 20[redacted])

Causality for UPADACITINIB (Blinded)

---

1) Acute pharyngitis (10001002) (Pharyngitis (10034835)) [v.23.0] [10001002]

Causality as per reporter (Drug/Vaccine): No reasonable possibility

Causality as per Mfr. (Drug/Vaccine): No reasonable possibility

Dechallenge: Not Applicable

Alternative Etiology for UPADACITINIB (Blinded)

Event of ACUTE PHARYNGITIS

- Investigator: Injury with fish born, bacterial infection

- AbbVie: Event is more likely due to injury from fish bone (per PI).

Relevant Laboratory & Other Diagnostic Tests

[redacted] **20[redacted] LARYNGOSCOPY:** White moss at mucosa of the right piriform fossa of the hypopharynx was found by follow up laryngoscopy. These finding were thought to be caused by fish bone injury.

[redacted] **20[redacted] LARYNGOSCOPY:** Swelling of the right cleft was found by laryngoscopy.

被験者番号 [redacted] (Investigator [redacted])

Reason for Narrative

Adverse Event Preferred Term(s)	Serious Adverse Event	Adverse Event Leading to Discontinuation of Study Drug	Death	Event of Interest
急性心筋梗塞	X			X

Treatment Group	Age at Study Start	Sex	Race
ABT-494 15 mg QD	4[redacted]	FEMALE	WHITE

Medical History	Onset Year
CARDIAC ARRHYTHMIA: ATRIAL FIBRILLATION	20[redacted]
OTHER: PSORIASIS VULGARIS	20[redacted]
OTHER: OSTEOPENIA	20[redacted]
ANEMIA: IRON DEFICIENCY	20[redacted]

Prior Procedures	Procedure Year
Not reported.	

Tobacco Use	Status	Number/Day	Number of Years	Year Stopped
CHEWING TOBACCO	NEVER			
CIGARETTES	CURRENT	0.5 PACK	23	
CIGARS	NEVER			
E-CIGARETTES	NEVER			
PIPES	NEVER			

Alcohol Use	Status	Number/Day
ALCOHOL	NEVER	

Study Drug Administration

Study Drug	Dose/Units	Route	Frequency	First Dose Date/Day	Last Dose Date/Day	Duration (Days)
ABT-494	15MG	ORAL	QD	[redacted]20[redacted] / 1	[redacted]20[redacted] / 168	168
ABT-494	15MG	ORAL	QD	[redacted]20[redacted] / 169	[redacted]20[redacted] / 392	224
ABT-494	15MG	ORAL	QD	[redacted]20[redacted] / 393	/	

Previous Therapy - Prior to baseline/enrollment

Medication Name (WHO Drug)	Dose/Units	Frequency	Start Year-Month / RX Day
BCG Vaccine	NOT REPORTED	NOT REPORTED	Y-M: 19[redacted]
LANSOPRAZOLE	15 mg	QD	Y-M: 20[redacted]
CALCIUM	200 mg	BID	Y-M: 20[redacted]
COLECALCIFEROL	1000 IU	QD	Y-M: 20[redacted]
ETANERCEPT	50 mg	EVERY WEEK	Y-M: 20[redacted]
BISOPROLOL	50 mg	QD	Y-M: 20[redacted]
DICLOFENAC	50 mg	TID	Y-M: 20[redacted]
FOLIC ACID	3 mg	OTHER: EVERY OTHER DAY	Y-M: 20[redacted]
METHOTREXATE	15 mg	EVERY WEEK	Y-M: 20[redacted]
FERROTRAT	114 mg	QD	Y-M: 20[redacted] / -99

Other Medications - Medications taken within 30 days prior to each narrative event until AE stopped or end of study

Medication Name (WHO Drug)	Dose/Units	Frequency	Start Year-Month / RX Day	Stop Year-Month / RX Day
LANSOPRAZOLE	15 mg	QD	Y-M: 20[redacted]	Not reported.
CALCIUM	200 mg	BID	Y-M: 20[redacted]	Not reported.
COLECALCIFEROL	1000 IU	QD	Y-M: 20[redacted]	Not reported.
BISOPROLOL	50 mg	QD	Y-M: 20[redacted]	Y-M: 20[redacted] / 630
DICLOFENAC	50 mg	TID	Y-M: 20[redacted]	Not reported.
FOLIC ACID	3 mg	OTHER: EVERY OTHER DAY	Y-M: 20[redacted]	Not reported.
METHOTREXATE	15 mg	EVERY WEEK	Y-M: 20[redacted]	Not reported.
FERROTRAT	114 mg	QD	Y-M: 20[redacted] / -99	Not reported.
CLOPIDOGREL	150 mg	QD	Y-M: 20[redacted] / 23	Not reported.
PERINDOPRIL	25 mg	QD	Y-M: 20[redacted] / 23	Not reported.
ROSUVASTATIN	40 mg	QD	Y-M: 20[redacted] / 23	Not reported.
ACETYLSALICYLIC ACID	100 mg	QD	Y-M: 20[redacted] / 23	Y-M: 20[redacted] / 630

Event #1: Serious Adverse Event, Study Specific Adverse Events of Interest, Positively Adjudicated Events

Event Description	ACUTE MYOCARDIAL INFARCTION
Preferred term	急性心筋梗塞
AE Onset Date / Rx Day	[redacted]20[redacted] / 20
Age at AE Onset	4[redacted]

Laboratory Testing

[redacted]20[redacted] (RX DAY 23): Creatine Kinase: 271 [24 - 170] U/L; Creatine Kinase: 239 [24 - 170] U/L; NPTST205-TROPONIN: 273.6 [0 - 19] ng/L; [redacted]20[redacted] (RX DAY 24): Creatine Kinase: 206 [24 - 170] U/L

Microbiology

NOT REPORTED

SAE Supplemental Procedure

[redacted]20[redacted] (RX DAY 23): CORONAROGRAPHIA: PROXIMAL LAD STENOSIS; ECG: SIGNS OF ANTERIOR ISCHEMIA; [redacted]20[redacted] (RX DAY 27): ECHOCARDIOGRAPHY: 2-3 MM PERICARDIAL FLUID TO THE RIGHT VENTRICLE

AE Stopped Rx Day	28
Duration of AE	9 DAYS
Relation to Study Drug by Investigator	NO REASONABLE POSSIBILITY
Investigator Alternative Etiology	CAN BE RELATED TO 23 YEARS OF SMOKING
Discontinued Study Drug Due to the Event	NO
SAE Criteria	REQUIRES OR PROLONGS HOSPITALIZATION

Generated: [redacted]
Program Source Code: [redacted]

Investigator No.: [redacted]

Subject Number: [redacted]

Protocol Number: M15-554

治験責任医師からの報告。本被験者はハンガリーの4[redacted]歳女性であり，ABT-494（ウパダシチニブ）の治験で盲検化された治験薬が投与され，急性心筋梗塞の事象を発現した。

Event 1 の臨床経過：

関連する病歴は心房細動，尋常性乾癬，乾癬性関節炎，現紙巻タバコ喫煙者（1 日 0.5 箱を 23 年間）及び非飲酒者であった。

20[redacted] 年 [redacted] 月 [redacted] 日，被験者は急性心筋梗塞を発現した。20[redacted] 年 [redacted] 月 [redacted] 日，急性心筋梗塞は消失した。

20[redacted] 年 [redacted] 月 [redacted] 日，胸痛，発汗を伴う咽喉絞扼感及び両腕の痛みが出現した。20[redacted] 年 [redacted] 月 [redacted] 日，被験者は心臓の検査を受け，不安定狭心症及び非 ST 上昇型心筋梗塞のため救急科に転科となった。

20[redacted] 年 [redacted] 月 [redacted] 日，被験者は入院し，冠動脈血管造影を受けたところ，著しい狭窄が認められ，Biomime ステントが挿入され，良好な結果が得られた。20[redacted] 年 [redacted] 月 [redacted] 日，理学療法が開始された。モビリゼーションで合併症は生じなかった。20[redacted] 年 [redacted] 月 [redacted] 日，高コレステロール血症（非重篤）も認められた。20[redacted] 年 [redacted] 月 [redacted] 日，被験者は退院した。[redacted] 月，リハビリテーションが開始された。本報告時において，被験者からの症状の訴えはない。

投与された薬剤は，xeter，ASA，coverex AS 及び trombex であった。

Causality for UPADACITINIB (Blinded)

---

1) Acute myocardial infarction (10000891) (Acute myocardial infarction (10000891)) [v.22.1] [10000891]

Causality as per reporter (Drug/Vaccine): No reasonable possibility

Causality as per Mfr. (Drug/Vaccine): No reasonable possibility

Dechallenge: Not Applicable

Alternative Etiology for UPADACITINIB (Blinded)

Event of ACUTE MYOCARDIAL INFARCTION

- Investigator: Can be related to 23 years of smoking.

- AbbVie: Event more likely related to history of smoking 0.5 PPD for 23 years. Additional risk factors include pre-existing atrial fibrillation and psoriasis.

Relevant Laboratory & Other Diagnostic Tests

[redacted] [redacted] **20[redacted] BLOOD SUGAR:** 52 MMOL/L

[redacted] **20[redacted] BUN:** 57 MMOL/L

[redacted] **20[redacted] CHOLESTEROL:** 5.31 MMOL/L

[redacted] **20[redacted] CK-MB:** 26 U/L

[redacted] **20[redacted] CORONARY ANGIOGRAPHY:** Successful PCI of the left anterior descending artery together with the implantation of BIOMIME stent

[redacted] **20[redacted] CREATININE:** 61 MMOL/L

[redacted] **20[redacted] CREATININE KINASE:** 297 IU/L

[redacted] **20[redacted] ECG:** Sinus rhythm. Heart rate: 61 bpm. PQ: 140 msec. QRS: 92 msec. QTc: 389 msec. Shallow negativepositive T waves and isoelectric ST segments in I-aVL. Positive T waves and isoelectric ST segments in II-III-aVF. R transition: V2-V3. Deep negative-positive T waves and isoelectric ST segments in V2-V4. Flattened positive-negative T waves and isoelectric ST segments in V5-V6

[redacted] **20[redacted] ECHO:** The heart chambers are of normal size. The basal two-thirds of the septum is slightly hypokinetic. Good left ventricular function. Good right ventricular systolic function. There is no evidence of thrombi in the heart chambers. The pericardial fluid is 2 to 3 mm in size at the right ventricle.

[redacted] **20[redacted] EKG:** ischemia in the area supplied by the LAD, positive-negative T waves in I-aVL and negative T waves in V1 through V6 in addition to a sinus rhythm

[redacted] **20[redacted] HDL:** 1.47 MMOL/L

[redacted] **20[redacted] HEMATOCRIT:** 31.10 %

[redacted] **20[redacted] HGB:** 10 G/DL

[redacted] **20[redacted] INR:** 0.93 NO UNIT

[redacted] **20[redacted] LACTATE DEHYDROGENASE:** 469 U/L

[redacted] **20[redacted] LDL:** 3.33 MMOL/L

[redacted] **20[redacted] PTT:** 12.70 SEC

[redacted] **20[redacted] RBC:** 3.79 million/mcL

[redacted] **20[redacted] TRIGLYCERIDE:** 1.12 MMOL/L

[redacted] **20[redacted] TROPONIN I:** 273.60 ng/L (normal 0 to 19)

[redacted] **20[redacted] X-RAY:** The diaphragm has distinct contours. The costophrenic angles are sharp. Currently, there is no evidence of abnormal intrapulmonary shadows. The vascular markings are normal. The heart is of normal size. The aorta is normal in diameter.

被験者番号 [redacted] (Investigator [redacted])

Reason for Narrative

Adverse Event Preferred Term(s)	Serious Adverse Event	Adverse Event Leading to Discontinuation of Study Drug	Death	Event of Interest
大腿骨頚部骨折	X			

Treatment Group	Age at Study Start	Sex	Race
ABT-494 30 mg QD	4[redacted]	MALE	WHITE

Medical History	Onset Year
OTHER: FRACTURE OF THE LEFT ANKLE	19[redacted]
OTHER: LEFT HAND V. FINGER FRACTURE	19[redacted]
OTHER: PLAQUE PSORIASIS	19[redacted]
OTHER: PAIN IN THE RIGHT HIP	20[redacted]

Prior Procedures	Procedure Year
Not reported.	

Tobacco Use	Status	Number/Day	Number of Years	Year Stopped
CHEWING TOBACCO	NEVER			
CIGARETTES	FORMER	1 PACK	18	20[redacted]
CIGARS	NEVER			
E-CIGARETTES	NEVER			
PIPES	NEVER			

Alcohol Use	Status	Number/Day
ALCOHOL	NEVER	

Study Drug Administration

Study Drug	Dose/Units	Route	Frequency	First Dose Date/Day	Last Dose Date/Day	Duration (Days)
ABT-494	30MG	ORAL	QD	[redacted]20[redacted] / 1	[redacted]20[redacted] / 169	169
ABT-494	30MG	ORAL	QD	[redacted]20[redacted] / 170	[redacted]20[redacted] / 392	223
ABT-494	30MG	ORAL	QD	[redacted]20[redacted] / 393	/	

Previous Therapy - Prior to baseline/enrollment

Medication Name (WHO Drug)	Dose/Units	Frequency	Start Year-Month / RX Day
BCG Vaccine	NOT REPORTED	NOT REPORTED	Y-M: 19[redacted]
FOLIC ACID	3 mg	OTHER: EVERY OTHER DAY	Y-M: 20[redacted]
METHOTREXATE	10 mg	EVERY WEEK	Y-M: 20[redacted]
SECUKINUMAB	150 mg	OTHER: EVERY 4 WEEKS	Y-M: 20[redacted]
ETORICOXIB	60 mg	QD	Y-M: 20[redacted] / -79

Other Medications - Medications taken within 30 days prior to each narrative event until AE stopped or end of study

Medication Name (WHO Drug)	Dose/Units	Frequency	Start Year-Month / RX Day	Stop Year-Month / RX Day
FOLIC ACID	3 mg	OTHER: EVERY OTHER DAY	Y-M: 20[redacted]	Not reported.
METHOTREXATE	10 mg	EVERY WEEK	Y-M: 20[redacted]	Not reported.
ETORICOXIB	60 mg	QD	Y-M: 20[redacted] / -79	Not reported.
ZINC	1 OTHER: DOSE	QD	Y-M: 20[redacted] / 322	Y-M: 20[redacted] / 323
ACICLOVIR	500 mg	OTHER: FIVE TIMES A DAY	Y-M: 20[redacted] / 322	Y-M: 20[redacted] / 328
NEUROBION	1 OTHER: CAPSULA	TID	Y-M: 20[redacted] / 322	Y-M: 20[redacted] / 328
EMOLLIENTS AND PROTECTIVES	1 OTHER: DOSE	BID	Y-M: 20[redacted] / 324	Y-M: 20[redacted] / 335

Event #1: Serious Adverse Event

Event Description RIGHT FEMORAL NECK FRACTURE

Preferred term 大腿骨頚部骨折

AE Onset Date / Rx Day [redacted]20[redacted] / 17

Age at AE Onset 4[redacted]

Laboratory Testing

NOT REPORTED

Microbiology

NOT REPORTED

SAE Supplemental Procedure

[redacted]20[redacted] (RX DAY 17): MRI: FEMORAL NECK FRACTURE; [redacted]20[redacted] (RX DAY 28): ABDOMINAL UH: NEGATIVE; HIP AP X-RAY: COXARTHROSIS; [redacted]20[redacted] (RX DAY 36): ISOTOPE EXAMINATION: NEGATIV; [redacted]20[redacted] (RX DAY 38): ABDOMINAL CT: NEGATIV; CHEST CT: NEGATIV; [redacted]20[redacted] (RX DAY 59): HIP MRI: FRACTURE LINE CAN BE IDENTIFIED, BUT HEALING, NO DISPLACEMENT; [redacted]20[redacted] (RX DAY 345): HIP MRI: NEGATIVE

AE Stopped Rx Day 345

Duration of AE 329 DAYS

Relation to Study Drug by Investigator	NO REASONABLE POSSIBILITY
Investigator Alternative Etiology	STRESS FRACTURE
Discontinued Study Drug Due to the Event	NO
SAE Criteria	REQUIRES OR PROLONGS HOSPITALIZATION

Generated: [redacted]
Program Source Code: [redacted]

Investigator No.: [redacted]

Subject Number: [redacted]

Protocol Number: M15-554

治験責任医師からの報告。本被験者はハンガリーの 4[redacted] 歳男性であり，ABT-494（ウパダシチニブ）の治験で盲検化された治験薬が投与され，右大腿骨頚部骨折の事象を発現した。

Event 1 の臨床経過：

関連する病歴は局面型乾癬，乾癬性関節炎，元喫煙者（1 日 1 箱を 18 年間）及び右股関節痛であった。

20[redacted] 年 [redacted] 月 [redacted] 日，被験者は右大腿骨頚部骨折を発現した。20[redacted] 年 [redacted] 月 [redacted] 日，右大腿骨頚部骨折は消失した。

組入れ前において右股関節痛の病歴があった。20[redacted] 年 [redacted] 月 [redacted] 日，MRI 検査が行われ，大腿骨頚部骨折が認められた。20[redacted] 年 [redacted] 月 [redacted] 日，被験者は右股関節痛の悪化のため入院した。外傷専門外科医はストレス骨折と判断した。20[redacted] 年 [redacted] 月 [redacted] 日，被験者は退院した。

被験者は肘杖を 2 本使用することを勧められ，理学療法を開始した。痛みは理学療法後に大幅に減少した。6 週間後，股関節の MRI 検査が行われ，著しい改善が認められた。

治験責任医師によれば，被験者は 20[redacted] 年 [redacted] 月から毎日ランニングをしていた。

The patient's past medications include:

SECUKINUMAB for PSORIATIC ARTHRITIS ([redacted] [redacted] 20[redacted] - [redacted] [redacted] 20[redacted])

Causality for UPADACITINIB (Blinded)

---

1) Femoral neck fracture (10016450) (Femoral neck fracture (10016450)) [v.22.1] [10016450]

Causality as per reporter (Drug/Vaccine): No reasonable possibility

Causality as per Mfr. (Drug/Vaccine): No reasonable possibility

Dechallenge: Not Applicable

Alternative Etiology for UPADACITINIB (Blinded)

Event of RIGHT FEMORAL NECK FRACTURE

- Investigator: STRESS FRACTURE.

- AbbVie: RISK FACTOR INCLUDES PRE-EXISTING PAIN IN THE RIGHT HIP and daily running training since [redacted] 20[redacted].

Relevant Laboratory & Other Diagnostic Tests

[redacted] **20[redacted] MRI:** Femoral neck fracture

[redacted] **20[redacted] MRI:** Hip: Fracture line can be identified, but healing, no displacement

[redacted] **20[redacted] MRI:** Hip: Negative

20[redacted] MRI HIP: SIGNIFICANT IMPROVEMENT.

被験者番号 [redacted] (Investigator [redacted])

Reason for Narrative

Adverse Event Preferred Term(s)	Serious Adverse Event	Adverse Event Leading to Discontinuation of Study Drug	Death	Event of Interest
肺炎	X	X		X

Treatment Group	Age at Study Start	Sex	Race
ABT-494 30 mg QD	6[redacted]	MALE	WHITE

Medical History	Onset Year
OTHER: LEFT WRIST FRACTURE	19[redacted]
OTHER: LEFT ANKLE FRACTURE	19[redacted]
OTHER: PSORIASIS VULGARIS	19[redacted]
HYPERTENSION	20[redacted]
OTHER: HYPERCHOLESTEROLEMIA	20[redacted]
OTHER: HYPERURICAEMIA	20[redacted]
OTHER: COLON HYPERPLASTIC POLYP	20[redacted]
OTHER: DIVERTICULOSIS SIGMAE	20[redacted]

Prior Procedures	Procedure Year
SURGERY: SQUINTING OPERATION OF THE RIGHT EYE	19[redacted]

Tobacco Use	Status	Number/Day	Number of Years	Year Stopped
CHEWING TOBACCO	NEVER			
CIGARETTES	NEVER			
CIGARS	NEVER			
E-CIGARETTES	NEVER			
PIPES	NEVER			

Alcohol Use	Status	Number/Day
ALCOHOL	CURRENT	Less than 2

Study Drug Administration

Study Drug	Dose/Units	Route	Frequency	First Dose Date/Day	Last Dose Date/Day	Duration (Days)
ABT-494	30MG	ORAL	QD	[redacted]20[redacted] / 1	[redacted]20[redacted] / 119	119

Previous Therapy - Prior to baseline/enrollment

Medication Name (WHO Drug)	Dose/Units	Frequency	Start Year-Month / RX Day
BCG Vaccine	NOT REPORTED	NOT REPORTED	Y-M: 19[redacted]
ALLOPURINOL	300 mg	QD	Y-M: 20[redacted]
LOSARTAN	50 mg	QD	Y-M: 20[redacted]
SIMVASTATIN	40 mg	QD	Y-M: 20[redacted]
FOLIC ACID	3 mg	OTHER: EVERY OTHER DAY	Y-M: 20[redacted]
METHOTREXATE	15 mg	EVERY WEEK	Y-M: 20[redacted]
INFLIXIMAB	8 mg/kg	OTHER: EVERY 8 WEEKS	Y-M: 20[redacted]

Other Medications - Medications taken within 30 days prior to each narrative event until AE stopped or end of study

Medication Name (WHO Drug)	Dose/Units	Frequency	Start Year-Month / RX Day	Stop Year-Month / RX Day
ALLOPURINOL	300 mg	QD	Y-M: 20[redacted]	ONGOING
SIMVASTATIN	40 mg	QD	Y-M: 20[redacted]	ONGOING
LOSARTAN	50 mg	QD	Y-M: 20[redacted]	Y-M: 20[redacted] / 139
FOLIC ACID	3 mg	OTHER: EVERY OTHER DAY	Y-M: 20[redacted]	ONGOING
METHOTREXATE	15 mg	EVERY WEEK	Y-M: 20[redacted]	ONGOING
MOXIFLOXACIN	400 mg	QD	Y-M: 20[redacted] / 117	Y-M: 20[redacted] / 119
CLARITHROMYCIN	500 mg	TID	Y-M: 20[redacted] / 119	Y-M: 20[redacted] / 131
MEROPENEM	1 g	TID	Y-M: 20[redacted] / 119	Y-M: 20[redacted] / 131
ACETYLCYSTEINE	600 mg	QD	Y-M: 20[redacted] / 131	ONGOING
DIHYDROXYALUMINUM SODIUM CARBONATE	40 mg	QD	Y-M: 20[redacted] / 131	ONGOING
FUROSEMIDE	40 mg	QD	Y-M: 20[redacted] / 131	ONGOING
POTASSIUM	600 mg	BID	Y-M: 20[redacted] / 131	ONGOING
THEOPHYLLINE	150 mg	BID	Y-M: 20[redacted] / 131	ONGOING
HYZAAR	100/25 mg	QD	Y-M: 20[redacted] / 140	ONGOING

Event #1: Serious Adverse Event, AE Leading to Discontinuation of Study Drug, Study Specific Adverse Events of Interest

Event Description	PNEUMONIA
Preferred term	肺炎
AE Onset Date / Rx Day	[redacted]20[redacted] / 117
Age at AE Onset	6[redacted]
Laboratory Testing	
[redacted]20[redacted] (RX DAY 120): NPTST056-CRP: 261.3 [0 - 5] mg/L	
Microbiology	
[redacted]20[redacted] (RX DAY 131): OTHER NOSE SECRETIONS NPTST143-MICROBIOLOGICAL CULTURE: NEGATIVE-STAPHYLOCOOCUS AUREUS CANNOT BE DETECTED; OTHER TRACHEA SECRETIONS NPTST143-MICROBIOLOGICAL CULTURE: POSITIVE-CANDIDA ALBICANS	
SAE Supplemental Procedure	
[redacted]20[redacted] (RX DAY 119): CHEST X RAY: SEVERE BILATERAL PNEUMONIA; OXYGEN THERAPY: END DATE [redacted]-[redacted]20[redacted]; [redacted]20[redacted] (RX DAY 134): CHEST CT SCAN: PNEUMONIA	
AE Stopped Rx Day	155 (36 DAYS AFTER LAST TREATMENT)
Duration of AE	39 DAYS
Relation to Study Drug by Investigator	NO REASONABLE POSSIBILITY
Investigator Alternative Etiology	INFECTION
Discontinued Study Drug Due to the Event	YES
SAE Criteria	REQUIRES OR PROLONGS HOSPITALIZATION

Generated: [redacted]
Program Source Code: [redacted]

Investigator No.: [redacted]

Subject Number: [redacted]

Protocol Number: M15-554

治験責任医師からの報告。本被験者はハンガリーの 6[redacted] 歳男性であり，ABT-494（ウパダシチニブ）の治験で盲検化された治験薬が投与され，肺炎の事象を発現した。

Event 1 の臨床経過：

関連する病歴は高血圧，乾癬性関節炎，非喫煙者及び現飲酒者（1 日 2 杯未満）であった。

20[redacted] 年 [redacted] 月 [redacted] 日，被験者は肺炎を発現した。20[redacted] 年 [redacted] 月 [redacted] 日，肺炎は消失した。

20[redacted] 年 [redacted] 月 [redacted] 日，咳嗽，喀出を伴う軽度の息詰まり及び発熱が認められた。同日，抗生物質の投与が開始された。20[redacted] 年 [redacted] 月 [redacted] 日，被験者は，症状が悪化したため救急治療室を受診した。被験者は重度の両側性肺炎のため ICU に入院した。酸素及び薬物の投与が行われた。本事象に

より治験薬の投与が完全に中止された。20[redacted] 年 [redacted] 月 [redacted] 日，被験者は状態が改善し，内科病棟に転棟した。20[redacted] 年 [redacted] 月 [redacted] 日，被験者は著しく改善した状態で退院した。

被験者はリハビリテーションのために別の施設に入院していた。被験者は 20[redacted] 年 [redacted] 月 [redacted] 日に同リハビリテーション施設を退院した。

投与された薬剤は，acc long，moxibiot，クラリスロマイシン，メロペネム及び theospirex であった。

The patient's past medications include:

REMICADE for PSORIATIC ARTHRITIS ([redacted] [redacted] 20[redacted] - [redacted] [redacted] 20[redacted])

Causality for UPADACITINIB (Blinded)

---

1) Pneumonia (10035664) (Pneumonia (10035664)) [v.22.0] [10035664]

Causality as per reporter (Drug/Vaccine): No reasonable possibility

Causality as per Mfr. (Drug/Vaccine): Reasonable possibility

Dechallenge: Yes

Rechallenge: No rechallenge was done, recurrence is not applicable

Alternative Etiology for UPADACITINIB (Blinded)

Event of PNEUMONIA

- Investigator: INFECTION

- AbbVie: Not applicable

Relevant Laboratory & Other Diagnostic Tests

[redacted] [redacted] **20[redacted] CHEST CT SCAN:** PNEUMONIA.

[redacted] **20[redacted] CHEST X-RAY:** Severe bilateral pneumonia

[redacted] **20[redacted] CHEST X-RAY (SCREENING):** Normal

[redacted] **20[redacted] CRP:** 261.3 MG/L (normal 0 to 5)

[redacted] **20[redacted] CULTURE:** Trachea secretions: Positive Candida albicans

[redacted] **20[redacted] CULTURE:** Nasal: Negative Staphylococcus aureas

被験者番号 [redacted] (Investigator [redacted])

Reason for Narrative

Adverse Event Preferred Term(s)	Serious Adverse Event	Adverse Event Leading to Discontinuation of Study Drug	Death	Event of Interest
乾癬性関節症	X	X		

Treatment Group	Age at Study Start	Sex	Race
ABT-494 15 mg QD	5[redacted]	MALE	WHITE

Medical History	Onset Year
CLOTTING/BLEEDING PROBLEMS: DEEP VEIN THROMBOSIS	NOT REPORTED
DIABETES MELLITUS	NOT REPORTED
HYPERTENSION	NOT REPORTED
LIVER DISEASE (EXCLUDING HEPATITIS): HEPATHOPATHIA	NOT REPORTED
OSTEOPOROSIS	NOT REPORTED
OTHER: RIB FRACTURES	NOT REPORTED
OTHER: PSORIASIS VULGARIS	19[redacted]

Prior Procedures	Procedure Year
Not reported.	

Tobacco Use	Status	Number/Day	Number of Years	Year Stopped
CHEWING TOBACCO	NEVER			
CIGARETTES	CURRENT	1 PACK	20	
CIGARS	NEVER			
E-CIGARETTES	NEVER			
PIPES	NEVER			

Alcohol Use	Status	Number/Day
ALCOHOL	NEVER	

Study Drug Administration

Study Drug	Dose/Units	Route	Frequency	First Dose Date/Day	Last Dose Date/Day	Duration (Days)
ABT-494	15MG	ORAL	QD	[redacted]20[redacted] /	[redacted]20[redacted] / 168	168
ABT-494	15MG	ORAL	QD	[redacted]20[redacted] / 169	[redacted]20[redacted] / 385	217
ABT-494	15MG	ORAL	QD	[redacted]20[redacted] / 386	[redacted]20[redacted] / 717	332

Previous Therapy - Prior to baseline/enrollment

Medication Name (WHO Drug)	Dose/Units	Frequency	Start Year-Month / RX Day
ACENOCOUMAROL	4 mg	QD	Y-M: 20[redacted]
METFORMIN	1000 mg	QD	Y-M: 20[redacted]
FOLIC ACID	5 mg	QD	Y-M: 20[redacted]-
METHOTREXATE	20 mg	EVERY WEEK	Y-M: 20[redacted]-
INFLIXIMAB	600 mg	EVERY WEEK	Y-M: 20[redacted]-
CELECOXIB	200 mg	QD	Y-M: 20[redacted]-
GOLIMUMAB	100 mg	OTHER: EVERY MONTH	Y-M: 20[redacted]-
DULAGLUTIDE	1.5 mg	EVERY WEEK	Y-M: 20[redacted]
GLIMEPIRIDE	2 mg	QD	Y-M: 20[redacted]
NEBIVOLOL	5 mg	QD	Y-M: 20[redacted]
SEBULEX	1 OTHER: APPLICATION	EVERY WEEK	Y-M: 20[redacted]
ADALIMUMAB	40 mg	EVERY WEEK	Y-M: 20[redacted]-
COLECALCIFEROL	1000 IU	QD	Y-M: 20[redacted]-
ETANERCEPT	50 mg	EVERY WEEK	Y-M: 20[redacted]-
METHOTREXATE	20 mg	EVERY WEEK	Y-M: 20[redacted]-

Other Medications - Medications taken within 30 days prior to each narrative event until AE stopped or end of study

Medication Name (WHO Drug)	Dose/Units	Frequency	Start Year-Month / RX Day	Stop Year-Month / RX Day
ACENOCOUMAROL	4 mg	QD	Y-M: 20[redacted]	Y-M: 20[redacted]- / 716
METFORMIN	1000 mg	QD	Y-M: 20[redacted]	Y-M: 20[redacted]- / 716
FOLIC ACID	5 mg	QD	Y-M: 20[redacted]-	ONGOING
CELECOXIB	200 mg	QD	Y-M: 20[redacted]-	ONGOING
NEBIVOLOL	5 mg	QD	Y-M: 20[redacted]	ONGOING
SEBULEX	1 OTHER: APPLICATION	EVERY WEEK	Y-M: 20[redacted]	ONGOING
GLIMEPIRIDE	2 mg	QD	Y-M: 20[redacted]	Y-M: 20[redacted]- /

DULAGLUTIDE	1.5 mg	EVERY WEEK	Y-M: 20[redacted]	716 Y-M: 20[redacted] / 743
COLECALCIFEROL	1000 IU	QD	Y-M: 20[redacted]-	ONGOING
METHOTREXATE	20 mg	EVERY WEEK	Y-M: 20[redacted]-	ONGOING
BI PREDONIUM	4/1.25 mg	QD	Y-M: 20[redacted]- / 716	ONGOING
COLCHICINE	0,5 mg	BID	Y-M: 20[redacted]- / 716	ONGOING
FAMOTIDINE	40 mg	QD	Y-M: 20[redacted]- / 716	ONGOING
FUROSEMIDE	40 mg	OTHER: EVERY TWO DAYS	Y-M: 20[redacted]- / 716	ONGOING
GLICLAZIDE	60 mg	QD	Y-M: 20[redacted]- / 716	ONGOING
METHYLPREDNISOLONE	60 mg	BID	Y-M: 20[redacted]- / 716	ONGOING
POTASSIUM	600 mg	QD	Y-M: 20[redacted]- / 716	ONGOING
RIVAROXABAN	20 mg	QD	Y-M: 20[redacted]- / 716	ONGOING
SULFASALAZINE	500 mg	TID	Y-M: 20[redacted]- / 716	ONGOING
VELMETIA	50 mg	BID	Y-M: 20[redacted]- / 716	ONGOING

Event #1: Serious Adverse Event, AE Leading to Discontinuation of Study Drug

Event Description	ARTHRITIS PSORIATICA
Preferred term	乾癬性関節症
AE Onset Date / Rx Day	[redacted]20[redacted] / 652
Age at AE Onset	5[redacted]

Laboratory Testing

[redacted]20[redacted] (RX DAY 723): Creatinine: 82 [53 - 115] umol/L; Hematocrit: 0 [0 - 0] fraction of 1; Hemoglobin: 150 [115 - 150] g/L; Leukocytes: 14.70 [4.2 - 10.8] g/L; NPTST057-CRP (C REAKTIV PROTEIN): 113.3 [8 - 100] mg/L; NPTST082-ERYTHROCYTE SEDIMENTATION RATE: 92 [2 - 20] mm/h; NPTST097-GOT (GLUTAMAT-OXALACETAT ASZPAR: 11 [40 - 40] U/L; NPTST098-GPT (GLUTAMAT-PIRUVAT ALANIN-AM: 21 [40 - 40] U/L; NPTST123-KARBAMID: 7.7 [2.6 - 6.7] mmol/L; NPTST199-THR (THROMBOCITA): 533 [150 - 400] g/L; [redacted]20[redacted] (RX DAY 728): Hematocrit: 0 [0 - 0] fraction of 1; Hemoglobin: 131 [115 - 150] g/L; NPTST058-CRP (C REAKTIV PROTEIN): 34.9 [8 - 100] mg/L; NPTST082-ERYTHROCYTE SEDIMENTATION RATE: 31 [2 - 20] mm/h; NPTST090-FVS: 20.6 [66 - 80] g/L; NPTST122-KALIUM: 4.3 [3.5 - 5.3] mmol/L; NPTST151-NATRIUM: 137 [133 - 148] mmol/L; NPTST200-THROMBOCITA: 591 [150 - 400] g/L

Microbiology

[redacted]20[redacted] (RX DAY 717): OTHER SYNOVIA NPTST125-KNEE PUNCTURE: NEGATIVE-PCR NEGATIVE (MYCOBACTERIUM TUBERCOLOSIS) KOCH: NEGATIV

SAE Supplemental Procedure

[redacted]20[redacted] (RX DAY 718): KNEE X-RAYS: SYNOVIALIS POLIFERATIO; [redacted]20[redacted] (RX DAY 721): CHEST X-RAY: NEGATIVE; [redacted]20[redacted] (RX DAY 722): COLORDOPPLER EXAMINATION: DEEP

VEIN THROMBOSIS NOT DEMONSTRATED; [redacted] 20[redacted] (RX DAY 728): COLOR-DOPPLER EXAMINATION CONTROLL: NEGATIVE

AE Stopped Rx Day	ONGOING
Duration of AE	ONGOING
Relation to Study Drug by Investigator	NO REASONABLE POSSIBILITY
Investigator Alternative Etiology	SECONDARY LOSS OFF EFFICACY
Discontinued Study Drug Due to the Event	YES
SAE Criteria	REQUIRES OR PROLONGS HOSPITALIZATION

Generated: [redacted]
Program Source Code: [redacted]

Investigator No.: [redacted]

Subject Number: [redacted]

Protocol Number: M15-554

治験責任医師からの報告。本被験者はハンガリーの 5[redacted] 歳男性であり，ABT-494（ウパダシチニブ）の治験で盲検化された治験薬が投与され，乾癬性関節炎の事象を発現した。

Event 1 の臨床経過：
関連する病歴は尋常性乾癬，乾癬性関節炎，深部静脈血栓症，糖尿病，現喫煙者（1 日 1 箱を 20 年間）及び非飲酒者であった。

20[redacted] 年 [redacted] 月，被験者は乾癬性関節炎を発現した。

20[redacted] 年 [redacted] 月 [redacted] 日，被験者は脱力及び関節痛のため入院した。被験者には右膝関節滑膜炎と多発性関節炎の徴候があった。被験者は膝関節穿刺を受けた。高用量ステロイド療法及び理学療法により被験者の炎症パラメータは低下し，滑膜炎は軽減した。20[redacted] 年 [redacted] 月 [redacted] 日，被験者は退院した。

The patient's past medications include:

METHOTREXAT for PSORIATIC ARTHRITIS ([redacted] 20[redacted] - [redacted] 20[redacted])

REMICADE for PSORIATIC ARTHRITIS ([redacted] 20[redacted] - [redacted] 20[redacted])

SIMPONI for PSORIATIC ARTHRITIS ([redacted] 20[redacted] - [redacted] 20[redacted])

HUMIRA for PSORIATIC ARTHRITIS ([redacted] 20[redacted] - [redacted] 20[redacted])

ENBREL for PSORIATIC ARTHRITIS ([redacted] 20[redacted] - [redacted] 20[redacted])

Causality for UPADACITINIB (Blinded)

---

1) Psoriatic arthritis (10037160) (Psoriatic arthropathy (10037162)) [v.23.0] [10037160]

Causality as per reporter (Drug/Vaccine): No reasonable possibility

Causality as per Mfr. (Drug/Vaccine): No reasonable possibility

Dechallenge: No

Alternative Etiology for UPADACITINIB (Blinded)

Event of ARTHRITIS PSORIATICA

- Investigator: Secondary loss of efficacy

- AbbVie: Event more likely related to pre-existing psoriatic arthritis.

Relevant Laboratory & Other Diagnostic Tests

[redacted] **20[redacted] CHEST XRAY:** negative

[redacted] **20[redacted] COLOR DOPPLER:** negative

[redacted] **20[redacted] CRP:** 113.3 MG/L (normal 8 to 100)

[redacted] **20[redacted] CRP:** 34.9 U/L (normal 8 to 100)

[redacted] **20[redacted] DOPPLER:** No deep vein thrombosis

[redacted] **20[redacted] FVS:** 20.6 U/L (normal 66 to 80)

[redacted] **20[redacted] GLUTAMÁT-OXÁLACETÁT ASZPARTÁT AMINOTRANSZFERÁZ:** 11 U/L (normal 40 to 40)

[redacted] **20[redacted] GLUTAMÁT-PIRUVÁT ALANIN-AMINOTRANSZFERÁZ:** 21 U/L (normal 40 to 40)

[redacted] **20[redacted] KARBAMID:** 7.7 MMOL/L (normal 2.6 to 6.7)

[redacted] **20[redacted] (SYNOVIA) KNEE PUNCTURE:** PCR NEGATIVE (MYCOBACTERIUM TUBERCOLOSIS) KOCH: NEGATIVE

[redacted] **20[redacted] THROMBOCYTES:** 533 G/L (normal 150 to 400)

[redacted] **20[redacted] THROMBOCYTES:** 591 G/L (normal 150 to 400)

[redacted] **20**[redacted] **WBC:** 14.7 G/L (normal 4.2 to 10.8)

[redacted] **20**[redacted] **X-RAY:** KNEE: synovialis poliferatio

被験者番号 [redacted] (Investigator [redacted])

Reason for Narrative

Adverse Event Preferred Term(s)	Serious Adverse Event	Adverse Event Leading to Discontinuation of Study Drug	Death	Event of Interest
子宮頚部上皮異形成	X			

Treatment Group	Age at Study Start	Sex	Race
ABT-494 15 mg QD	5[redacted]	FEMALE	WHITE

Medical History	Onset Year
OTHER: PLAQUE PSORIASIS	19[redacted]
DEPRESSION: BURNOUT	20
OTHER: STRESS FRACTURE RIGHT FOOT	20
OTHER: LUMBO ISCHIALGIA PAIN	20
OTHER: NAIL PSORIASIS	20
DEPRESSION: MILD CONTROLLED WITH MEDICATION	20
CLOTTING/BLEEDING PROBLEMS: TROMBOSIS LEFT UPPER ARM	20
OTHER: CERVICAL DISCARTROSIS	20
OTHER: POSTMENOPAUSAL	20
OTHER: BILATERAL HALLUX VALGUS	20
OTHER: EPICONDYLITIS LATERALIS RIGHT	20

Prior Procedures	Procedure Year
SURGERY: LUYMBALE SURGERY	20[redacted]
SURGERY: ANTEROLATERAL SPONDYLODESIS L3/L4 AND L4/L5	20

Tobacco Use	Status	Number/Day	Number of Years	Year Stopped
CHEWING TOBACCO	NEVER			
CIGARETTES	CURRENT	1 PACK	40	
CIGARS	NEVER			
E-CIGARETTES	NEVER			
PIPES	NEVER			

Alcohol Use	Status	Number/Day
ALCOHOL	NEVER	

Study Drug Administration

Study Drug	Dose/Units	Route	Frequency	First Dose Date/Day	Last Dose Date/Day	Duration (Days)
ABT-494	15MG	ORAL	QD	[redacted]20[redacted] / 1	[redacted]20[redacted] / 168	168
ABT-494	15MG	ORAL	QD	[redacted]20[redacted] / 169	[redacted]20[redacted] / 392	224
ABT-494	15MG	ORAL	QD	[redacted]20[redacted] / 393	/	

Previous Therapy - Prior to baseline/enrollment

Medication Name (WHO Drug)	Dose/Units	Frequency	Start Year-Month / RX Day
PAROXETINE	20 mg	QD	Y-M: 20[redacted]
OXYCODONE	20 mg	PRN	Y-M: 20[redacted]
SULFASALAZINE	500 mg	QD	Y-M: 20[redacted]
SULFASALAZINE	500 mg	BID	Y-M: 20[redacted]
SULFASALAZINE	500 mg	TID	Y-M: 20[redacted]
SULFASALAZINE	1000 mg	BID	Y-M: 20[redacted]
FOLIC ACID	5 mg	EVERY WEEK	Y-M: 20[redacted]
METHOTREXATE	10 mg	EVERY WEEK	Y-M: 20[redacted]
METHOTREXATE	15 mg	EVERY WEEK	Y-M: 20[redacted]
FOLIC ACID	10 mg	EVERY WEEK	Y-M: 20[redacted]
METHOTREXATE	20 mg	EVERY WEEK	Y-M: 20[redacted]
FENTANYL	100 OTHER: MCG	QD	Y-M: 20[redacted]
NAPROXEN	500 mg	PRN	Y-M: 20[redacted]
SULFASALAZINE	500 mg	BID	Y-M: 20[redacted]
SULFASALAZINE	500 mg	TID	Y-M: 20[redacted]
SULFASALAZINE	1000 mg	BID	Y-M: 20[redacted]
ETANERCEPT	50 mg	EVERY WEEK	Y-M: 20[redacted]
ETANERCEPT	25 mg	OTHER: TWO TIMES A WEEK	Y-M: 20[redacted]
ADALIMUMAB	40 mg	EVERY 2 WEEKS	Y-M: 20[redacted]

Other Medications - Medications taken within 30 days prior to each narrative event until AE stopped or end of study

Medication Name (WHO Drug)	Dose/Units	Frequency	Start Year-Month / RX Day	Stop Year-Month / RX Day
PAROXETINE	20 mg	QD	Y-M: 20[redacted]	Not reported.
FOLIC ACID	10 mg	EVERY WEEK	Y-M: 20[redacted]	Y-M: 20[redacted] / 240
METHOTREXATE	20 mg	EVERY WEEK	Y-M: 20[redacted]	Y-M: 20[redacted] / 240
FENTANYL	100 OTHER: MCG	QD	Y-M: 20[redacted]	Not reported.
NAPROXEN	500 mg	PRN	Y-M: 20[redacted]	Not reported.
SULFASALAZINE	1000 mg	BID	Y-M: 20[redacted]	Not reported.

PANTOPRAZOLE	40 mg	QD	Y-M: 20[redacted] / 233	Not reported.
TIBOLONE	2.5 mg	QD	Y-M: 20[redacted] / 233	Not reported.
HPV VACCINE	0.5 mL	QD	Y-M: 20[redacted] / 253	Y-M: 20[redacted] / 253
METHOTREXATE	15.0 mg	EVERY WEEK	Y-M: 20[redacted] / 652	Y-M: 20[redacted] / 708
FOLIC ACID	5.0 mg	EVERY WEEK	Y-M: 20[redacted] / 653	Y-M: 20[redacted] / 708
VALACICLOVIR	500.0 mg	TID	Y-M: 20[redacted] / 678	Y-M: 20[redacted] / 687

Event #1: Serious Adverse Event

Event Description	HIGH-GRADE SQUAMOUS INTRAEPITHELIAL LESIONS (CIN2)
Preferred term	子宮頚部上皮異形成
AE Onset Date / Rx Day	[redacted]20[redacted] / 230
Age at AE Onset	5[redacted]

Laboratory Testing
NOT REPORTED

Microbiology
[redacted]20[redacted] (RX DAY 230): OTHER CERVIX BIOSY NPTST158-PAP SMEAR: POSITIVE-HSIL (CIN2)

SAE Supplemental Procedure
[redacted]20[redacted] (RX DAY 230): COLPOSCOPY: HIGH GRADE LESSION; [redacted]20[redacted] (RX DAY 253): LLETZ PROCEDURE: DYSPLASIA TREATED

AE Stopped Rx Day	253
Duration of AE	24 DAYS
Relation to Study Drug by Investigator	NO REASONABLE POSSIBILITY
Investigator Alternative Etiology	FEMALE SUBJECT
Discontinued Study Drug Due to the Event	NO
SAE Criteria	OTHER MEDICALLY IMPORTANT SERIOUS EVENT

Generated: [redacted]
Program Source Code: [redacted]

Investigator No.: [redacted]

Subject Number: [redacted]

Protocol Number: M15-554

治験責任医師からの報告。本被験者はベルギーの 5[redacted] 歳女性であり，ABT-494（ウパダシチニブ）の治験で盲検化された治験薬が投与され，高度扁平上皮内病変（CIN2）の事象を発現した。

Event 1 の臨床経過：

関連する病歴は乾癬性関節炎，閉経後，現紙巻タバコ喫煙者（1 日 1 箱を 40 年間）及び禁酒であった。

20[redacted] 年 [redacted] 月 [redacted] 日，被験者は高度扁平上皮内病変（CIN2）を発現した。20[redacted] 年 [redacted] 月 [redacted] 日，高度扁平上皮内病変（CIN2）は消失した。

定期婦人科検査で，高度扁平上皮内病変（CIN2）が認められた。20[redacted] 年 [redacted] 月 [redacted] 日，被験者は入院した。砕石位にて全身麻酔下で大口径ループ型電極を用いた移行帯ループ切除術（LLETZ）が行われた。ルゴール検査の結果は陰性であった。異形成の治療は成功した。同日，被験者は退院した。

投与された薬剤はサーバリックスであった。

Causality for UPADACITINIB (Blinded)

---

1) High grade squamous intraepithelial lesion (10064451) (Cervical dysplasia (10008263)) [v.22.1] [10064451]

Causality as per reporter (Drug/Vaccine): No reasonable possibility

Causality as per Mfr. (Drug/Vaccine): No reasonable possibility

Dechallenge: Yes

Rechallenge: No rechallenge was done, recurrence is not applicable

Alternative Etiology for UPADACITINIB (Blinded)

Event of HIGH-GRADE SQUAMOUS INTRAEPITHELIAL LESIONS (CIN2)

- **Investigator:** FEMALE SUBJECT

- **AbbVie:** EVENT'S ETIOLOGY COMMONLY ASSOCIATED WITH HPV INFECTION. ADDITIONAL RISK FACTOR INCLUDES CURRENT SMOKING STATUS.

Relevant Laboratory & Other Diagnostic Tests

[redacted] **20[redacted] CERVIX BIOSY PAP SMEAR:** HSIL (CIN2)　MACROSCOPIC EXAMINATION: Specimen with dimensions 2.5 x 1 x 0.2 cm. Layered and fully enclosed in B1 to B3. MICROSCOPIC EXAMINATION: The biopsies are constructed of endocervix and exocervix. For the time being, no transformation zone was observed. The endocervix is outlined with a properly differentiated, single-layered, mucinous epithelium. The exocervical squamous epithelium displayed normal stratification and retained maturation.The deeper sections revealed a limited transformation zone containing the presence of obvious koilocytosis. For the most part, we did not observe widening of the basal cell layer or high reaching mitoses. These areas were consistent with an LSIL. In biopsy B1 we observed a zone at the edge of one section in which the epithelial cells appeared extensively coagulated. Morphologically, the entire epithelium appeared to be taken over by atypical cells. However, the nuclear detail was not properly readable. However, a diffuse aberrant expression of p16 was present here. The Ki-67 stain showed a proliferation reaching up into the superior layers of the epithelium. This zone was consistent with an HSIL. The dysplastic epithelium reached up into the section here. No evidence of invasion. No abnormalities of the underlying stroma. ADDITIONAL TECHNIQUES: B2: Ki-67 stain: no increase in the proliferative compartment. However, staining of a few koilocytes. CONCLUSION: LLETZ conisation: HSIL, focally reaching up into the section.

[redacted] **20[redacted] COLPOSCOPY:** HIGH GRADE LESSION

被験者番号 [redacted] (Investigator [redacted])

Reason for Narrative

Adverse Event Preferred Term(s)	Serious Adverse Event	Adverse Event Leading to Discontinuation of Study Drug	Death	Event of Interest
インフルエンザ性肺炎	X			X

Treatment Group	Age at Study Start	Sex	Race
ABT-494 30 mg QD	6[redacted]	FEMALE	WHITE

Medical History	Onset Year
OTHER: TINNITUS	20[redacted]
OTHER: GASTRIC BLEEDING	20[redacted]
OTHER: TRAPEZIUS SYNDROME	20[redacted]
CARDIAC ARRHYTHMIA: SINUSAL TACHYCARDIA	20[redacted]
OTHER: PLAQUES PSORIASIS	20[redacted]

Prior Procedures	Procedure Year
SURGERY: HYSTERECTOMIA	19[redacted]
SURGERY: MENISCUS SURGERY	19[redacted]

Tobacco Use	Status	Number/Day	Number of Years	Year Stopped
CHEWING TOBACCO	NEVER			
CIGARETTES	CURRENT	0.5 PACK	20	
CIGARS	NEVER			
E-CIGARETTES	NEVER			
PIPES	NEVER			

Alcohol Use	Status	Number/Day
ALCOHOL	NEVER	

Study Drug Administration

Study Drug	Dose/Units	Route	Frequency	First Dose Date/Day	Last Dose Date/Day	Duration (Days)
ABT-494	30MG	ORAL	QD	[redacted]20[redacted] / 1	[redacted]20[redacted] / 168	168
ABT-494	30MG	ORAL	QD	[redacted]20[redacted] / 169	[redacted]20[redacted] / 385	217
ABT-494	30MG	ORAL	QD	[redacted]20[redacted] / 386	/	

Previous Therapy - Prior to baseline/enrollment

Medication Name (WHO Drug)	Dose/Units	Frequency	Start Year-Month / RX Day
OMEPRAZOLE	20 mg	QD	Y-M: 20[redacted]
DIAZEPAM	2.5 mg	QD	Y-M: 20[redacted]
FLUPENTIXOL	0.5 mg	QD	Y-M: 20[redacted]
PROPRANOLOL	40 mg	BID	Y-M: 20[redacted]
HYDROCORTISONE	1 OTHER: APPLICATION	PRN	Y-M: 20[redacted]
UREA	1 OTHER: APLLICATION	PRN	Y-M: 20[redacted]
SULFASALAZINE	2 g	PRN	Y-M: 20[redacted]
METHOTREXATE	15 mg	OTHER: SINGLE DOSE	Y-M: 20[redacted] / -129
ADALIMUMAB	40 mg	EVERY 2 WEEKS	Y-M: 20[redacted] / -99
METHYLPREDNISOLONE	1 mL	QD	Y-M: 20[redacted] / -34
DIPROSPAN	1 mL	QD	Y-M: 20[redacted] / -32
PARACETAMOL	500 mg	PRN	Y-M: 20[redacted] / -12

Other Medications - Medications taken within 30 days prior to each narrative event until AE stopped or end of study

Medication Name (WHO Drug)	Dose/Units	Frequency	Start Year-Month / RX Day	Stop Year-Month / RX Day
OMEPRAZOLE	20 mg	QD	Y-M: 20[redacted]	Not reported.
DIAZEPAM	2.5 mg	QD	Y-M: 20[redacted]	Not reported.
FLUPENTIXOL	0.5 mg	QD	Y-M: 20[redacted]	Not reported.
PROPRANOLOL	40 mg	BID	Y-M: 20[redacted]	Not reported.
PARACETAMOL	500 mg	PRN	Y-M: 20[redacted] / -12	Not reported.
CORICIDIN	1 OTHER: TABLET	BID	Y-M: 20[redacted] / 368	Y-M: 20[redacted] / 378
SOFRASOLONE O.R.L.	1 OTHER: APPLICATION	PRN	Y-M: 20[redacted] / 368	Y-M: 20[redacted] /378
PARACETAMOL	1 g	PRN	Y-M: 20[redacted] / 385	Not reported.
BRONCHOSEDAL	5 mL	PRN	Y-M: 20[redacted] / 385	Y-M: 20[redacted] / 392
COMBIVENT	2.5 mL	QID	Y-M: 20[redacted] / 392	Y-M: 20[redacted] / 399
ENOXAPARIN	40 mg	QD	Y-M: 20[redacted] /	Y-M: 20[redacted] /

			392	399
MICONAZOLE	1 OTHER: APLLICATION	PRN	Y-M: 20[redacted] / 400	Y-M: 20[redacted] /405
FLUCONAZOLE	50 mg	QD	Y-M: 20[redacted] / 406	Y-M: 20[redacted] /416

Event #1: Serious Adverse Event, Study Specific Adverse Events of Interest

Event Description	PNEUMONIA INFLUENZAL
Preferred term	インフルエンザ性肺炎
AE Onset Date / Rx Day	[redacted]20[redacted] / 385
Age at AE Onset	6[redacted]

Laboratory Testing
[redacted]20[redacted] (RX DAY 392): NPTST056-CRP: 12.8 [0 - 3] mg/L

Microbiology
[redacted]20[redacted] (RX DAY 395): SPUTUM NPTST145-MOLECULAR BIOLOGY: POSITIVE-INFLUENZA A VIRUS RNA

SAE Supplemental Procedure
[redacted]20[redacted] (RX DAY 392): CT PNEUMANGIOGRAPHY: BIBASAL INFILTRATE COMPATIBLE WITH VIRAL PNEUMONIA

AE Stopped Rx Day	NOT REPORTED
Duration of AE	NOT REPORTED
Relation to Study Drug by Investigator	NO REASONABLE POSSIBILITY
Investigator Alternative Etiology	INFLUENZA A VIRUS
Discontinued Study Drug Due to the Event	NO
SAE Criteria	REQUIRES OR PROLONGS HOSPITALIZATION

Generated: [redacted]
Program Source Code: [redacted]

Investigator No.: [redacted]

Subject Number: [redacted]

Protocol Number: M15-554

治験責任医師からの報告。本被験者はベルギーの 6[redacted] 歳女性であり，ABT-494（ウパダシチニブ）の治験で盲検化された治験薬が投与され，インフルエンザ性肺炎の事象を発現した。

Event 1 の臨床経過：
関連する病歴は子宮摘出術，洞性頻脈，乾癬性関節炎，非飲酒者及び現喫煙者（1 日 0.5 箱を 20 年間）であった。

20[redacted] 年 [redacted] 月 [redacted] 日，被験者はインフルエンザ性肺炎を発現した。

20[redacted] 年 [redacted] 月 [redacted] 日，被験者は重度の咳嗽，発熱，全身倦怠及びインフルエンザ様症状で病院を受診した。胸部 CT 検査でインフルエンザ A 型肺炎が認められ，呼吸器検体の分子生物学的検査でインフルエンザウイルス A 型が認められた。被験者は同日に入院し対症療法を受けた。被験者の状態は改善し，20[redacted] 年 [redacted] 月 [redacted] 日に退院した。

投与された薬剤は，クレキサン，dafalgan，bronchosedal 及び combivent であった。

The patient's past medications include:

CORTISONE CREAM for PSORIASIS (20[redacted] - [redacted] 20[redacted])

UREUM CREAM for PSORIASIS (20[redacted] - [redacted] 20[redacted])

SULPHASALAZINE for PSORIATIC ARTHRITIS ([redacted] 20[redacted] - [redacted] 20[redacted])

METHOTREXATE for PSORIATIC ARTHRITIS ([redacted] 20[redacted] - [redacted] 20[redacted])

HUMIRA for PSORIATIC ARTHRITIS ([redacted] 20[redacted] - [redacted] 20[redacted])

DEPO MEDROL for PSORIATIC ARTHRITIS ([redacted] 20[redacted] - [redacted] 20[redacted])

DIPROPHOS for PSORIATIC ARTHRITIS ([redacted] 20[redacted] - [redacted] 20[redacted])

Causality for UPADACITINIB (Blinded)

---

1) Pneumonia influenzal (10035714) (Pneumonia influenzal (10035714)) [v.22.1][10035714]

Causality as per reporter (Drug/Vaccine): No reasonable possibility

Causality as per Mfr. (Drug/Vaccine): No reasonable possibility

Dechallenge: Not Applicable

Alternative Etiology for UPADACITINIB (Blinded)

Event of PNEUMONIA INFLUENZAL

- Investigator: Influenza A virus.

- AbbVie: Event of pneumonia is more likely related to an acute Influenza A infection which is a common seasonal infection in the general population.

Relevant Laboratory & Other Diagnostic Tests

[redacted] **20[redacted] CRP:** 12.8 MG/L (normal 0 to 3)

[redacted] **20[redacted] CT PNEUMANGIOGRAPHY:** Bibasal infiltrate compatible with viral pneumonia.

[redacted] **20[redacted] INFLUENZA A VIRUS RNA (SPUTUM):** POSITIVE

被験者番号 [redacted] (Investigator [redacted])

Reason for Narrative

Adverse Event Preferred Term(s)	Serious Adverse Event	Adverse Event Leading to Discontinuation of Study Drug	Death	Event of Interest
自然流産	X	X		
1 型糖尿病	X			

Treatment Group	Age at Study Start	Sex	Race
ABT-494 30 mg QD	2[redacted]	FEMALE	WHITE

Medical History	Onset Year
DIABETES MELLITUS: DIABETES MELLITUS TYPE 1	20[redacted]
OTHER: PLAQUE PSORIASIS	20[redacted]

Prior Procedures	Procedure Year
Not reported.	

Tobacco Use	Status	Number/Day	Number of Years	Year Stopped
CHEWING TOBACCO	NEVER			
CIGARETTES	NEVER			
CIGARS	NEVER			
E-CIGARETTES	NEVER			
PIPES	NEVER			

Alcohol Use	Status	Number/Day
ALCOHOL	NEVER	

Study Drug Administration

Study Drug	Dose/Units	Route	Frequency	First Dose Date/Day	Last Dose Date/Day	Duration (Days)
ABT-494	30MG	ORAL	QD	[redacted]20[redacted] /1	[redacted]20[redacted] / 168	168
ABT-494	30MG	ORAL	QD	[redacted]20[redacted] / 169	[redacted]20[redacted] / 395	227
ABT-494	30MG	ORAL	QD	[redacted]20[redacted] / 396	[redacted]20[redacted] / 491	96

Previous Therapy - Prior to baseline/enrollment

Medication Name (WHO Drug)	Dose/Units	Frequency	Start Year-Month / RX Day
BCG Vaccine	NOT REPORTED	NOT REPORTED	Y-M: 19[redacted]-
BCG Vaccine	NOT REPORTED	NOT REPORTED	Y-M: 19[redacted]-
HEPATITIS B IMMUNIZATION	NOT REPORTED	NOT REPORTED	Y-M: 20[redacted]-

HEPATITIS B IMMUNIZATION	NOT REPORTED	NOT REPORTED	Y-M: 20[redacted]
HEPATITIS B IMMUNIZATION	NOT REPORTED	NOT REPORTED	Y-M: 20[redacted]
INSULIN GLARGINE	0+16+14 IU	BID	Y-M: 20[redacted]
FOLIC ACID	10 mg	EVERY WEEK	Y-M: 20[redacted]
ADALIMUMAB	40 mg	EVERY 2 WEEKS	Y-M: 20[redacted]
INSULIN GLULISINE	100 ug	PRN	Y-M: 20[redacted]
DICLOFENAC	75 mg	BID	Y-M: 20[redacted] / -32
METHOTREXATE	25 mg	EVERY WEEK	Y-M: 20[redacted] / -32

Other Medications - Medications taken within 30 days prior to each narrative event until AE stopped or end of study

Medication Name (WHO Drug)	Dose/Units	Frequency	Start Year-Month / RX Day	Stop Year-Month / RX Day
FOLIC ACID	10 mg	EVERY WEEK	Y-M: 20[redacted]	Y-M: 20[redacted] / 473
INSULIN GLULISINE	100 ug	PRN	Y-M: 20[redacted]	ONGOING
METHOTREXATE	25 mg	EVERY WEEK	Y-M: 20[redacted] / - 32	Y-M: 20[redacted] / 294
INSULIN GLARGINE	0+14+8 IU	BID	Y-M: 20[redacted] / 113	ONGOING
METRONIDAZOLE	10 OTHER: MG/G	QD	Y-M: 20[redacted] / 169	Y-M: 20[redacted] / 259
OTHER DERMATOLOGICALS	1 OTHER: APPLICATION	QD	Y-M: 20[redacted] / 332	ONGOING
EMOLLIENTS AND PROTECTIVES	1 OTHER: APPLICATION	BID	Y-M: 20[redacted] / 332	Y-M: 20[redacted] / 403
OTHER DERMATOLOGICALS	1 OTHER: APPLICATION	BID	Y-M: 20[redacted] / 332	Y-M: 20[redacted] / 403
EMOLLIENTS AND PROTECTIVES	1 OTHER: APPLICATION	QD	Y-M: 20[redacted] / 403	ONGOING
DOXYCYCLINE	50 mg	QD	Y-M: 20[redacted] / 403	Y-M: 20[redacted] / 413
MISOPROSTOL	4 OTHER: PILLS (DOSE IS UNKNOWN)	QD	Y-M: 20[redacted] / 413	Y-M: 20[redacted] / 413
INSULIN	6 OTHER: U/H	QD	Y-M: 20[redacted] / 435	Y-M: 20[redacted] / 435
INSULIN GLARGINE	10 IU	QD	Y-M: 20[redacted] / 435	Y-M: 20[redacted] / 435
POTASSIUM	10 OTHER: MEQ PER HOUR	QD	Y-M: 20[redacted] / 435	Y-M: 20[redacted] / 435
SODIUM CHLORIDE	4000 OTHER: CC	QD	Y-M: 20[redacted] / 435	Y-M: 20[redacted] / 435

Event #3: Serious Adverse Event, AE Leading to Discontinuation of Study Drug

Event Description	SPONTANEOUS MISCARRIAGE
Preferred term	自然流産
AE Onset Date / Rx Day	[redacted]20[redacted] / 412
Age at AE Onset	2[redacted]

Laboratory Testing

NOT REPORTED

Microbiology

NOT REPORTED

SAE Supplemental Procedure

[redacted]20[redacted] (RX DAY 413): SCRAPING OF THE UTERUS WITH 4 PILLS OF VAGINAL MISOPROLOL: PROCEDURE WENT WELL

AE Stopped Rx Day	413
Duration of AE	2 DAYS
Relation to Study Drug by Investigator	NO REASONABLE POSSIBILITY
Investigator Alternative Etiology	PROBABLE CAUSE OF MISCARRIAGE IS DECOMPENSATION OF TYPE 1 DIABETES
Discontinued Study Drug Due to the Event	YES
SAE Criteria	OTHER MEDICALLY IMPORTANT SERIOUS EVENT

Event #4: Serious Adverse Event

Event Description	DECOMPENSATION OF TYPE 1 DIABETES
Preferred term	1 型糖尿病
AE Onset Date / Rx Day	[redacted]20[redacted] / 434
Age at AE Onset	2[redacted]

Laboratory Testing

[redacted]20[redacted] (RX DAY 434): Alanine Aminotransferase: 35 [0 - 55] U/L; Albumin: 48 [35 - 50] g/L; Alkaline Phosphatase: 105 [40 - 150] U/L; Aspartate Aminotransferase: 31 [5 - 34] U/L; Basophils: 0.04 [0.02 - 1] 10^9/L; Bilirubin: 13.68 [3.42 - 20.52] umol/L; Creatinine: 88.4 [53.04 - 97.24] umol/L; Eosinophils: 0.02 [0.1 - 1] 10^9/L; Erythrocytes: 5 [4 - 5.2] 10^12/L; Hematocrit: 0.41 [0.36 - 0.46] fraction of 1; Hemoglobin: 152 [120 - 160] g/L; Leukocytes: 10.9 [4 - 11] 10^9/L; Lymphocytes: 2.16 [1 - 4.5] 10^9/L; Monocytes: 0.46 [0.2 - 1] 10^9/L; NPTST038-C-REACTIVE PROTEIN: 1.2 [NOT REPORTED - 5] mg/L; NPTST081-ERYTHROBLASTS: 0 [0 - 0.11] 10^9/L; NPTST116-IMMATURE GRANULOCYTES: 0.07 [0.2 - 1] 10^9/L; NPTST136-MAGNESIUM: 0.89 [0.66 - 1.07] mmol/L; NPTST140-MEAN CORPUSCULAR HEMOGLOBIN: 30.6 [26 - 34] pg; NPTST141-MEAN CORPUSCULAR HEMOGLOBIN CON: 36.7 [31 - 37] g/dL; NPTST142-MEAN CORPUSCULAR VOLUME: 83.5 [80 - 100] fL; NPTST185-RED CELL DISTRIBUTION WIDTH: 11.6 [11.6 - 14] %; NPTST214-UREA: 59 [15 - 40] mg/dL; NPTST219- URINE TEST STRIP: HIGH KETONE BODIES [NOT REPORTED - NOT REPORTED] UNIT NOT REPORTED; NPTST219-URINE TEST STRIP: HIGH GLUCOSE [NOT REPORTED - NOT REPORTED] UNIT NOT REPORTED; Neutrophils: 8.15 [1.8 - 8] 10^9/L; Phosphate: 1.49 [0.74 - 1.52] mmol/L; Platelets: 393 [150 - 450] 10^9/L; Potassium: 5.1 [3.5 - 5.1] mmol/L; Protein: 79 [64 - 83] g/L; Sodium: 129 [136 - 145] mmol/L

Microbiology

NOT REPORTED

SAE Supplemental Procedure

[redacted]20[redacted] (RX DAY 434): MEASUREMENT OF GLUCOSE THROUGH PATIENT'S OWN GLUCOMETER: ALERT OF HIGH GLUCOSE VALUE

AE Stopped Rx Day	435
Duration of AE	2 DAYS
Relation to Study Drug by Investigator	NO REASONABLE POSSIBILITY
Investigator Alternative Etiology	THE DISEASE ITSELF AND POOR CONTROL OF THE DISEASE BY THE PARTICIPANT
Discontinued Study Drug Due to the Event	NO
SAE Criteria	REQUIRES OR PROLONGS HOSPITALIZATION

Generated: [redacted]
Program Source Code: [redacted]

Subject Number: [redacted]

Protocol Number: M15-554

治験責任医師からの報告。本被験者はポルトガルの2[redacted]歳女性であり，ABT-494（ウパダシチニブ）の治験で盲検化された治験薬が投与され，1 型糖尿病の代償不全、並びに自然流産及び非重篤な妊娠時の母体の曝露の事象を発現した。

Event 3～4 の臨床経過：
関連する病歴は 1 型糖尿病，乾癬性関節炎，非飲酒者及び非喫煙者であった。

被験者は妊娠時の母体の曝露を発現した（日付不明）。20[redacted]年[redacted]月[redacted]日，被験者は自然流産を発現した。20[redacted]年[redacted]月[redacted]日，被験者は 1 型糖尿病の代償不全を発現した。20[redacted]年[redacted]月[redacted]日，1 型糖尿病の代償不全は消失した。

20[redacted]年[redacted]月[redacted]日，救急治療室での尿検査で妊娠が確認された。報告時点での胎児の推定在胎週数（EGA）は不明であった。被験者の最終月経は20[redacted]年[redacted]月（日付不明）であった。分娩予定日（EDD）は不明であった。胎児は受精前から妊娠第一期までの期間，（子宮内で）母体のウパダシチニブ使用に曝露されていた。20[redacted]年[redacted]月[redacted]日，被験者は自然流産を発現した。被験者は子宮内掻爬のため入院し，ミソプロストール 4 錠の経腟投与を受け，同日退院した。

20[redacted]年[redacted]月[redacted]日，被験者はびまん性腹痛及び多尿で救急科を受診した。高血糖及び軽微な糖尿病性ケトアシドーシスを伴う 1 型糖尿病代償不全のため入院した。被験者は治療を受け，状態は改善した。被験者は20[redacted]年[redacted]月[redacted]日に退院した。

投与された薬剤は，ミソプロストール，生理食塩液，カリウム補給剤，インスリン及びインスリングラルギンであった。

The patient's past medications include:

ADALIMUMAB for PSORIATIC ARTHRITIS ([redacted] 20[redacted] - [redacted] 20[redacted])

METEX for PSORIATIC ARTHRITIS ([redacted])

VOLTAREN for PSORIATIC ARTHRITIS ([redacted])

Causality for UPADACITINIB (Blinded)

---

1) Type I diabetes mellitus (10045228) (Type 1 diabetes mellitus (10067584)) [v.23.0] [10045228]

Causality as per reporter (Drug/Vaccine): No reasonable possibility

Causality as per Mfr. (Drug/Vaccine): No reasonable possibility

Dechallenge: Yes

Rechallenge: rechallenge was done, reaction did not recur

2) Miscarriage (10027649) (Abortion spontaneous (10000234)) [v.23.0] [10027649]

Causality as per reporter (Drug/Vaccine): No reasonable possibility

Causality as per Mfr. (Drug/Vaccine): No reasonable possibility

Dechallenge: Yes

Rechallenge: rechallenge was done, reaction did not recur

3) Maternal exposure duringpregnancy (10071408) (Maternal exposure during pregnancy (10071408)) [v.23.0] [10071408]

Causality as per reporter (Drug/Vaccine): Not Reported

Causality as per Mfr. (Drug/Vaccine): No reasonable possibility

Dechallenge: Not Applicable

Alternative Etiology for UPADACITINIB (Blinded)

Event of DECOMPENSATION OF TYPE 1 DIABETES

- Investigator: THE DISEASE ITSELF AND POOR CONTROL OF THE DISEASE BY THE PARTICIPANT

- AbbVie: Event more likely related to pre-existing diabetes mellitus type 1. The poor control of the disease by the participant that was noted by the investigator is an additional risk factor.

Event of SPONTANEOUS MISCARRIAGE

- Investigator: PROBABLE CAUSE OF MISCARRIAGE IS DECOMPENSATION OF TYPE 1 DIABETES

- AbbVie: Spontaneous abortions in the 1st trimester are common and are more likely associated to structural or chromosomal abnormalities of the embryo. Pre-existing diabetes mellitus type 1 is an additional risk factor.

Event of MATERNAL EXPOSURE DURING PREGNANCY

- Investigator: Not applicable

- AbbVie: Special situation of maternal use of active pharmaceutical ingredient.

Relevant Laboratory & Other Diagnostic Tests

[redacted] **BLOOD GLUCOSE:** Alert of high glucose value

[redacted] **HEMATOCRIT:** 41.10 % (normal 36.0 to 46.00)

[redacted] **HEMOGLOBIN:** 15.2 G/DL (normal 12.0 to 16.0)

[redacted] **LYMPHOCYTES ABS:** 2.16 X10**9/L (normal 1.00 to 4.50)

[redacted] **NEUTROPHILS ABS:** 8.15 X10**9/L (normal 1.80 to 8.00)

[redacted] **PREGNANCY TEST:** Negative

[redacted] **PREGNANCY TEST:** Positive

[redacted] **RED BLOOD CELLS:** 4.96 X10**12/L (normal 4.00 to 5.20)

[redacted] **UREA:** 59 mg/dL (normal 15 to 40)

[redacted] **URINE TEST:** High ketone bodies

[redacted] **URINE TEST:** High glucose

[redacted] **WHITE BLOOD CELLS:** 10.9 X10**9/L (normal 4.0 to 11.0)

被験者番号 [redacted] (Investigator [redacted])

Reason for Narrative

Adverse Event Preferred Term(s)	Serious Adverse Event	Adverse Event Leading to Discontinuation of Study Drug	Death	Event of Interest
前立腺癌	X	X		X

Treatment Group	Age at Study Start	Sex	Race
ABT-494 15 mg QD	7[redacted]	MALE	WHITE

Medical History	Onset Year
OTHER: INSOMNIA	19[redacted]
CORONARY ARTERY DISEASE: ISCHEMIC CARDIOPATHY	19
OTHER: ANXIETY	19
HYPERTENSION	20
OTHER: BILIAR DYSKINESIA	20
OTHER: PLAQUE PSORIASIS	20
HYPERLIPIDEMIA: DYSLIPIDEMIA	20
OTHER: LEFT HAND PARESTHESIAS	20
BENIGN PROSTATIC HYPERPLASIA	20
TUBERCULOSIS: LATENT TB	20

Prior Procedures	Procedure Year
SURGERY: CATARACT ON THE RIGHT EYE	20[redacted]
SURGERY: CATARACT SURGERY ON THE RIGHT EYE	20

Tobacco Use	Status	Number/Day	Number of Years	Year Stopped
CHEWING TOBACCO	NEVER			
CIGARETTES	FORMER	3 PACK	6	19[redacted]
CIGARS	NEVER			
E-CIGARETTES	NEVER			
PIPES	NEVER			

Alcohol Use	Status	Number/Day
ALCOHOL	CURRENT	2 - 4

Study Drug Administration

Study Drug	Dose/Units	Route	Frequency	First Dose Date/Day	Last Dose Date/Day	Duration (Days)
ABT-494	15MG	ORAL	QD	[redacted]20[redacted] / 1	[redacted]20[redacted] / 83	83

Previous Therapy - Prior to baseline/enrollment

Medication Name (WHO Drug)	Dose/Units	Frequency	Start Year-Month / RX Day
AMLODIPINE	10 mg	QD	Y-M: 19
BISOPROLOL	5 mg	QD	Y-M: 19
ACETYLSALICYLIC ACID	100 mg	QD	Y-M: 20
PANKREOFLAT	170 + 80 mg	QD	Y-M: 20
ETANERCEPT	50 mg	EVERY WEEK	Y-M: 20
PRITORPLUS	80 + 12.5 mg	QD	Y-M: 20
HYALURONIC ACID	0.15/10 OTHER: MG/ML	BID	Y-M: 20
VALERIANA OFFICINALIS	125 mg	PRN	Y-M: 20
FORTICOL	230+180 mg	QD	Y-M: 20
LANSOPRAZOLE	30 mg	QD	Y-M: 20
EZETIMIBE	10 mg	QD	Y-M: 20
ROSUVASTATIN	20 mg	QD	Y-M: 20
NAPROXEN	500 mg	PRN	Y-M: 20 -
SILODOSIN	8 mg	QD	Y-M: 20 -
RIFAMPICIN	300 mg	QD	Y-M: 20 - / - 239

Other Medications - Medications taken within 30 days prior to each narrative event until AE stopped or end of study

Medication Name (WHO Drug)	Dose/Units	Frequency	Start Year-Month / RX Day	Stop Year-Month / RX Day
AMLODIPINE	10 mg	QD	Y-M: 19	Not reported.
BISOPROLOL	5 mg	QD	Y-M: 19	Not reported.
ACETYLSALICYLIC ACID	100 mg	QD	Y-M: 20	Not reported.
PANKREOFLAT	170 + 80 mg	QD	Y-M: 20	Not reported.
PRITORPLUS	80 + 12.5 mg	QD	Y-M: 20	Not reported.
HYALURONIC ACID	0.15/10 OTHER: MG/ML	BID	Y-M: 20	Not reported.
FORTICOL	230+180 mg	QD	Y-M: 20	Not reported.
LANSOPRAZOLE	30 mg	QD	Y-M: 20	Not reported.
EZETIMIBE	10 mg	QD	Y-M: 20	Not reported.
ROSUVASTATIN	20 mg	QD	Y-M: 20	Not reported.
NAPROXEN	500 mg	PRN	Y-M: 20 -	Not reported.
SILODOSIN	8 mg	QD	Y-M: 20 -	Not reported.
ZOLPIDEM	10 mg	QD	Y-M: 20 - / 1	Not reported.
PARACETAMOL	1000 mg	QD	Y-M: 20 - / 72	Y-M: 20 - / 72
SODIUM CHLORIDE	5000 mg	QD	Y-M: 20 - / 72	Y-M: 20 - / 72

CEFTRIAXONE	2000 mg	QD	Y-M: 20[redacted] / 73	Y-M: 20[redacted] 73
CIPROFLOXACIN	200 mg	QD	Y-M: 20[redacted] / 73	Y-M: 20[redacted] 73
ESOMEPRAZOLE	40 mg	QD	Y-M: 20[redacted] / 73	Y-M: 20[redacted] 73
METOCLOPRAMIDE	10 mg	QD	Y-M: 20[redacted] / 73	Y-M: 20[redacted] 73
LEVOFLOXACIN	500 mg	QD	Y-M: 20[redacted] / 74	Y-M: 20[redacted] 75
IBUPROFEN	400 mg	TID	Y-M: 20[redacted] / 76	Y-M: 20[redacted] 80
BACTRIM	800 + 160 mg	BID	Y-M: 20[redacted] / 76	Y-M: 20[redacted] 88
PREDNISOLONE	5 mg	QD	Y-M: 20[redacted] / 112	Y-M: 20[redacted] 397
GOSERELIN	10.8 mg	OTHER: EVERY 3 MONTHS	Y-M: 20[redacted] / 134	Not reported.
LOPERAMIDE	2 mg	QD	Y-M: 20[redacted] / 155	Y-M: 20[redacted] 157
SACCHAROMYCES BOULARDII	250 mg	BID	Y-M: 20[redacted] / 155	Y-M: 20[redacted] 161
VITAMINS NOS	1 OTHER: TABLET	QD	Y-M: 20[redacted] / 182	Y-M: 20[redacted] 212
CALCIUM WITH VITAMIN D	1250 + 400 OTHER: MG + IU	QD	Y-M: 20[redacted] / 216	Not reported.
AZITHROMYCIN	500 mg	QD	Y-M: 20[redacted] / 237	Y-M: 20[redacted] 239
VALERIANA OFFICINALIS	125 mg	QD	Y-M: 20[redacted] / 252	Not reported.
PARACETAMOL	1000 mg	QD	Y-M: 20[redacted] / 303	Y-M: 20[redacted] 303
LIDOCAINE	2 mL	QD	Y-M: 20[redacted] / 377	Y-M: 20[redacted] 377
METHYLPREDNISOLONE	1 mL	QD	Y-M: 20[redacted] / 377	Y-M: 20[redacted] 377
PREDNISOLONE	2.5 mg	QD	Y-M: 20[redacted] / 397	Not reported.

Event #1: Serious Adverse Event, AE Leading to Discontinuation of Study Drug, Study Specific Adverse Events of Interest

Event Description	ADENOCARCINOMA OF PROSTATE GLAND 7 (3 + 4)
Preferred term	前立腺癌
AE Onset Date / Rx Day	[redacted]20[redacted] / 71
Age at AE Onset	7[redacted]
Laboratory Testing	
[redacted]20[redacted] (RX DAY -812): NPTST175-PSA: 4.6 [0.5 - 4.4] ng/mL; [redacted]20[redacted] (RX DAY -231): NPTST175-PSA: 4.65 [0.5 - 4.4] ng/mL; [redacted]20[redacted] (RX DAY -156): NPTST175-PSA: 7.68 [0.5 - 4.4] ng/mL; [redacted]20[redacted] (RX DAY 28): NPTST175-PSA: 10.08 [0.5 - 4.4] ng/mL	
Microbiology	
NOT REPORTED	
SAE Supplemental Procedure	
[redacted]20[redacted] (RX DAY 71): PROSTATIC BIOPSY: ADENOCARCINOMA GLEASON GRADE 7 (3 + 4), PROGNOSTIC GRADE GROUP 2, INVOLVING THE LEFT PROSTATE LOBE PROSTATE	
AE Stopped Rx Day	NOT REPORTED
Duration of AE	NOT REPORTED
Relation to Study Drug by Investigator	NO REASONABLE POSSIBILITY
Investigator Alternative Etiology	AGE AND PREVIOUS TREATMENT WITH BIOLOGIC THERAPY
Discontinued Study Drug Due to the Event	YES
SAE Criteria	OTHER MEDICALLY IMPORTANT SERIOUS EVENT

Generated: [redacted]
Program Source Code: [redacted]

Investigator No.: [redacted]

Subject Number: [redacted]

Protocol Number: M15-554

治験責任医師からの報告。本被験者はポルトガルの7[redacted]歳男性であり，ABT-494（ウパダシチニブ）の治験で盲検化された治験薬が投与され，前立腺腺癌（グレード7［3＋4］）の事象を発現した。

Event 1 の臨床経過：

関連する病歴は元紙巻タバコ喫煙者（1日3箱を6年間），不安，虚血性心筋症，高血圧，局面型乾癬，脂質異常症，乾癬性関節炎，良性前立腺肥大症及び潜伏性結核であった。

試験の盲検を解除。

20[redacted] 年 [redacted] 月 [redacted] 日，被験者は前立腺腺癌（グレード 7［3 + 4］）を発現した。

20[redacted] 年以降，PSA 値が増加し始めた。20[redacted] 年 [redacted] 月 [redacted] 日，泌尿器科を受診した。20[redacted] 年 [redacted] 月 [redacted] 日，前立腺生検が行われ，前立腺左葉にグリーソングレード 7 の腺癌が認められた。20[redacted] 年 [redacted] 月 [redacted] 日から 20[redacted] 年 [redacted] 月 [redacted] 日，被験者は急性前立腺炎（非重篤）を発現した。20[redacted] 年 [redacted] 月 [redacted] 日，この被験者の治験参加は完全に中止された。

投与された薬剤は，loperamida，UL-250，ゴセレリン及びカルシウム&ビタミン D であった。

The patient's past medications include:

ETANERCEPT for PSORIASIS (20[redacted] - [redacted] 20[redacted])

RIFAMPICIN for LATENT TB ([redacted] 20[redacted] - [redacted] 20[redacted])

Causality for UPADACITINIB (Blinded)

---

1) Adenocarcinoma of prostate (10001186) (Prostate cancer (10060862)) [v.22.1] [10001186]

Causality as per reporter (Drug/Vaccine): No reasonable possibility

Causality as per Mfr. (Drug/Vaccine): No reasonable possibility

Dechallenge: No

Alternative Etiology for UPADACITINIB (Blinded)

Event of ADENOCARCINOMA OF PROSTATE GLAND 7 (3 + 4)

- **Investigator:** Age and previous treatment with biologic therapy

- **AbbVie:** Weak temporal association , with just over 2 months study drug exposure. Additional risk factors include age and per PI subject was having elevated PSA' s since 20[redacted].

Relevant Laboratory & Other Diagnostic Tests

[redacted] **20[redacted] PROSTATIC BIOPSY:** adenocarcinoma Gleason grade 7 (3 + 4), prognostic grade group 2, involving the left prostate lobe prostate

[redacted] **20[redacted] PSA:** 4.60 NG/ML (normal 0.5 to 4.4)

[redacted] **20[redacted] PSA:** 4.65 NG/ML (normal 0.5 to 4.4)

[redacted] **20[redacted] PSA:** 7.68 NG/ML (normal 0.5 to 4.4)

[redacted] **20[redacted] PSA:** 10.08 NG/ML (normal 0.5 to 4.4)

被験者番号 [redacted] (Investigator [redacted])

Reason for Narrative

Adverse Event Preferred Term(s)	Serious Adverse Event	Adverse Event Leading to Discontinuation of Study Drug	Death	Event of Interest
ウイルス性上気道感染	X			X

Treatment Group	Age at Study Start	Sex	Race
Placebo/ABT-494 30 mg QD	6[redacted]	FEMALE	WHITE

Medical History	Onset Year
OTHER: PLAQUE PSORIASIS	20[redacted]
OTHER: POST-MENOPAUSAL	20
OSTEOPOROSIS	20
OTHER: FRACTURE LEFT WRIST	20
DRUG ALLERGIES/REACTIONS: SALICYLATES	20
OTHER: FRACTURE RIGHT WRIST	20
OTHER: VITAMIN D DEFICIENCY	20
GASTROESOPHAGEAL REFLUX DISEASE: UPPER GI ENDOSCOPY [redacted]/[redacted]20[redacted]	20
OTHER: BRONCHIECTASIS	20
HYPERTENSION	20
OTHER: HUMAN PAPILLOMAVIRUS/ CERVICAL SQUAMOUS INTRAEPITHELIAL NEOPLASIA 1	20
DEGENERATIVE DISC DISEASE: MINOR ANTERIOR WEDGE COMPRESSION INVOLVING T7	20
DRUG ALLERGIES/REACTIONS: HAYFEVER	20

Prior Procedures	Procedure Year
SURGERY: TRIANGULAR FIBROCARTILAGE COMPLEX DAMAGE R WRIST - ARTHROSCOPIC DEBRIDEMENT	20

Tobacco Use	Status	Number/Day	Number of Years	Year Stopped
CHEWING TOBACCO	NEVER			
CIGARETTES	FORMER	0.25 PACK	38	20[redacted]
CIGARS	NEVER			
E-CIGARETTES	NEVER			
PIPES	NEVER			

Alcohol Use	Status	Number/Day
ALCOHOL	CURRENT	Less than 2

Study Drug Administration

Study Drug	Dose/Units	Route	Frequency	First Dose Date/Day	Last Dose Date/Day	Duration (Days)
PLACEBO		ORAL	QD	[redacted] / 1	[redacted] / 167	167
ABT-494	30MG	ORAL	QD	[redacted] / 168	[redacted] / 391	224
ABT-494	30MG	ORAL	QD	[redacted] / 392	/	

Previous Therapy - Prior to baseline/enrollment

Medication Name (WHO Drug)	Dose/Units	Frequency	Start Year-Month / RX Day
COLECALCIFEROL	1.25 mg	OTHER: MONTHLY	Y-M: [redacted]
SALBUTAMOL	2 OTHER: PUFFS	OTHER: PRN	Y-M: [redacted]
SERETIDE	1 OTHER: PUFF	BID	Y-M: [redacted]
CILAZAPRIL	2.5 mg	QD	Y-M: [redacted]
CETIRIZINE	10 mg	QD	Y-M: [redacted]
LEFLUNOMIDE	10 mg	QD	Y-M: [redacted]
ADALIMUMAB	40 mg	EVERY 2 WEEKS	Y-M: [redacted]
ADALIMUMAB	40 mg	EVERY 2 WEEKS	Y-M: [redacted]
ETANERCEPT	50 mg	EVERY WEEK	Y-M: [redacted]
FOLIC ACID	5 mg	QD	Y-M: [redacted]
HYDROXYCHLOROQUINE	200 mg	QD	Y-M: [redacted]
METHOTREXATE	10 mg	EVERY WEEK	Y-M: [redacted]
LEFLUNOMIDE	20 mg	QD	Y-M: [redacted]
LEFLUNOMIDE	10 mg	QD	Y-M: [redacted]
CETOMACROGOL	1 OTHER: APPLICATION	PRN	Y-M: [redacted] / -261
FENTANYL	50 ug	OTHER: ONCE ONLY	Y-M: [redacted] / -2
MIDAZOLAM	3 mg	OTHER: ONCE ONLY	Y-M: [redacted] / -2

Other Medications - Medications taken within 30 days prior to each narrative event until AE stopped or end of study

Medication Name (WHO Drug)	Dose/Units	Frequency	Start Year-Month / RX Day	Stop Year-Month / RX Day
COLECALCIFEROL	1.25 mg	OTHER: MONTHLY	Y-M: 20[redacted]	Not reported.
SALBUTAMOL	2 OTHER: PUFFS	OTHER: PRN	Y-M: 20[redacted]	Not reported.
SERETIDE	1 OTHER: PUFF	BID	Y-M: 20[redacted]	Not reported.
CILAZAPRIL	2.5 mg	QD	Y-M: 20[redacted]	Y-M: 20[redacted] / 502
CETIRIZINE	10 mg	QD	Y-M: 20[redacted]	Not reported.
LEFLUNOMIDE	10 mg	QD	Y-M: 20[redacted]	Not reported.
CETOMACROGOL	1 OTHER: APPLICATION	PRN	Y-M: 20[redacted] / -261	Not reported.
AMOXICILLIN	500 mg	TID	Y-M: 20[redacted] / 278	Y-M: 20[redacted] / 288
CODEINE	30 mg	PRN	Y-M: 20[redacted] / 283	Y-M: 20[redacted] / 283
PARACETAMOL	1 g	PRN	Y-M: 20[redacted] / 283	Y-M: 20[redacted] / 283
MYLANTA	2 OTHER: TABLETS	PRN	Y-M: 20[redacted] / 288	Not reported.
RANITIDINE	300 mg	QD	Y-M: 20[redacted] / 288	Not reported.
CODEINE	30 mg	PRN	Y-M: 20[redacted] / 288	Y-M: 20[redacted] / 288
PARACETAMOL	1 g	PRN	Y-M: 20[redacted] / 288	Y-M: 20[redacted] / 293

Event #1: Serious Adverse Event, Study Specific Adverse Events of Interest

Event Description	UPPER RESPIRATORY VIRAL ILLNESS
Preferred term	ウイルス性上気道感染
AE Onset Date / Rx Day	[redacted]20[redacted] / 278
Age at AE Onset	6[redacted]

Laboratory Testing

[redacted]20[redacted] (RX DAY 288): Alanine Aminotransferase: 25 [0 - 45] U/L; Albumin: 39 [32 - 48] g/L; Alkaline Phosphatase: 89 [40 - 130] U/L; Basophils: 0.02 [0 - 0.2] 10^9/L; Bilirubin: 10 [0 - 24] umol/L; Calcium: 2.36 [2.1 - 2.55] mmol/L; Chloride: 100 [95 - 110] mmol/L; Creatine Kinase: 57 [30 - 180] U/L; Creatinine: 69 [0 - 90] umol/L; Eosinophils: 0.1 [0 - 0.5] 10^9/L; Erythrocytes: 3.6 [3.6 - 5.6] 10^12/L; Glucose: 7.5 [3.5 - 7.7] mmol/L; Hematocrit: 0.33 [0.35 - 0.46] fraction of 1; Hemoglobin: 103 [115 - 155] g/L; Leukocytes: 6.9 [4 - 11] 10^9/L; Lymphocytes: 1.12 [1 - 4] 10^9/L; Monocytes: 0.56 [0.2 - 1] 10^9/L; NPTST056-CRP: 71 [0 - 5] mg/L; NPTST094-GGT: 21 [0 - 50] U/L; NPTST095-GLOBULIN: 36 [25 - 41] g/L; NPTST116-IMMATURE GRANULOCYTES: 0.04 [0 - 0.06] 10^9/L; NPTST137-MCH: 30 [27 - 33] pg; NPTST139-MCV: 93 [80 - 99] fL; NPTST164-PHOSPHATE: 0.72 [0.7 - 1.5] mmol/L; NPTST181-RDW: 13.5 [12 - 15] %; NPTST214-UREA: 3.1 [3.2 - 7.7] mmol/L; Neutrophils: 5.02 [1.9 - 7.5] 10^9/L; Platelets: 265 [150 - 400] 10^9/L; Potassium: 4 [3.5 - 5.2] mmol/L; Protein: 75 [66 - 84] g/L; Sodium: 140 [135 - 145] mmol/L

Microbiology

[redacted]20[redacted] (RX DAY 288): BLOOD NPTST063-CULTURE: NEGATIVE; URINE NPTST063-CULTURE: NOT APPLICABLE-CONTAMINATED

SAE Supplemental Procedure

[redacted]20[redacted] (RX DAY 288): CHEST X-RAY: CARDIAC, MEDIASTINAL AND HILAR CONTOURS ARE SATISFACTORY AND THE HEART SIZE IS WITHIN NORMAL LIMITS. THE LUNG AND PLEURAL SPACES ARE CLEAR.; LUMBAR SPINE MRI: NO SIGNS OF DISCITIS, COLLECTION OR OSTEOMYELITIS; VITAL SIGNS: TEMP: 36.2, PULSE: 100, RESPS: 16, BP: 139/65 NO DISCHARGE VITAL SIGNS RECORDED.

AE Stopped Rx Day	305
Duration of AE	28 DAYS
Relation to Study Drug by Investigator	REASONABLE POSSIBILITY
Investigator Alternative Etiology	NOT REPORTED
Discontinued Study Drug Due to the Event	NO
SAE Criteria	REQUIRES OR PROLONGS HOSPITALIZATION

Generated: [redacted]
Program Source Code: [redacted]

Investigator No.: [redacted]

Subject Number: [redacted]

Protocol Number: M15-554

治験責任医師からの報告。本被験者はニュージーランドの6[redacted]歳女性であり，ABT-494（ウパダシチニブ）の治験で盲検化された治験薬が投与され，ウイルス性上気道感染症の事象を発現した。

Event 1 の臨床経過：

関連する病歴は気管支拡張症，元喫煙者（1 日 0.25 箱を 38 年間），乾癬性関節炎及び現飲酒者（1 日 2 杯未満）であった。

被験者は，最初の 24 週間，本治験の盲検プラセボ対照期に組み入れられていた。20[redacted] 年[redacted] 月[redacted] 日，ABT-494 の盲検投与が開始された。

20[redacted] 年[redacted] 月[redacted] 日，被験者はウイルス性上気道感染症を発現した。

20[redacted] 年[redacted] 月[redacted] 日，被験者は，咽喉痛，発熱，乾性咳嗽及び鈍い痛み・鋭い痛みといった症状で入院した。20[redacted] 年[redacted] 月[redacted] 日，被験者は退院した。

投与された薬剤は，アモキシシリン，アセトアミノフェン及びリン酸コデインであった。

The patient's past medications include:

CILAZAPRIL for HYPERTENSION ([redacted] 20[redacted] - [redacted] 20[redacted])

AMOXICILLIN for UPPER RESPIRATORY TRACT INFECTION, THROAT INFECTION and UPPER RESPIRATORY VIRAL ILLNESS ([redacted] 20[redacted] - [redacted] 20[redacted], [redacted] 20[redacted] - [redacted] 20[redacted])

Causality for UPADACITINIB (Blinded)

---

1) Viral upper respiratory tract infection (10047482) (Viral upper respiratory tract infection (10047482)) [v.22.0] [10047482]

Causality as per reporter (Drug/Vaccine): Reasonable possibility

Causality as per Mfr. (Drug/Vaccine): No reasonable possibility

Dechallenge: Not Applicable

Alternative Etiology for UPADACITINIB (Blinded)

Event of UPPER RESPIRATORY VIRAL ILLNESS

- Investigator: Not applicable

- AbbVie: Common in the general population. Risk factors also include pre-existing bronchiectasis and prior smoking history.

Relevant Laboratory & Other Diagnostic Tests

[redacted] 20[redacted] **BLOOD CULTURE:** Negative

[redacted] 20[redacted] **BLOOD PRESSURE:** 139/65 mmHg

[redacted] 20[redacted] **CHEST X-RAY:** Cardiac, mediastinal and hilar contours are satisfactory and the heart size is within normal limits. The lung and pleural spaces are clear.

[redacted] 20[redacted] **CRP:** 71 MG/L (normal 0 to 5)

[redacted] **20[redacted] EOSINOPHILS ABS:** 0.10 X10**9/L (normal 0 to 0.5)

[redacted] **20[redacted] LUMBAR SPINE MRI:** NO SIGNS OF DISCITIS, COLLECTION OSTEOMYELITIS.

[redacted] **20[redacted] PULSE:** 100 bpm

[redacted] **20[redacted] RBC:** 3.59 X10**12/L (normal 3.6 to 5.6)

[redacted] **20[redacted] URINE CULTURE:** Contaminated specimen

被験者番号 [redacted] (Investigator [redacted])

Reason for Narrative

Adverse Event Preferred Term(s)	Serious Adverse Event	Adverse Event Leading to Discontinuation of Study Drug	Death	Event of Interest
出血性十二指腸潰瘍	X			

Treatment Group	Age at Study Start	Sex	Race
ABT-494 15 mg QD	5[redacted]	MALE	WHITE

Medical History	Onset Year
OTHER: ALOPECIA AREATA	19[redacted]
OTHER: PLAQUE PSORIASIS	20[redacted]
HYPERTENSION	20[redacted]
OTHER: RUPTURED BAKER'S CYST	20[redacted]
OSTEOARTHRITIS: BILATERAL KNEES, HANDS AND FEET	20[redacted]
ANEMIA: ANAEMIA	20[redacted]
OTHER: IMPAIRED GLUCOSE TOLERANCE	20[redacted]

Prior Procedures	Procedure Year
Not reported.	

Tobacco Use	Status	Number/Day	Number of Years	Year Stopped
CHEWING TOBACCO	NEVER			
CIGARETTES	FORMER	0.25 PACK	40	20[redacted]
CIGARS	NEVER			
E-CIGARETTES	NEVER			
PIPES	NEVER			

Alcohol Use	Status	Number/Day
ALCOHOL	CURRENT	2 - 4

Study Drug Administration

Study Drug	Dose/Units	Route	Frequency	First Dose Date/Day	Last Dose Date/Day	Duration (Days)
ABT-494	15MG	ORAL	QD	[redacted]20[redacted] / 1	[redacted]20[redacted] / 168	168
ABT-494	15MG	ORAL	QD	[redacted]20[redacted] / 169	[redacted]20[redacted] / 392	224

Previous Therapy - Prior to baseline/enrollment

Medication Name (WHO Drug)	Dose/Units	Frequency	Start Year-Month / RX Day
BCG Vaccine	NOT REPORTED	NOT REPORTED	Y-M: 19[redacted]
NAPROXEN	1 g	QD	Y-M: 20[redacted]
METHOTREXATE	20 mg	EVERY WEEK	Y-M: 20[redacted]
SULFASALAZINE	1 g	BID	Y-M: 20[redacted]
QUINAPRIL	5 mg	QD	Y-M: 20[redacted]
LEFLUNOMIDE	20 mg	QD	Y-M: 20[redacted]
ADALIMUMAB	40 mg	EVERY 2 WEEKS	Y-M: 20[redacted]
PREDNISONE	10 mg	QD	Y-M: 20[redacted]

Other Medications - Medications taken within 30 days prior to each narrative event until AE stopped or end of study

Medication Name (WHO Drug)	Dose/Units	Frequency	Start Year-Month / RX Day	Stop Year-Month / RX Day
NAPROXEN	1 g	QD	Y-M: 20[redacted]	Y-M: 20[redacted] / 336
LEFLUNOMIDE	20 mg	QD	Y-M: 20[redacted]	ONGOING
PREDNISONE	7.5 mg	QD	Y-M: 20[redacted] / 55	Y-M: 20[redacted] / 336
QUINAPRIL	20 mg	QD	Y-M: 20[redacted] / 156	ONGOING
TRAMADOL	100 mg	TID	Y-M: 20[redacted] / 308	ONGOING
RED BLOOD CELLS	579 mL	OTHER: ONCE ONLY	Y-M: 20[redacted] / 336	Y-M: 20[redacted] / 336
OMEPRAZOLE	40 mg	BID	Y-M: 20[redacted] / 336	Y-M: 20[redacted] / 337
RINGER-LACTATE	2 L	OTHER: ONCE ONLY	Y-M: 20[redacted] / 336	Y-M: 20[redacted] / 337
PREDNISONE	10 mg	QD	Y-M: 20[redacted] / 337	ONGOING
FENTANYL	50 OTHER: MCG	OTHER: ONCE ONLY	Y-M: 20[redacted] / 337	Y-M: 20[redacted] / 337
LIDOCAINE	6 OTHER: SPRAY	OTHER: ONCE ONLY	Y-M: 20[redacted] / 337	Y-M: 20[redacted] / 337
MIDAZOLAM	3 mg	OTHER: ONCE ONLY	Y-M: 20[redacted] / 337	Y-M: 20[redacted] / 337
OXYGEN	2 OTHER: L/MIN	OTHER: ONCE ONLY	Y-M: 20[redacted] / 337	Y-M: 20[redacted] / 337
SODIUM CHLORIDE	500 mL	OTHER: ONCE ONLY	Y-M: 20[redacted] / 337	Y-M: 20[redacted] / 337
NYSTATIN	2 mL	BID	Y-M: 20[redacted] / 337	Y-M: 20[redacted] / 338
OMEPRAZOLE	40 mg	BID	Y-M: 20[redacted]	Y-M: 20[redacted]

OMEPRAZOLE	20 mg	BID	/ 337 Y-M: 20[redacted]-[redacted] / 338	/ 338 ONGOING

Event #1: Serious Adverse Event

Event Description	UPPER GI BLEED DUE TO DUODENAL ULCERS
Preferred term	出血性十二指腸潰瘍
AE Onset Date / Rx Day	[redacted]20[redacted] / 327
Age at AE Onset	6[redacted]

Laboratory Testing

[redacted]20[redacted] (RX DAY 336): Erythrocytes: 2.2 [4.3 - 6] 10^12/L; Hematocrit: 0.21 [0.4 - 0.52] fraction of 1; Hemoglobin: 84 [130 - 175] g/L; Hemoglobin: 68 [130 - 175] g/L; NPTST016-APPT: 21 [25 - 38] sec; NPTST089-FOLATE: 30.5 [5 - 45] pmol/L; NPTST095-GLOBULIN: 19 [25 - 41] g/L; NPTST214-UREA: 13.9 [3.2 - 7.7] mmol/L; NPTST221-VITAMIN B12: 264 [170 - 800] pmol/L; Protein: 54 [66 - 84] g/L; [redacted]20[redacted] (RX DAY 337): NPTST016-APPT: 29 [25 - 38] sec; [redacted]20[redacted] (RX DAY 338): Erythrocytes: 2.6 [4.3 - 6] 10^12/L; Hematocrit: 0.24 [0.4 - 0.52] fraction of 1; Hemoglobin: 79 [130 - 175] g/L; NPTST214-UREA: 3.7 [3.2 - 7.7] mmol/L

Microbiology

[redacted]20[redacted] (RX DAY 337): OTHER BIOPSIES OF DUODENUM NPTST108-HELICOBACTER PYLORI TEST: NEGATIVE

SAE Supplemental Procedure

[redacted]20[redacted] (RX DAY 336): 2 UNITS OF RED BLOOD CELLS: HAEMOGLOBIN INCREASED TO 84G/L(130-175); CHEST X-RAY: NO FREE AIR UNDER THE DIAPHRAGM. HEART SIZE AND CONTOUR IS NORMAL. THE LUNGS AND PLEURAL SPACES ARE CLEAR.; ELECTROCARDIOGRAM: NORMAL SINUS RHYTHM NORMAL ECG; [redacted]20[redacted] (RX DAY 337): UPPER GI ENDOSCOPY: MULTIPLE SMALL ULCERS AND A CRATERED ULCER TOGETHER WITH EROSIONS FOUND IN THE 1ST PART OF D1, LIKELY SECONDARY TO NSAID USE. FEW EROSIONS ALSO SEEN AT THE PYLORUS.

AE Stopped Rx Day	338
Duration of AE	12 DAYS
Relation to Study Drug by Investigator	NO REASONABLE POSSIBILITY
Investigator Alternative Etiology	CONCOMITANT MEDICATIONS
Discontinued Study Drug Due to the Event	NO
SAE Criteria	REQUIRES OR PROLONGS HOSPITALIZATION, OTHER MEDICALLY IMPORTANT SERIOUS EVENT

Generated: [redacted]
Program Source Code: [redacted]

Investigator No.: [redacted]

Subject Number: [redacted]

Protocol Number: M15-554

治験責任医師からの報告。本被験者はニュージーランドの 6[redacted] 歳男性であり，ABT-494（ウパダシチニブ）の治験で盲検化された治験薬が投与され，十二指腸潰瘍による上部消化管出血の事象を発現した。

Event 1 の臨床経過：

関連する病歴は局面型乾癬，乾癬性関節炎，高血圧，元喫煙者（1 日 0.25 箱を 40 年間），貧血及び現飲酒者（1 日 2～4 杯）であった。

20[redacted] 年 [redacted] 月 [redacted] 日，被験者は十二指腸潰瘍による上部消化管出血を発現した。20[redacted] 年 [redacted] 月 [redacted] 日，十二指腸潰瘍による上部消化管出血は消失した。

20[redacted] 年 [redacted] 月 [redacted] 日，被験者は，10 日前からのメレナ，悪心，食欲不振，並びに 1 週間前からの全身倦怠，頭部ふらふら感，発汗及び心窩部痛で，さらなる治療のため入院した。入院時のバイタルサインは正常で発熱はなかった。臨床検査の検体が採取され，心電図検査と胸部 X 線検査が行われた。ヘモグロビン低下のため赤血球 2 単位が投与された。赤血球輸血後，ヘモグロビン値は 84 g/L に上昇した。また，オメプラゾールが静脈内投与された。内視鏡検査で十二指腸潰瘍が認められた。被験者の状態は安定しており，さらなるメレナはなく，通常通りに飲食していた。20[redacted] 年 [redacted] 月 [redacted] 日，被験者は退院し，経口でオメプラゾールを継続した。

被験者に本事象に関連する危険因子があり，現在使用中の薬剤は naprosyn 及び prednisone であった。

投与された薬剤は，ハルトマン輸液，オメプラゾール，赤血球液及び生理食塩液であった。

The patient's past medications include:

METHOTREXATE for PSORIATIC ARTHRITIS ([redacted] 20[redacted] - [redacted] 20[redacted])

SULPHASALAZINE for PSORIATIC ARTHRITIS ([redacted] 20[redacted] - [redacted] 20[redacted])

ADALIMUM for PSORIATIC ARTHRITIS ([redacted] 20[redacted] - [redacted] 20[redacted])

Causality for UPADACITINIB (Blinded)

---

1) Duodenal ulcer hemorrhage (10013845)(Duodenal ulcer haemorrhage (10013839)) [v.22.1] [10013845]

Causality as per reporter (Drug/Vaccine): No reasonable possibility

Causality as per Mfr. (Drug/Vaccine): No reasonable possibility

Dechallenge: Yes

Rechallenge: rechallenge was done, reaction did not recur

Alternative Etiology for UPADACITINIB (Blinded)

Event of UPPER GI BLEED DUE TO DUODENAL ULCERS

- Investigator: Concomitant medications.

- AbbVie: Event is more likely related to the concomitant duodenal ulcers risk factor for which includes NSAID use.

Relevant Laboratory & Other Diagnostic Tests

[redacted] **BLOOD PRESSURE:** 130/78 mmHg

[redacted] **CHEST X-RAY:** normal

[redacted] **ECG:** normal

[redacted] **FOLATE:** 30.5 PMOL/L (normal 5 to 45)

[redacted] **GLOBULIN:** 19 G/L (normal 25 to 41)

[redacted] **HEART RATE:** 87 /min

[redacted] **HELICOBACTER PYLORI TEST:** Biopsies of duodenum: Negative

[redacted] **HEMATOCRIT:** 0.21 G/L (normal 0.4 to 0.52)

[redacted] **HEMATOCRIT:** 0.24 G/L (normal 0.4 to 0.52)

[redacted] **HEMOGLOBIN:** 68 G/L (normal 130 to 175)

[redacted] **HEMOGLOBIN:** 84 G/L (normal 130 to 175)

[redacted] **HEMOGLOBIN:** 79 G/L (normal 130 to 175)

[redacted] **O2 SATURATION:** 99 %

[redacted] **PPT:** 21 SEC (normal 25 to 36)

[redacted] **PPT:** 29 SEC (normal 25 to 36)

[redacted] **20[redacted] PROTEIN:** 54 G/L (normal 66 to 84)

[redacted] **20[redacted] RED BLOOD CELLS:** 2.17 X10**12/L (normal 4.3 to 6)

[redacted] **20[redacted] RED BLOOD CELLS:** 2.57 X10**12/L (normal 4.3 to 6)

[redacted] **20[redacted] RESPIRATIONS:** 12 /min

[redacted] **20[redacted] UPPER GI ENDOSCOPY:** MULTIPLE SMALL ULCERS AND A CRATERED ULCER TOGETHER WITH EROSIONS FOUND IN THE 1ST PART OF D1, LIKELY SECONDARY TO NSAID USE. FEW EROSIONS ALSO SEEN AT THE PYLORUS.

[redacted] **20[redacted] UREA:** 13.9 MMOL/L (normal 3.2 to 7.7)

[redacted] **20[redacted] UREA:** 3.7 MMOL/L (normal 3.2 to 7.7)

[redacted] **20[redacted] VITAMIN B12:** 264 PMOL/L (normal 170 to 800)

被験者番号 [redacted] (Investigator [redacted])

Reason for Narrative

Adverse Event Preferred Term(s)	Serious Adverse Event	Adverse Event Leading to Discontinuation of Study Drug	Death	Event of Interest
ウイルス性胃腸炎	X			X
蜂巣炎	X			X
敗血症	X			X

Treatment Group	Age at Study Start	Sex	Race
ABT-494 30 mg QD	6[redacted]	FEMALE	NATIVE HAWAIIAN OR OTHER PACIFIC ISLANDER

Medical History	Onset Year
OTHER: ANAPHYLAXIS	19[redacted]
ASTHMA	19
OTHER: PLAQUE PSORIASIS	19
OTHER: POST MENOPAUSE	20
OBESITY: MORBID OBESITY	20
HYPERTENSION	20
OTHER: INTERSTITIAL NEPHRITIS	20
OSTEOARTHRITIS: OSTEOARTHRITIS SPINE	20

Prior Procedures	Procedure Year
SURGERY: LAPROSCOPIC CHOLECYSTECTOMY	19[redacted]

Tobacco Use	Status	Number/Day	Number of Years	Year Stopped
CHEWING TOBACCO	NEVER			
CIGARETTES	FORMER	0.1 PACK	15	19[redacted]
CIGARS	NEVER			
E-CIGARETTES	NEVER			
PIPES	NEVER			

Alcohol Use	Status	Number/Day
ALCOHOL	CURRENT	Less than 2

Study Drug Administration

Study Drug	Dose/Units	Route	Frequency	First Dose Date/Day	Last Dose Date/Day	Duration (Days)
ABT-494	30MG	ORAL	QD	[redacted]20[redacted] / 1	[redacted]20[redacted] / 161	161
ABT-494	30MG	ORAL	QD	[redacted]20[redacted] / 162	[redacted]20[redacted] / 255	94

Previous Therapy - Prior to baseline/enrollment

Medication Name (WHO Drug)	Dose/Units	Frequency	Start Year-Month / RX Day
SERETIDE	125/25 OTHER: MCG	PRN	Y-M: 19[redacted]
PARACETAMOL	1 g	PRN	Y-M: 20[redacted]
METHOTREXATE	15 mg	EVERY WEEK	Y-M: 20[redacted]
SULFASALAZINE	500 mg	BID	Y-M: 20[redacted]
LEFLUNOMIDE	10 mg	QD	Y-M: 20[redacted]
CETIRIZINE	10 mg	QD	Y-M: 20[redacted]
COLECALCIFEROL	2.5 mg	OTHER: MONTHLY	Y-M: 20[redacted]
DICLOFENAC	75 mg	PRN	Y-M: 20[redacted]
USTEKINUMAB	90 mg	OTHER: 12 WEEKLY	Y-M: 20[redacted]
OMEPRAZOLE	20 mg	QD	Y-M: 20[redacted]
ADALIMUMAB	40 mg	EVERY 2 WEEKS	Y-M: 20[redacted]
CANDESARTAN	32 mg	QD	Y-M: 20[redacted]
DAIVOBET	1 OTHER: APPLICATION	BID	Y-M: 20[redacted]
ETANERCEPT	50 mg	EVERY WEEK	Y-M: 20[redacted]
INFLIXIMAB	5MG/KG mg	OTHER: 8 WEEKLY	Y-M: 20[redacted]
CELECOXIB	200 mg	BID	Y-M: 20[redacted] / -121
PREDNISONE	10 mg	QD	Y-M: 20[redacted] / -28

Other Medications - Medications taken within 30 days prior to each narrative event until AE stopped or end of study

Medication Name (WHO Drug)	Dose/Units	Frequency	Start Year-Month / RX Day	Stop Year-Month / RX Day
SERETIDE	125/25 OTHER: MCG	PRN	Y-M: 19[redacted]	ONGOING
PARACETAMOL	1 g	PRN	Y-M: 20[redacted]	ONGOING
CETIRIZINE	10 mg	QD	Y-M: 20[redacted]	ONGOING
COLECALCIFEROL	2.5 mg	OTHER: MONTHLY	Y-M: 20[redacted]	ONGOING
DICLOFENAC	75 mg	PRN	Y-M: 20[redacted]	ONGOING
OMEPRAZOLE	20 mg	QD	Y-M: 20[redacted]	ONGOING
CANDESARTAN	32 mg	QD	Y-M: 20[redacted]	Y-M: 20[redacted] / 203
CELECOXIB	200 mg	BID	Y-M: 20[redacted] / -121	ONGOING
FISH OIL	1000 mg	QD	Y-M: 20[redacted] / 22	ONGOING
MAGNESIUM	400 mg	QD	Y-M: 20[redacted] / 74	Y-M: 20[redacted] / 292
CO-TRIMOXAZOLE	960 mg	BID	Y-M: 20[redacted] / 187	Y-M: 20[redacted] / 197
CANDESARTAN	16 mg	QD	Y-M: 20[redacted] / 204	Y-M: 20[redacted] / 288
ONDANSETRON	8 mg	TID	Y-M: 20[redacted] / 242	Y-M: 20[redacted] / 244
EL-4	1 L	OTHER: ONCE	Y-M: 20[redacted] / 243	Y-M: 20[redacted] / 243
ELECTROLYTES NOS	1 L	OTHER: ONCE	Y-M: 20[redacted] / 243	Y-M: 20[redacted] / 243
METOCLOPRAMIDE	10 mg	TID	Y-M: 20[redacted] / 243	Y-M: 20[redacted] / 244
POTASSIUM	2 OTHER: TABLEST	BID	Y-M: 20[redacted] / 244	Y-M: 20[redacted] / 244
METOCLOPRAMIDE	10 mg	TID	Y-M: 20[redacted] / 245	ONGOING
POTASSIUM	1200 mg	BID	Y-M: 20[redacted] / 245	Y-M: 20[redacted] / 246
VITAMINS NOS	10 mg	TID	Y-M: 20[redacted] / 245	Y-M: 20[redacted] / 251
DAIVOBET	1 OTHER: APPLICATION	QD	Y-M: 20[redacted] / 256	ONGOING
CYCLIZINE	25-50 mg	TID	Y-M: 20[redacted] / 286	ONGOING
ENOXAPARIN	40 mg	QD	Y-M: 20[redacted] / 286	ONGOING
ONDANSETRON	4-8 mg	TID	Y-M: 20[redacted] / 286	ONGOING

GENTAMICIN	400 mg	QD	Y-M: 20[redacted] / Y-M: 20[redacted] / 286 286
EMOLLIENTS AND PROTECTIVES	1 OTHER: APPLICATION	OTHER: HOURLY	Y-M: 20[redacted] / 288 ONGOING
HYDROCORTISONE	1 OTHER: APPLICATION	OTHER: EVERY 3-4 DAYS	Y-M: 20[redacted] / 288 ONGOING
SALBUTAMOL	2-4 OTHER: PUFFS	PRN	Y-M: 20[redacted] / 288 ONGOING
THIAMINE	200 mg	BID	Y-M: 20[redacted] / 288 ONGOING
POTASSIUM	2 OTHER: TABLETS	BID	Y-M: 20[redacted] / 288 Y-M: 20[redacted] / 291
HALOPERIDOL	5 mg	QD	Y-M: 20[redacted] / 289 Y-M: 20[redacted] / 289
PARENTROVITE	5 mL	QD	Y-M: 20[redacted] / 290 Y-M: 20[redacted] / 291
FOLIC ACID	5 mg	QD	Y-M: 20[redacted] / 290 Y-M: 20[redacted] / 296
BENZYLPENICILLIN	1.2 g	OTHER: 4 HOURLY	Y-M: 20[redacted] / 291 ONGOING
OXYCODONE	2.5-5 mg	OTHER: 3-4 HOURLY	Y-M: 20[redacted] / 292 ONGOING
POTASSIUM	2 OTHER: TABLETS	TID	Y-M: 20[redacted] / 293 Y-M: 20[redacted] / 295
MAGNESIUM	450 mg	TID	Y-M: 20[redacted] / 294 ONGOING
SODIUM CITROTARTRATE	1 OTHER: SACHET	TID	Y-M: 20[redacted] / 295 ONGOING
FOLIC ACID	5 mg	EVERY WEEK	Y-M: 20[redacted] / 297 ONGOING
BENZYLPENICILLIN	1.2 g	OTHER: ONCE	Y-M: 20[redacted] / 298 Y-M: 20[redacted] / 298
DEXAMETHASONE	4 mg	OTHER: ONCE	Y-M: 20[redacted] / 298 Y-M: 20[redacted] / 298
FENTANYL	100 OTHER: MCG	OTHER: ONCE	Y-M: 20[redacted] / 298 Y-M: 20[redacted] / 298
MORPHINE	7 mg	OTHER: ONCE	Y-M: 20[redacted] / 298 Y-M: 20[redacted] / 298
ONDANSETRON	4 mg	OTHER: ONCE	Y-M: 20[redacted] / 298 Y-M: 20[redacted] / 298
PLASMA LYTE 148	1000 mL	OTHER: ONCE	Y-M: 20[redacted] / 298 Y-M: 20[redacted] / 298
TRAMADOL	100 mg	OTHER: ONCE	Y-M: 20[redacted] / 298 Y-M: 20[redacted] / 298
VITAMINS NOS	2 OTHER: TABLETS	BID	Y-M: 20[redacted] / 333 ONGOING

Event #1: Serious Adverse Event, Study Specific Adverse Events of Interest

Event Description	VIRAL GASTROENTERITIS
Preferred term	ウイルス性胃腸炎
AE Onset Date / Rx Day	[redacted]20[redacted] / 227
Age at AE Onset	6[redacted]

Laboratory Testing

[redacted]20[redacted] (RX DAY 242): Aspartate Aminotransferase: 112 [NOT REPORTED - 45] U/L; Bicarbonate: 21 [22 - 31] mmol/L; Chloride: 88 [95 - 110] mmol/L; Potassium: 3.2 [3.5 - 5.2] mmol/L; Sodium: 130 [135 - 145] mmol/L; [redacted]20[redacted] (RX DAY 243): Aspartate Aminotransferase: 85 [NOT REPORTED - 45] U/L; Chloride: 92 [95 - 110] mmol/L; Sodium: 131 [135 - 145] mmol/L; [redacted]20[redacted] (RX DAY 244): Aspartate Aminotransferase: 86 [NOT REPORTED - 45] U/L; NPTST136 -MAGNESIUM: 0.56 [0.7 - 1] mmol/L; Potassium: 3.2 [3.5 - 5.2] mmol/L; Potassium: 3.2 [3.5 - 5.2] mmol/L

Microbiology

NOT REPORTED

SAE Supplemental Procedure

[redacted]20[redacted] (RX DAY 242): CHEST XRAY: HEART SIZE IS NORMAL. THE LUNGS AND PLEURAL SPACES ARE CLEAR. HEART SIZE IS NORMAL. CARDIAC AND MEDIASTINAL CONTOURS ARE NORMAL. THE LUNGS AND PLEURAL SPACES ARE CLEAR.; [redacted]20[redacted] (RX DAY 244): DIETICIAN CONSULT: ADVISED ON BALANCE DIET AND STARTED MULTIVITE

AE Stopped Rx Day	245
Duration of AE	19 DAYS
Relation to Study Drug by Investigator	REASONABLE POSSIBILITY
Investigator Alternative Etiology	NOT REPORTED
Discontinued Study Drug Due to the Event	NO
SAE Criteria	REQUIRES OR PROLONGS HOSPITALIZATION

Event #5: Serious Adverse Event, Study Specific Adverse Events of Interest

Event Description	SEPSIS SECONDARY TO RIGHT LOWER LEG CELLULITIS
Preferred term	蜂巣炎
AE Onset Date / Rx Day	[redacted]20[redacted] / 282 (27 DAYS AFTER LAST TREATMENT)
Age at AE Onset	6[redacted]

Laboratory Testing

[redacted]20[redacted] (RX DAY 286): Albumin: 26 [32 - 48] g/L; Chloride: 77 [95 - 110] mmol/L; Creatinine: 105 [45 - 90] umol/L; Leukocytes: 13.6 [4 - 11] 10^9/L; NPTST087-FIBRINOGEN: 6.7 [1.5 - 4] g/L; NPTST094-GGT: 223 [0 - 50] U/L; NPTST116-IMMATURE GRANULOCYTES: 1.4 [0 - 0.06] 10^9/L; NPTST172-PROCALCITONIN: 50.5 [0 - 0.1] ug/L; Neutrophils: 11.4 [1.9 - 7.5] 10^9/L; Potassium: 3.2 [3.5 - 5.2] mmol/L; Sodium: 121 [135 - 145] mmol/L; [redacted]20[redacted] (RX DAY 287): Chloride: 92 [95 - 110] mmol/L; Creatinine: 103 [45 - 90] umol/L; Leukocytes: 10.9 [4 - 11] 10^9/L; Lymphocytes: 0.4 [1 - 4] 10^9/L; Neutrophils: 9.2 [1.9 - 7.5] 10^9/L; Potassium: 3.4 [3.5 - 5.2] mmol/L; Sodium: 131 [135 - 145] mmol/L; [redacted]20[redacted] (RX DAY 290): Alkaline Phosphatase: 170 [40 - 120] U/L

Microbiology

[redacted]20[redacted] (RX DAY 286): BLOOD NPTST007-ADULT BLOOD CULTURE: POSITIVE-STAPHYLOCOCCUS LUGDUNENSIS ISOLATED

SAE Supplemental Procedure

[redacted]20[redacted] (RX DAY 286): AURICULAR TEMPERATURE: >38 DEGREE CELCIUS; RIGHT ANKLE X-RAY: BIMALLEOLAR SOFT TISSUE SWELLING.; [redacted]20[redacted] (RX DAY 298): RIGHT LOWER LEG

DEBRIDEMENT OF NECROTIC TISSUE UNDER GENERAL ANAESTHESIA: DEBRIDED NECROTIC TISSUE. APPLICATION OF VACUUM ASSISTED CLOSURE DRESSING

AE Stopped Rx Day	ONGOING
Duration of AE	ONGOING
Relation to Study Drug by Investigator	NO REASONABLE POSSIBILITY
Investigator Alternative Etiology	HAD A FALL ON [redacted]20[redacted] AFTER SYMPTOMS OF POSTURAL SYNCOPE. SUSTAINED ABRASION ON RIGHT LOWER LEG. SWELLING AND FEVER FOLLOWING 72 HOURS.
Discontinued Study Drug Due to the Event	NO
SAE Criteria	REQUIRES OR PROLONGS HOSPITALIZATION

Event #6: Serious Adverse Event, Study Specific Adverse Events of Interest

Event Description	SEPSIS SECONDARY TO RIGHT LOWER LEG CELLULITIS
Preferred term	敗血症
AE Onset Date / Rx Day	[redacted]20[redacted] / 282 (27 DAYS AFTER LAST TREATMENT)
Age at AE Onset	6[redacted]

Laboratory Testing

[redacted]20[redacted] (RX DAY 286): Albumin: 26 [32 - 48] g/L; Chloride: 77 [95 - 110] mmol/L; Creatinine: 105 [45 - 90] umol/L; Leukocytes: 13.6 [4 - 11] 10^9/L; NPTST087-FIBRINOGEN: 6.7 [1.5 - 4] g/L; NPTST094-GGT: 223 [0 - 50] U/L; NPTST116-IMMATURE GRANULOCYTES: 1.4 [0 - 0.06] 10^9/L; NPTST172-PROCALCITONIN: 50.5 [0 - 0.1] ug/L; Neutrophils: 11.4 [1.9 - 7.5] 10^9/L; Potassium: 3.2 [3.5 - 5.2] mmol/L; Sodium: 121 [135 - 145] mmol/L; [redacted]20[redacted] (RX DAY 287): Chloride: 92 [95 - 110] mmol/L; Creatinine: 103 [45 - 90] umol/L; Leukocytes: 10.9 [4 - 11] 10^9/L; Lymphocytes: 0.4 [1 - 4] 10^9/L; Neutrophils: 9.2 [1.9 - 7.5] 10^9/L; Potassium: 3.4 [3.5 - 5.2] mmol/L; Sodium: 131 [135 - 145] mmol/L; [redacted]20[redacted] (RX DAY 290): Alkaline Phosphatase: 170 [40 - 120] U/L

Microbiology

[redacted]20[redacted] (RX DAY 286): BLOOD NPTST007-ADULT BLOOD CULTURE: POSITIVE-STAPHYLOCOCCUS LUGDUNENSIS ISOLATED

SAE Supplemental Procedure

[redacted]20[redacted] (RX DAY 286): AURICULAR TEMPERATURE: >38 DEGREE CELCIUS; RIGHT ANKLE X-RAY: BIMALLEOLAR SOFT TISSUE SWELLING.; [redacted]20[redacted] (RX DAY 298): RIGHT LOWER LEG DEBRIDEMENT OF NECROTIC TISSUE UNDER GENERAL ANAESTHESIA: DEBRIDED NECROTIC TISSUE. APPLICATION OF VACUUM ASSISTED CLOSURE DRESSING

AE Stopped Rx Day	ONGOING
Duration of AE	ONGOING
Relation to Study Drug by Investigator	NO REASONABLE POSSIBILITY
Investigator Alternative Etiology	HAD A FALL ON [redacted]20[redacted] AFTER SYMPTOMS OF POSTURAL SYNCOPE. SUSTAINED ABRASION ON RIGHT LOWER LEG. SWELLING AND FEVER FOLLOWING 72 HOURS.
Discontinued Study Drug Due to the Event	NO
SAE Criteria	REQUIRES OR PROLONGS HOSPITALIZATION

Generated: [redacted]
Program Source Code: [redacted]

Investigator No.: [redacted]

Subject Number: [redacted]

Protocol Number: M15-554

治験責任医師からの報告。本被験者はニュージーランドの 6[redacted] 歳女性であり，ABT-494（ウパダシチニブ）の治験で盲検化された治験薬が投与され，ウイルス性胃腸炎の事象を発現した。

Event 1 の臨床経過：

関連する病歴は元喫煙者（1 日 0.1 箱を 15 年間），局面型乾癬，病的肥満及び現飲酒者（1 日 2 杯未満）であった。

被験者は，最初の 24 週間，本治験の盲検プラセボ対照期に組み入れられていた。20[redacted] 年 [redacted] 月 [redacted] 日，ABT-494 の盲検投与が開始された。

20[redacted] 年 [redacted] 月 [redacted] 日，被験者はウイルス性胃腸炎を発現した。20[redacted] 年 [redacted] 月 [redacted] 日，ウイルス性胃腸炎は消失した。

入院の 2 週間前に，被験者は下痢及び複数回の失神を来すようになり，続いて 2～3 週間にわたって主観的な発熱が出現と消失を繰り返した。1 週間前には，嘔吐が 1 日 3～4 回出現した。20[redacted] 年 [redacted] 月 [redacted] 日，被験者は静脈内輸液治療及び投薬のため入院し，ケトン食療法に関心があったことから栄養士を紹介された。20[redacted] 年 [redacted] 月 [redacted] 日，栄養士がバランスの取れた食事について指導し，Multivite の服用を開始するようアドバイスした。入院後，嘔吐やさらなる下痢は認められなかった。食欲も改善した。20[redacted] 年 [redacted] 月 [redacted] 日，被験者は退院した。

投与された薬剤は，maxolon，chlorvescent，塩化カリウム，総合ビタミン剤，plasmalyte 148 + 20 KCL，塩酸メトクロプラミド及び multivite であった。

The patient's past medications include:

METHOTREXATE for PSORIATIC ARTHRITIS (20[redacted] - 20[redacted])

SALAZOPYRIN for PSORIATIC ARTHRITIS ([redacted] [redacted] 20[redacted] - [redacted] [redacted] 20[redacted])

LEFLUNOMIDE for PSORIATIC ARTHRITIS ([redacted] [redacted] 20[redacted] - [redacted] [redacted] 20[redacted])

USTEKINUMAB for PSORIATIC ARTHRITIS ([redacted] 20[redacted] - 20[redacted])

ADALIMUMAB for PSORIATIC ARTHRITIS ([redacted] 20[redacted] - [redacted] 20[redacted])

DAIVOBET for PSORIASIS ([redacted] 20[redacted] - [redacted] 20[redacted])

ETANERCEPT for PSORIATIC ARTHRITIS ([redacted] 20[redacted] - [redacted] 20[redacted])

INFLIXIMAB for PSORIATIC ARTHRITIS ([redacted] 20[redacted] - [redacted] 20[redacted])

PREDNISONE for PSORIATIC ARTHRITIS and BRONCHIAL EXACERBATION OF ASTHMA ([redacted] 20[redacted] - [redacted] 20[redacted], [redacted] 20[redacted] - [redacted] 20[redacted], [redacted] 20[redacted] - [redacted] 20[redacted], [redacted] 20[redacted] - [redacted] 20[redacted])

Causality for ABT-494 (Blinded)

---

1) Viral gastroenteritis (10047445) (Gastroenteritis viral (10017918)) [v.22.0] [10047445]

Causality as per reporter (Drug/Vaccine): Reasonable possibility

Causality as per Mfr. (Drug/Vaccine): No reasonable possibility

Dechallenge: Yes

Rechallenge: rechallenge was done, reaction did not recur

Alternative Etiology for ABT-494 (Blinded)

Event of VIRAL GASTROENTERITIS

- **Investigator:** Not applicable

- **AbbVie:** Event is common in the general population

Relevant Laboratory & Other Diagnostic Tests

[redacted] 20[redacted] **ASPARTATE AMINO TRANSFERASE:** 112 U/L

[redacted] 20[redacted] **ASPARTATE AMINO TRANSFERASE:** 85 U/L (normal <45)

[redacted] 20[redacted] **ASPARTATE AMINO TRANSFERASE:** 86 U/L (normal <45)

[redacted] **20[redacted] BICARBONATE:** 21 MMOL/L (normal 22 to 31)

[redacted] **20[redacted] CHEST XRAY:** HEART SIZE IS NORMAL. CARDIAC AND MEDIASTINAL CONTOURS ARE NORMAL. THE LUNGS AND PLEURAL SPACES ARE CLEAR.

[redacted] **20[redacted] CHLORIDE:** 88 MMOL/L (normal 95 to 110)

[redacted] **20[redacted] CHLORIDE:** 92 MMOL/L (normal 95 to 110)

[redacted] **20[redacted] MAGNESIUM:** 0.56 MMOL/L (normal 0.70 to 1.00)

[redacted] **20[redacted] POTASSIUM:** 3.2 MMOL/L (normal 3.5 to 5.2)

[redacted] **20[redacted] POTASSIUM:** 3.2 MMOL/L (normal 3.5 to 5.2)

[redacted] **20[redacted] SODIUM:** 130 MMOL/L (normal 135 to 145)

[redacted] **20[redacted] SODIUM:** 131 MMOL/L (normal 135 to 145)
Investigator No.: [redacted]

Subject Number: [redacted]

Protocol Number: M15-554

治験責任医師からの報告。本被験者はニュージーランドの 6[redacted] 歳女性であり，ABT-494（ウパダシチニブ）の治験で盲検化された治験薬が投与され，右下肢蜂巣炎による敗血症の事象を発現した。

Event 5 及び 6 の臨床経過：

関連する病歴は元喫煙者（1 日 0.1 箱を 15 年間），局面型乾癬，乾癬性関節炎，閉経後，病的肥満，高血圧及び現飲酒者（1 日 2 杯未満）であった。

被験者は，最初の 24 週間，本治験の盲検プラセボ対照期に組み入れられていた。20[redacted] 年 [redacted] 月 [redacted] 日，ABT-494 の盲検投与が開始された。

20[redacted] 年 [redacted] 月 [redacted] 日，被験者は右下肢蜂巣炎による敗血症を発現した。

20[redacted] 年 [redacted] 月 [redacted] 日，被験者は起立性失神の症状発現後に転倒した。被験者は右下肢に擦過傷を負った。その後，被験者は，右下肢の腫脹，紅斑，疼痛及び表在性の滲出物が 72 時間続いたため，救急科を受診した。また，悪寒及び震えを伴う主観的な発熱が 48 時間続いていた。右下肢は足からすねの中央まで腫れていた。被験者は，右下肢の創傷及び蜂巣炎による敗血症のため，20[redacted] 年 [redacted] 月 [redacted] 日に入院した。鎮痛剤及び静脈内輸液の投与，VTE の予防及び抗生物質の静脈内投与が行われた。20[redacted] 年 [redacted] 月 [redacted] 日に幻聴及び幻視を発現し，治療としてビタミン補給が行われた。20[redacted] 年 [redacted] 月 [redacted] 日，陰圧閉鎖療法による右下肢壊死組織のデブリードマンが全身麻酔下で行

われた。20[redacted] 年 [redacted] 月 [redacted] 日，被験者は退院した。

投与された薬剤は，シクリジン，span K，ゲンタマイシン，葉酸，ペニシリン，マグネシウム，ural，oxynorm，ハロペリドール，pabrinex，ペニシリン G，デキサメタゾン，plasmalyte，モルヒネ，オンダンセトロン，チアミン及びトラマドールであった。

The patient's past medications include:

METHOTREXATE for PSORIATIC ARTHRITIS (20[redacted] - 20[redacted])

SALAZOPYRIN for PSORIATIC ARTHRITIS ([redacted] 20[redacted] - [redacted] 20[redacted])

LEFLUNOMIDE for PSORIATIC ARTHRITIS ([redacted] 20[redacted] - [redacted] 20[redacted])

USTEKINUMAB for PSORIATIC ARTHRITIS ([redacted] 20[redacted] - 20[redacted])

ADALIMUMAB for PSORIATIC ARTHRITIS ([redacted] 20[redacted] - [redacted] 20[redacted])

DAIVOBET for PSORIASIS ([redacted] 20[redacted] - [redacted] 20[redacted])

ETANERCEPT for PSORIATIC ARTHRITIS ([redacted] 20[redacted] - [redacted] 20[redacted])

INFLIXIMAB for PSORIATIC ARTHRITIS (20[redacted] - [redacted] 20[redacted])

PREDNISONE for PSORIATIC ARTHRITIS and BRONCHIAL EXACERBATION OF ASTHMA ([redacted] 20[redacted] - [redacted] 20[redacted], [redacted] 20[redacted] - [redacted] 20[redacted], [redacted] 20[redacted] - [redacted] 20[redacted], [redacted] 20[redacted] - [redacted] 20[redacted], [redacted] 20[redacted] - [redacted] 20[redacted])

Causality for UPADACITINIB (Blinded)

---

1) Sepsis secondary (10040053) (Sepsis (10040047)) [v.22.1] [10040053]

Causality as per reporter (Drug/Vaccine): No reasonable possibility

Causality as per Mfr. (Drug/Vaccine): No reasonable possibility

Dechallenge: Not Applicable

2) Cellulitis of leg (10007912) (Cellulitis (10007882)) [v.22.1] [10007912]

Causality as per reporter (Drug/Vaccine): No reasonable possibility

Causality as per Mfr. (Drug/Vaccine): No reasonable possibility

Dechallenge: Not Applicable

Alternative Etiology for UPADACITINIB (Blinded)

Event of SEPSIS SECONDARY TO RIGHT LOWER LEG CELLULITIS

- Investigator: HAD A FALL ON 20APR2019 AFTER SYMPTOMS OF POSTURAL SYNCOPE. SUSTAINED ABRASION ON RIGHT LOWER LEG. SWELLING AND FEVER FOLLOWING 72 HOURS.

- AbbVie: Event is more likely due to preceding abrasion and pre-existing morbid obesity. Additionally, lack of temporal association, with last dose of study drug close to a month prior to onset of event.

Relevant Laboratory & Other Diagnostic Tests

[redacted] **20[redacted] ADULT BLOOD CULTURE:** Positive: Staphylococcus Lugdunensis Isolated.

[redacted] **20[redacted] ALBUMIN:** 26 G/L (normal 32 to 48)

[redacted] **20[redacted] ALKALINE PHOSPHATASE:** 170 U/L (normal 40 to 120)

[redacted] **20[redacted] CHLORIDE:** 77 mmol/L (normal 95 to 110)

[redacted] **20[redacted] CHLORIDE:** 92 mmol/L (normal 95 to 110)

[redacted] **20[redacted] CREATININE:** 105 umol/L (normal 45 to 90)

[redacted] **20[redacted] CREATININE:** 103 umol/L (normal 45 to 90)

[redacted] **20[redacted] FIBRINOGEN:** 6.7 G/L (normal 1.5 to 4.0)

[redacted] **20[redacted] GGT:** 223 U/L (normal 0 to 50)

[redacted] **20[redacted] IMMATURE GRANULOCYTES:** 1.4 X10**9/L (normal 0.0 to 0.06)

[redacted] **20[redacted] LYMPHOCYTES ABS:** 0.4 X10**9/L (normal 1.0 to 4.0)

[redacted] **20[redacted] NEUTROPHILS ABS:** 11.4 X10**9/L (normal 1.9 to 7.5)

[redacted] **20[redacted] NEUTROPHILS ABS:** 9.2 X10**9/L (normal 1.9 to 7.5)

[redacted] **20[redacted] POTASSIUM:** 3.2 mmol/L (normal 3.5 to 5.2)

[redacted] **20[redacted] POTASSIUM:** 3.4 mmol/L (normal 3.5 to 5.2)

[redacted] **20[redacted] PROCALCITONIN:** 50.50 UG/L (normal 0 to 0.1)

[redacted] **20[redacted] RIGHT ANKLE X-RAY:** Bimalleolar soft tissue swelling.

[redacted] **20[redacted] SODIUM:** 121 mmol/L (normal 135 to 145)

[redacted] **20[redacted] SODIUM:** 131 mmol/L (normal 135 to 145)

[redacted] **20[redacted] WHITE BLOOD CELLS:** 13.6 X10**9/L (normal 4.0 to 11.0)

[redacted] **20[redacted] WHITE BLOOD CELLS:** 10.9 X10**9/L (normal 4.0 to 11.0)

被験者番号 [redacted] (Investigator [redacted])

Reason for Narrative

Adverse Event Preferred Term(s)	Serious Adverse Event	Adverse Event Leading to Discontinuation of Study Drug	Death	Event of Interest
変形性関節症	X			

Treatment Group	Age at Study Start	Sex	Race
ABT-494 15 mg QD	5[redacted]	FEMALE	WHITE

Medical History	Onset Year
OTHER: PLAQUE PSORIASIS	19[redacted]
OTHER: FRACTURE LEFT 5TH METATARSAL	19
OTHER: DEGENERATIVE DISEASE L5/S1	20
OTHER: OSTEOARTHRITIS KNEES	20
DEPRESSION: DEPRESSION	20
OTHER: POST MENOPAUSE	20
GASTROESOPHAGEAL REFLUX DISEASE	20
OTHER: INSOMNIA	20
HYPERTENSION	20
OTHER: ROTATOR CUFF INJURY	20
OTHER: DIFFUSE HEPATIC STEATOSIS	20
OTHER: OBSTRUCTIVE SLEEP APNEA	20

Prior Procedures	Procedure Year
Not reported.	

Tobacco Use	Status	Number/Day	Number of Years	Year Stopped
CHEWING TOBACCO	NEVER			
CIGARETTES	NEVER			
CIGARS	NEVER			
E-CIGARETTES	NEVER			
PIPES	NEVER			

Alcohol Use	Status	Number/Day
ALCOHOL	CURRENT	Less than 2

Study Drug Administration

Study Drug	Dose/Units	Route	Frequency	First Dose Date/Day	Last Dose Date/Day	Duration (Days)
ABT-494	15MG	ORAL	QD	[redacted]20[redacted] / 1	[redacted]20[redacted] / 169	169
ABT-494	15MG	ORAL	QD	[redacted]20[redacted] / 170	[redacted]20[redacted] / 316	147

Previous Therapy - Prior to baseline/enrollment

Medication Name (WHO Drug)	Dose/Units	Frequency	Start Year-Month / RX Day
BCG Vaccine	NOT REPORTED	NOT REPORTED	Y-M: 19[redacted]
PARACETAMOL	1 g	PRN	Y-M: 20[redacted]
OXAZEPAM	10 mg	QD	Y-M: 20[redacted]
ZOPICLONE	3.75 mg	QD	Y-M: 20[redacted]
TRIAZOLAM	125 OTHER: MCG	QD	Y-M: 20[redacted]
LEFLUNOMIDE	20 mg	QD	Y-M: 20[redacted]
ADALIMUMAB	40 mg	EVERY 2 WEEKS	Y-M: 20[redacted]
BENDROFLUMETHIAZIDE	2.5 mg	QD	Y-M: 20[redacted]
VENLAFAXINE	225 mg	QD	Y-M: 20[redacted]
ETANERCEPT	50 mg	EVERY WEEK	Y-M: 20[redacted]
COLECALCIFEROL	2000 IU	QD	Y-M: 20[redacted]
CROCUS SATIVUS;CURCUMA LONGA	350 mg	QD	Y-M: 20[redacted]
FIBROPLEX	210 g	QD	Y-M: 20[redacted]
FLUCONAZOLE	100 mg	EVERY 2 WEEKS	Y-M: 20[redacted]
MAGNESIUM CITRATE	330 mg	QD	Y-M: 20[redacted]
PITAVASTATIN	3.4 g	QD	Y-M: 20[redacted]
PROGESTERONE	1 OTHER: APPLICATION	QD	Y-M: 20[redacted]
VITAMIN B COMPLEX	500 mg	QD	Y-M: 20[redacted]
TEMAZEPAM	20 mg	QD	Y-M: 20[redacted]
INFLIXIMAB	440 mg	OTHER: 6-8 WEEKLY	Y-M: 20[redacted]
CLOTRIMAZOLE	1 OTHER: APPLICATION	QD	Y-M: 20[redacted] / 198
MIRTAZAPINE	15 mg	QD	Y-M: 20[redacted] / 198
FOLIC ACID	5 mg	OTHER: TWICE/WEEK	Y-M: 20[redacted] / 184
METHOTREXATE	10 mg	EVERY WEEK	Y-M: 20[redacted] / 177
POTASSIUM	600 mg	BID	Y-M: 20[redacted] / 173
TRAMADOL	100 mg	PRN	Y-M: 20[redacted] / 77
CODEINE	30 mg	TID	Y-M: 20[redacted] / -

IBUPROFEN	800 mg	PRN	Y-M: 20[redacted]-[redacted] / -12	

Other Medications - Medications taken within 30 days prior to each narrative event until AE stopped or end of study

Medication Name (WHO Drug)	Dose/Units	Frequency	Start Year-Month / RX Day	Stop Year-Month / RX Day
PARACETAMOL	1 g	PRN	Y-M: 20[redacted]	ONGOING
OXAZEPAM	10 mg	QD	Y-M: 20[redacted]	ONGOING
ZOPICLONE	3.75 mg	QD	Y-M: 20[redacted]	ONGOING
TRIAZOLAM	125 OTHER: MCG	QD	Y-M: 20[redacted]	ONGOING
BENDROFLUMETHIAZIDE	2.5 mg	QD	Y-M: 20[redacted]	Y-M: 20[redacted] / 193
VENLAFAXINE	225 mg	QD	Y-M: 20[redacted]	ONGOING
COLECALCIFEROL	2000 IU	QD	Y-M: 20[redacted]	ONGOING
CROCUS SATIVUS;CURCUMA LONGA	350 mg	QD	Y-M: 20[redacted]	ONGOING
FIBROPLEX	210 g	QD	Y-M: 20[redacted]	ONGOING
MAGNESIUM CITRATE	330 mg	QD	Y-M: 20[redacted]	ONGOING
PITAVASTATIN	3.4 g	QD	Y-M: 20[redacted]	ONGOING
PROGESTERONE	1 OTHER: APPLICATION	QD	Y-M: 20[redacted]	ONGOING
VITAMIN B COMPLEX	500 mg	QD	Y-M: 20[redacted]	ONGOING
TEMAZEPAM	20 mg	QD	Y-M: 20[redacted]	ONGOING
CLOTRIMAZOLE	1 OTHER: APPLICATION	QD	Y-M: 20[redacted] / -198	ONGOING
MIRTAZAPINE	15 mg	QD	Y-M: 20[redacted] / -198	ONGOING
POTASSIUM	600 mg	BID	Y-M: 20[redacted] / -173	Y-M: 20[redacted] / 211
TRAMADOL	100 mg	PRN	Y-M: 20[redacted] / -77	ONGOING
IBUPROFEN	800 mg	PRN	Y-M: 20[redacted] / -12	ONGOING
MULTIVITAMINS, COMBINATIONS	1 OTHER: TABLET	QD	Y-M: 20[redacted] / 45	ONGOING
NORTRIPTYLINE	20 mg	QD	Y-M: 20[redacted] / 113	ONGOING
FOLIC ACID	5 mg	EVERY WEEK	Y-M: 20[redacted] / 120	ONGOING
METHOTREXATE	20 mg	EVERY WEEK	Y-M: 20[redacted] / 120	ONGOING
PREDNISONE	5 mg	QD	Y-M: 20[redacted] / 127	Y-M: 20[redacted] / 134
CEFACLOR	500 mg	TID	Y-M: 20[redacted] /	Y-M: 20[redacted] /

PREDNISONE	2.5 mg	QD	Y-M: 20[redacted]-[redacted] 129	Y-M: 20[redacted]-[redacted] 137
FUROSEMIDE	20 mg	QD	Y-M: 20[redacted]-[redacted] 135	Y-M: 20[redacted]-[redacted] 139
FUROSEMIDE	40 mg	QD	Y-M: 20[redacted]-[redacted] 169	Y-M: 20[redacted]-[redacted] 192
CEFALEXIN	500 mg	TID	Y-M: 20[redacted]-[redacted] 193	Y-M: 20[redacted]-[redacted] 211
HYPROMELLOSE	0.3 %	QID	Y-M: 20[redacted]-[redacted] 228	Y-M: 20[redacted]-[redacted] 235
METHYLPREDNISOLONE	80 mg	OTHER: ONCE	Y-M: 20[redacted]-[redacted] 228	Y-M: 20[redacted]-[redacted] 235
CEFAZOLIN	1 g	TID	Y-M: 20[redacted]-[redacted] 246	Y-M: 20[redacted]-[redacted] 246
CEFAZOLIN	2 g	OTHER: ONCE	Y-M: 20[redacted]-[redacted] 286	Y-M: 20[redacted]-[redacted] 286
FENTANYL	50 pg	OTHER: ONCE	Y-M: 20[redacted]-[redacted] 286	Y-M: 20[redacted]-[redacted] 286
GENTAMICIN	80 mg	OTHER: ONCE	Y-M: 20[redacted]-[redacted] 286	Y-M: 20[redacted]-[redacted] 286
LORATADINE	10 mg	OTHER: ONCE	Y-M: 20[redacted]-[redacted] 286	Y-M: 20[redacted]-[redacted] 286
MIDAZOLAM	1.5 mg	OTHER: ONCE	Y-M: 20[redacted]-[redacted] 286	Y-M: 20[redacted]-[redacted] 286
ONDANSETRON	4 mg	OTHER: ONCE	Y-M: 20[redacted]-[redacted] 286	Y-M: 20[redacted]-[redacted] 286
RANITIDINE	150 mg	OTHER: ONCE	Y-M: 20[redacted]-[redacted] 286	Y-M: 20[redacted]-[redacted] 286
OXYCODONE	10 mg	BID	Y-M: 20[redacted]-[redacted] 286	Y-M: 20[redacted]-[redacted] 288
OXYCODONE	5-10 mg	PRN	Y-M: 20[redacted]-[redacted] 286	Y-M: 20[redacted]-[redacted] 289

Event #1: Serious Adverse Event

Event Description	RIGHT KNEE OSTEOARTHRITIS
Preferred term	変形性関節症
AE Onset Date / Rx Day	[redacted]20[redacted] / 161
Age at AE Onset	5[redacted]

Laboratory Testing

NOT REPORTED

Microbiology

NOT REPORTED

SAE Supplemental Procedure

[redacted]20[redacted] (RX DAY 286): RIGHT TOTAL KNEE JOINT REPLACEMENT: FOR SECONDARY TO OSTEOARTHRITIS

AE Stopped Rx Day 287

Duration of AE	127 DAYS
Relation to Study Drug by Investigator	NO REASONABLE POSSIBILITY
Investigator Alternative Etiology	CAUSE OF EVENT IS OSTEOARTHRITIS
Discontinued Study Drug Due to the Event	NO
SAE Criteria	REQUIRES OR PROLONGS HOSPITALIZATION

Generated: [redacted]
Program Source Code: [redacted]

Investigator No.: [redacted]

Subject Number: [redacted]

Protocol Number: M15-554

治験責任医師からの報告。本被験者はニュージーランドの 5[redacted] 歳女性であり，ABT-494（ウパダシチニブ）の治験で盲検化された治験薬が投与され，右膝変形性関節症の事象を発現した。

Event 1 の臨床経過：

関連する病歴は局面型乾癬，乾癬性関節炎及び変形性膝関節症であった。

20[redacted] 年 [redacted] 月 [redacted] 日，被験者は右膝変形性関節症を発現した。20[redacted] 年 [redacted] 月 [redacted] 日，右膝変形性関節症は消失した。

20[redacted] 年 [redacted] 月 [redacted] 日，被験者は二次性変形性関節症の治療として膝関節置換術を受けるため入院した。被験者は滲出液及び膝蓋前皮下包滲出液の徴候・症状を呈していた。20[redacted] 年 [redacted] 月 [redacted] 日，被験者は退院した。

投与された薬剤はオキシコドンであった。

Causality for UPADACITINIB (Blinded)

---

1) Knee osteoarthritis (10023476) (Osteoarthritis (10031161)) [v.22.1] [10023476]

Causality as per reporter (Drug/Vaccine): No reasonable possibility

Causality as per Mfr. (Drug/Vaccine): No reasonable possibility

Dechallenge: Yes

Rechallenge: rechallenge was done, reaction did not recur

Alternative Etiology for UPADACITINIB (Blinded)

Event of RIGHT KNEE OSTEOARTHRITIS

- Investigator: Cause of event is osteoarthritis

- AbbVie: Event more likely related to pre-existing osteoarthritis knees. Additional risk factor includes obesity.

被験者番号 [redacted] (Investigator [redacted])

Reason for Narrative

Adverse Event Preferred Term(s)	Serious Adverse Event	Adverse Event Leading to Discontinuation of Study Drug	Death	Event of Interest
鼠径ヘルニア	X			

Treatment Group	Age at Study Start	Sex	Race
Placebo/ABT-494 30 mg QD	6[redacted]	MALE	WHITE

Medical History	Onset Year
OTHER: PLAQUE PSORIASIS	19[redacted]
OTHER: BILATERAL DUPUYTREN	20[redacted]

Prior Procedures	Procedure Year
SURGERY: UMBILICOPLASTY	20[redacted]
SURGERY: RIGHT INGUINAL HERNIORRHAPHY	20[redacted]

Tobacco Use	Status	Number/Day	Number of Years	Year Stopped
CHEWING TOBACCO	NEVER			
CIGARETTES	NEVER			
CIGARS	NEVER			
E-CIGARETTES	NEVER			
PIPES	NEVER			

Alcohol Use	Status	Number/Day
ALCOHOL	NEVER	

Study Drug Administration

Study Drug	Dose/Units	Route	Frequency	First Dose Date/Day	Last Dose Date/Day	Duration (Days)
PLACEBO		ORAL	QD	[redacted]20[redacted] / 1	[redacted]20[redacted] / 168	168
ABT-494	30MG	ORAL	QD	[redacted]20[redacted] / 169	[redacted]20[redacted] / 393	225
ABT-494	30MG	ORAL	QD	[redacted]20[redacted] / 394	/	

Previous Therapy - Prior to baseline/enrollment

Medication Name (WHO Drug)	Dose/Units	Frequency	Start Year-Month / RX Day
FOLIC ACID	5 mg	EVERY WEEK	Y-M: 20[redacted]
METHOTREXATE	10 mg	EVERY WEEK	Y-M: 20[redacted]
METHOTREXATE	15 mg	EVERY WEEK	Y-M: 20[redacted]
OMEPRAZOLE	20 mg	QD	Y-M: 20[redacted]
METHOTREXATE	20 mg	EVERY WEEK	Y-M: 20[redacted]
ACECLOFENAC	100 mg	QD	Y-M: 20[redacted]
PREDNISONE	10 mg	QD	Y-M: 20[redacted]
IXEKIZUMAB	80 mg	EVERY 2 WEEKS	Y-M: 20[redacted]

Other Medications - Medications taken within 30 days prior to each narrative event until AE stopped or end of study

Medication Name (WHO Drug)	Dose/Units	Frequency	Start Year-Month / RX Day	Stop Year-Month / RX Day
FOLIC ACID	5 mg	EVERY WEEK	Y-M: 20[redacted]	Not reported.
OMEPRAZOLE	20 mg	QD	Y-M: 20[redacted]	Not reported.
METHOTREXATE	20 mg	EVERY WEEK	Y-M: 20[redacted]	Not reported.
ACECLOFENAC	100 mg	QD	Y-M: 20[redacted]	Not reported.
PREDNISONE	10 mg	QD	Y-M: 20[redacted]	Not reported.
HYDROCORTISONE	100 mg	OTHER: ONE DOSE	Y-M: 20[redacted] / 325	Y-M: 20[redacted] / 325
RANITIDINE	50 mg	OTHER: ONE DOSE	Y-M: 20[redacted] / 325	Y-M: 20[redacted] / 325

Event #1: Serious Adverse Event

Event Description	LEFT INGUINOSCROTAL HERNIA
Preferred term	単径ヘルニア
AE Onset Date / Rx Day	[redacted]20[redacted] / 225
Age at AE Onset	6[redacted]

Laboratory Testing

NOT REPORTED

Microbiology

NOT REPORTED

SAE Supplemental Procedure

[redacted]20[redacted] (RX DAY 325): LEFT INGUINOESCROTAL HERNIOPLASTY: [redacted]20[redacted]. ON [redacted], HERNIOPLASTY WAS PERFORMED.

AE Stopped Rx Day	325
Duration of AE	101 DAYS
Relation to Study Drug by Investigator	NO REASONABLE POSSIBILITY
Investigator Alternative Etiology	LEFT INGUINOSCROTAL HERNIOPLASTY
Discontinued Study Drug Due to the Event	NO
SAE Criteria	REQUIRES OR PROLONGS HOSPITALIZATION

Generated: [redacted]
Program Source Code: [redacted]

Investigator No.: [redacted]

Subject Number: [redacted]

Protocol Number: M15-554

治験責任医師からの報告。本被験者はスペインの 6[redacted] 歳男性であり，ABT-494（ウパダシチニブ）の治験で盲検化された治験薬が投与され，左鼠径陰嚢ヘルニアの事象を発現した。

Event 1 の臨床経過：

関連する病歴は局面型乾癬，臍形成術，右鼠径部ヘルニア縫合，両側性デュピュイトラン拘縮，乾癬性関節炎，非喫煙者及び非飲酒者であった。

20[redacted] 年 [redacted] 月 [redacted] 日，被験者は左鼠径陰嚢ヘルニアを発現した。

被験者は 20[redacted] 年 [redacted] 月 [redacted] 日に入院し，20[redacted] 年 [redacted] 月 [redacted] 日に左鼠径陰嚢ヘルニア根治術を受けた。20[redacted] 年 [redacted] 月 [redacted] 日，被験者は退院した。

投与された薬剤は，clexane，ラニチジン及びヒドロコルチゾンであった。

Causality for UPADACITINIB (Blinded)

---

1) Left inguinal hernia (10024109) (Inguinal hernia (10022016)) [v.22.1] [10024109]

Causality as per reporter (Drug/Vaccine): No reasonable possibility

Causality as per Mfr. (Drug/Vaccine): No reasonable possibility

Dechallenge: Yes

Rechallenge: rechallenge was done, reaction did not recur

Alternative Etiology for UPADACITINIB (Blinded)

Event of LEFT INGUINOSCROTAL HERNIA

- Investigator: Not Reported

- AbbVie: Risk factor includes prior history of inguinal herniorrhaphy ([redacted] 20[redacted]) and current significant tobacco history

被験者番号 [redacted] (Investigator [redacted])

Reason for Narrative

Adverse Event Preferred Term(s)	Serious Adverse Event	Adverse Event Leading to Discontinuation of Study Drug	Death	Event of Interest
膿瘍	X	X		X

Treatment Group	Age at Study Start	Sex	Race
Placebo/ABT-494 15 mg QD	5[redacted]	FEMALE	WHITE

Medical History	Onset Year
HYPERLIPIDEMIA: DYSLIPIDEMIA	20[redacted]
HYPERTENSION: SYSTEMIC ARTERIAL HYPERTENSION	20
OTHER: DYSPEPSIA	20
OTHER: MENOPAUSAL	20
OTHER: PLAQUE PSORIASIS	20
OTHER: ISCHEMIC HEART DISEASE	20
DEPRESSION: MILD DEPRESSION	20
OTHER: INSOMNIA	20

Prior Procedures	Procedure Year
Not reported.	

Tobacco Use	Status	Number/Day	Number of Years	Year Stopped
CHEWING TOBACCO	NEVER			
CIGARETTES	NEVER			
CIGARS	NEVER			
E-CIGARETTES	NEVER			
PIPES	NEVER			

Alcohol Use	Status	Number/Day
ALCOHOL	NEVER	

Study Drug Administration

Study Drug	Dose/Units	Route	Frequency	First Dose Date/Day	Last Dose Date/Day	Duration (Days)
PLACEBO		ORAL	QD	[redacted]20[redacted] / 1	[redacted]20[redacted] / 168	168
ABT-494	15MG	ORAL	QD	[redacted]20[redacted] / 169	[redacted]20[redacted] / 391	223
ABT-494	15MG	ORAL	QD	[redacted]20[redacted] / 392	[redacted]20[redacted] / 437	46

[redacted]

Previous Therapy - Prior to baseline/enrollment

Medication Name (WHO Drug)	Dose/Units	Frequency	Start Year-Month / RX Day
BCG Vaccine	NOT REPORTED	NOT REPORTED	Y-M: 19[redacted]
ATENOLOL	25 mg	BID	Y-M: 20[redacted]
HYDROCHLOROTHIAZIDE	25 mg	QD	Y-M: 20[redacted]
SIMVASTATIN	20 mg	QD	Y-M: 20[redacted]
PANTOPRAZOLE	40 mg	QD	Y-M: 20[redacted]
TANDRILAX	50 + 300 + 125 mg	QD	Y-M: 20[redacted]
FOLIC ACID	5 mg	QD	Y-M: 20[redacted]
ETANERCEPT	50 mg	EVERY WEEK	Y-M: 20[redacted]
HEPATITIS B IMMUNIZATION	NOT REPORTED	NOT REPORTED	Y-M: 20[redacted]
METHOTREXATE	20 mg	EVERY WEEK	Y-M: 20[redacted]
TRIMETAZIDINE	35 mg	BID	Y-M: 20[redacted]
QUETIAPINE	50 mg	BID	Y-M: 20[redacted] / -31
TRAZODONE	50 mg	QD	Y-M: 20[redacted] / -31
ZOLPIDEM	10 mg	QD	Y-M: 20[redacted] / -31

Other Medications - Medications taken within 30 days prior to each narrative event until AE stopped or end of study

Medication Name (WHO Drug)	Dose/Units	Frequency	Start Year-Month / RX Day	Stop Year-Month / RX Day
ATENOLOL	25 mg	BID	Y-M: 20[redacted]	ONGOING
SIMVASTATIN	20 mg	QD	Y-M: 20[redacted]	ONGOING
PANTOPRAZOLE	40 mg	QD	Y-M: 20[redacted]	ONGOING
FOLIC ACID	5 mg	QD	Y-M: 20[redacted]	ONGOING
TRIMETAZIDINE	35 mg	BID	Y-M: 20[redacted]	ONGOING
QUETIAPINE	25 mg	OTHER: 2 TABLETS EVERY MORNING; 4 TABLETS EVER7 NIGHT	Y-M: 20[redacted] / 16	ONGOING
TRAZODONE	100 mg	QD	Y-M: 20[redacted] / 16	ONGOING
TANDRILAX	50 + 300 + 125 mg	BID	Y-M: 20[redacted] / 114	ONGOING
HYDROCHLOROTHIAZIDE	12.5 mg	QD	Y-M: 20[redacted] /	ONGOING

CEFALEXIN	500 mg	QID	167 Y-M: 20[redacted] / 310	ONGOING
METHOTREXATE	2.5 mg	QD	Y-M: 20[redacted] / 355	Y-M: 20[redacted] / [redacted] / 438
MUPIROCIN	IT'S TOPICAL. THERE IS NO EXACT QUANTITY OTHER: TOPICAL	TID	Y-M: 20[redacted] / 434	ONGOING
CEFALEXIN	500 mg	OTHER: EVERY 6 HOURS	Y-M: 20[redacted] / 438	ONGOING
AMOXICILLIN W/CLAVULANATE POTASSIUM	500+125 mg	TID	Y-M: 20[redacted] / 449	Y-M: 20[redacted] / [redacted] / 456

Event #1: Serious Adverse Event, AE Leading to Discontinuation of Study Drug, Study Specific Adverse Events of Interest

Event Description	LEFT AXIAL ABSCESS
Preferred term	膿瘍
AE Onset Date / Rx Day	[redacted]20[redacted] / 433
Age at AE Onset	5[redacted]

Laboratory Testing

NOT REPORTED

Microbiology

NOT REPORTED

SAE Supplemental Procedure

[redacted]20[redacted] (RX DAY 445): LEFT AXIAL ABCESS SURGERY: BY PHONE CONTACT REALIZED ON [redacted]20[redacted], PATIENT WAS STILL HOSPITALIZED BUT RECOVERING WELL

AE Stopped Rx Day	450 (13 DAYS AFTER LAST TREATMENT)
Duration of AE	18 DAYS
Relation to Study Drug by Investigator	REASONABLE POSSIBILITY
Investigator Alternative Etiology	NOT REPORTED
Discontinued Study Drug Due to the Event	YES
SAE Criteria	REQUIRES OR PROLONGS HOSPITALIZATION, OTHER MEDICALLY IMPORTANT SERIOUS EVENT

Generated: [redacted]
Program Source Code: [redacted]

Investigator No.: [redacted]

Subject Number: [redacted]

Protocol Number: M15-554

治験責任医師からの報告。本被験者はブラジルの 5[redacted] 歳女性であり，ABT-494（ウパダシチニブ）の治験で盲検化された治験薬が投与され，左軸性膿瘍の事象を発現した。

Event 1 の臨床経過：

関連する病歴は脂質異常症，全身性動脈性高血圧，局面型乾癬，乾癬性関節炎，虚血性心疾患，軽度のうつ病，非喫煙者及び非飲酒者であった。

被験者は，最初の 24 週間，本治験の盲検プラセボ対照期に組み入れられていた。20[redacted] 年 [redacted] 月 [redacted] 日，ABT-494 の盲検投与が開始された。

20[redacted] 年 [redacted] 月 [redacted] 日，被験者は左軸性膿瘍を発現した。20[redacted] 年 [redacted] 月 [redacted] 日，左軸性膿瘍は消失した。

20[redacted] 年 [redacted] 月 [redacted] 日，被験者は医師の指示に従って病院に行った。病院にて，被験者は，左軸性膿瘍のドレナージを受けるため翌日再度来院するよう指示された。

20[redacted] 年 [redacted] 月 [redacted] 日，被験者は入院し，膿瘍を除去するための左軸性膿瘍の手術を局所麻酔下で受けた。入院中，抗生物質が投与された。20[redacted] 年 [redacted] 月 [redacted] 日，被験者は退院した。

被験者は治験への参加を取り止めたいと申し出た。被験者は，良くなり次第，治験中止のために来院するよう指示された。

投与された薬剤は，外用ムピロシン及び cephalexin であった。

The patient's past medications include:

ETANERCEPT for PSORIATIC ARTHRITIS ([redacted] 20[redacted] - [redacted] [redacted] 20[redacted])

AMOXICILLIN + CLAVULANATE for CUTANEOUS ABSCESS ([redacted] [redacted] 20[redacted] - [redacted] [redacted] 20[redacted])

AMOXICILLIN for SINUSITIS ([redacted] [redacted] 20[redacted] - [redacted] [redacted] 20[redacted])

Causality for UPADACITINIB (Blinded)

---

1) Abscess (10000269) (Abscess (10000269)) [v.22.0] [10000269]

Causality as per reporter (Drug/Vaccine): Reasonable possibility

Causality as per Mfr. (Drug/Vaccine): Reasonable possibility

Dechallenge: Yes

Rechallenge: No rechallenge was done, recurrence is not applicable

Alternative Etiology for UPADACITINIB (Blinded)

Event of LEFT AXIAL ABSCESS

- Investigator: Not applicable

- AbbVie: Not applicable

被験者番号 [redacted] (Investigator [redacted])

Reason for Narrative

Adverse Event Preferred Term(s)	Serious Adverse Event	Adverse Event Leading to Discontinuation of Study Drug	Death	Event of Interest
腎結石症	X			

Treatment Group	Age at Study Start	Sex	Race
ABT-494 15 mg QD	4[redacted]	MALE	WHITE

Medical History	Onset Year
OTHER: MODERATE ANTRAL EROSIVE GASTRITIS	20[redacted]
OTHER: TREATMENT OF HELICOBACTER PYLORI	20[redacted]
OSTEOPOROSIS	20[redacted]
OTHER: UNCONFIRMED HISTORY OF HERPES ZOSTER	20[redacted]
OTHER: PLAQUE PSORIASIS	20[redacted]
OTHER: BRADYCARDIA	20[redacted]

Prior Procedures	Procedure Year
Not reported.	

Tobacco Use	Status	Number/Day	Number of Years	Year Stopped
CHEWING TOBACCO	NEVER			
CIGARETTES	CURRENT	1 PACK	19	
CIGARS	NEVER			
E-CIGARETTES	NEVER			
PIPES	NEVER			

Alcohol Use	Status	Number/Day
ALCOHOL	NEVER	

Study Drug Administration

Study Drug	Dose/Units	Route	Frequency	First Dose Date/Day	Last Dose Date/Day	Duration (Days)
ABT-494	15MG	ORAL	QD	[redacted]20[redacted] / 1	[redacted]20[redacted] / 167	167
ABT-494	15MG	ORAL	QD	[redacted]20[redacted] / 168	[redacted]20[redacted] / 393	226
ABT-494	15MG	ORAL	QD	[redacted]20[redacted] / 394	/	

Previous Therapy - Prior to baseline/enrollment

Medication Name (WHO Drug)	Dose/Units	Frequency	Start Year-Month / RX Day
BCG Vaccine	NOT REPORTED	NOT REPORTED	Y-M: 19[redacted]
DICLOFENAC	50 mg	PRN	Y-M: 20[redacted]
ADALIMUMAB	40 mg	EVERY 2 WEEKS	Y-M: 20[redacted]
HEPATITIS B IMMUNIZATION	NOT REPORTED	NOT REPORTED	Y-M: 20[redacted]
FOLIC ACID	5 mg	EVERY WEEK	Y-M: 20[redacted] / -146
METHOTREXATE	10 mg	EVERY WEEK	Y-M: 20[redacted] / -49

Other Medications - Medications taken within 30 days prior to each narrative event until AE stopped or end of study

Medication Name (WHO Drug)	Dose/Units	Frequency	Start Year-Month / RX Day	Stop Year-Month / RX Day
DICLOFENAC	50 mg	PRN	Y-M: 20[redacted]	Not reported.
FOLIC ACID	5 mg	EVERY WEEK	Y-M: 20[redacted] / -146	Not reported.
METHOTREXATE	10 mg	EVERY WEEK	Y-M: 20[redacted] / -49	Y-M: 20[redacted] / 393

Event #1: Serious Adverse Event

Event Description	RENAL LITHIASIS ON THE RIGHT
Preferred term	腎結石症
AE Onset Date / Rx Day	[redacted]20[redacted] / 164
Age at AE Onset	4[redacted]

Laboratory Testing

NOT REPORTED

Microbiology

NOT REPORTED

SAE Supplemental Procedure

[redacted]20[redacted] (RX DAY 160): TOTAL ULTRASOUND ABDOMEN: SHOWS KIDNEY STONE OF 4.5MM IN RIGHT KIDNEY.; [redacted]20[redacted] (RX DAY 198): TOTAL ULTRASOUND ABDOMEN: NORMAL RESULT. THERE'RE NO KIDNEY STONES.

AE Stopped Rx Day	168
Duration of AE	5 DAYS
Relation to Study Drug by Investigator	NO REASONABLE POSSIBILITY
Investigator Alternative Etiology	DIET AND LOW WATER INTAKE
Discontinued Study Drug Due to the Event	NO
SAE Criteria	REQUIRES OR PROLONGS HOSPITALIZATION

Generated: [redacted]
Program Source Code: [redacted]

Investigator No.: [redacted]

Subject Number: [redacted]

Protocol Number: M15-554

治験責任医師からの報告。本被験者はブラジルの 4[redacted] 歳男性であり，ABT-494（ウパダシチニブ）の治験で盲検化された治験薬が投与され，右腎結石症の事象を発現した。

Event 1 の臨床経過：

関連する病歴は乾癬性関節炎，骨粗鬆症，骨減少症，局面型乾癬，現喫煙者（1 日 20 本を 19 年間）及び非飲酒者であった。

20[redacted] 年 [redacted] 月 [redacted] 日，被験者は右腎結石症を発現した。20[redacted] 年 [redacted] 月 [redacted] 日，右腎結石症は消失した。

20[redacted] 年 [redacted] 月 [redacted] 日，超音波検査が行われ，右腎に 4.5 mm の腎結石が認められた。

20[redacted] 年 [redacted] 月 [redacted] 日，被験者は中等度で重篤な腰部痛を訴えた。20[redacted] 年 [redacted] 月 [redacted] 日，被験者は入院した。20[redacted] 年 [redacted] 月 [redacted] 日，被験者は退院した。20[redacted] 年 [redacted] 月 [redacted] 日に行われたエコー検査でさらなる腎結石は認められなかった。併用薬に関する情報は不明である。

The patient's past medications include:

ADALIMUMAB for PSORIATIC ARTHRITIS ([redacted] 20[redacted] - [redacted] 20[redacted])

Causality for UPADACITINIB (Blinded)

---

1) Nephrolithiasis (10029148) (Nephrolithiasis (10029148)) [v.22.1] [10029148]

Causality as per reporter (Drug/Vaccine): No reasonable possibility

Causality as per Mfr. (Drug/Vaccine): No reasonable possibility

Dechallenge: No

Alternative Etiology for UPADACITINIB (Blinded)

Event of RENAL LITHIASIS ON THE RIGHT

- Investigator: DIET AND LOW WATER INTAKE.

- AbbVie: EVENT IS NOT CONSISTENT WITH STUDY DRUG'S MECHANISM OF ACTION. Additional risk factors include subject's diet and low water intake as noted by PI.

Relevant Laboratory & Other Diagnostic Tests

[redacted] **20[redacted] ECHOGRAPHY:** No further kidney stone

[redacted] **20[redacted] ABDOMINAL ULTRASOUND:** KIDNEY STONE OF 4.5MM IN RIGHT KIDNEY

被験者番号 [redacted] (Investigator [redacted])

Reason for Narrative

Adverse Event Preferred Term(s)	Serious Adverse Event	Adverse Event Leading to Discontinuation of Study Drug	Death	Event of Interest
肺炎	X			X
敗血症	X			X

Treatment Group	Age at Study Start	Sex	Race
Placebo/ABT-494 30 mg QD	2[redacted]	FEMALE	BLACK OR AFRICAN AMERICAN

Medical History	Onset Year
OTHER: POLYARTHRITIS	20[redacted]
OTHER: HUMAN T-LYMPHOTROPIC VIRUS CARRIER	20[redacted]
OTHER: PSORIASIS PLAQUES	20[redacted]
HYPERTENSION	20[redacted]
HYPERTHYROIDISM	20[redacted]
OTHER: NAIL DYSTROPHY OF THE 3RD LEFT CHIROPRACTOR	20[redacted]

Prior Procedures	Procedure Year
Not reported.	

Tobacco Use	Status	Number/Day	Number of Years	Year Stopped
CHEWING TOBACCO	NEVER			
CIGARETTES	NEVER			
CIGARS	NEVER			
E-CIGARETTES	NEVER			
PIPES	NEVER			

Alcohol Use	Status	Number/Day
ALCOHOL	NEVER	

Study Drug Administration

Study Drug	Dose/Units	Route	Frequency	First Dose Date/Day	Last Dose Date/Day	Duration (Days)
PLACEBO		ORAL	QD	[redacted]20[redacted] / 1	[redacted]20[redacted] / 172	172
ABT-494	30MG	ORAL	QD	[redacted]20[redacted] / 173	[redacted]20[redacted] / 390	218
ABT-494	30MG	ORAL	QD	[redacted]20[redacted] / 391	/	

Previous Therapy - Prior to baseline/enrollment

Medication Name (WHO Drug)	Dose/Units	Frequency	Start Year-Month / RX Day
BCG Vaccine	NOT REPORTED	NOT REPORTED	Y-M: 19[redacted]
ETANERCEPT	50 mg	EVERY WEEK	Y-M: 20[redacted]
FOLIC ACID	10 mg	EVERY WEEK	Y-M: 20[redacted]
HEPATITIS B IMMUNIZATION	NOT REPORTED	NOT REPORTED	Y-M: 20[redacted]
METHOTREXATE	20 mg	EVERY WEEK	Y-M: 20[redacted]
PREDNISONE	10 mg	QD	Y-M: 20[redacted]
ABATACEPT	750 mg	OTHER: EVERY 4 WEEKS	Y-M:20[redacted]
LOSARTAN	50 mg	BID	Y-M:20[redacted]

Other Medications - Medications taken within 30 days prior to each narrative event until AE stopped or end of study

Medication Name (WHO Drug)	Dose/Units	Frequency	Start Year-Month / RX Day	Stop Year-Month / RX Day
FOLIC ACID	10 mg	EVERY WEEK	Y-M: 20[redacted]	Not reported.
METHOTREXATE	20 mg	EVERY WEEK	Y-M: 20[redacted]	Not reported.
PREDNISONE	10 mg	QD	Y-M: 20[redacted]	Not reported.
LOSARTAN	50 mg	BID	Y-M: 20[redacted]	Not reported.
ENOXAPARIN	60 mg	QD	Y-M: 20[redacted] / 409	Y-M: 20[redacted] / 443
RANITIDINE	150 mg	QD	Y-M: 20[redacted] / 409	Y-M: 20[redacted] / 443
CEFTRIAXONE	2 g	QD	Y-M: 20[redacted] / 428	Y-M: 20[redacted] / 439
MEROPENEM	1 g	QD	Y-M: 20[redacted] / 428	Y-M: 20[redacted] / 439
PIP/TAZO	4,5 mg	QD	Y-M: 20[redacted] / 428	Y-M: 20[redacted] / 439
VANCOMYCIN	1 g	QD	Y-M: 20[redacted] / 428	Y-M: 20[redacted] / 439
METHYLPREDNISOLONE	125 mg	QD	Y-M: 20[redacted] / 437	Y-M: 20[redacted] / 439

Event #1: Serious Adverse Event, Study Specific Adverse Events of Interest

Event Description	PNEUMONIA
Preferred term	肺炎
AE Onset Date / Rx Day	[redacted]20[redacted] / 409
Age at AE Onset	2[redacted]

Laboratory Testing

NOT REPORTED

Microbiology

[redacted]20[redacted] (RX DAY 430): BLOOD NPTST029-BLOOD CULTURE: NEGATIVE;
[redacted]20[redacted] (RX DAY 434): BLOOD NPTST029-BLOOD CULTURE: NEGATIVE

SAE Supplemental Procedure

[redacted]20[redacted] (RX DAY 417): COMPUTED TOMOGRAPHY OF THE TOTAL ABDOMEN: SMALL AMOUNT OF INTRACAVITARY FLUID; [redacted]20[redacted] (RX DAY 428): COMPUTED TOMOGRAPHY ANGIOGRAPHY (CT-ANGIOGRAPHY) OF THE CHEST: ABSENCE OF SIGNS OF PTE + BILATERAL PLEURAL EFFUSION + MODERATE PERICARDIAL EFFUSION + CARDIOMEGALY; [redacted]20[redacted] (RX DAY 435): TRANSTHORACIC ECHOCARDIOGRAM: MILD PERICARDIAL EFFUSION, PRESENCE OF MILD FIBRIN IN PERICARDIUM, PRESERVED FE

AE Stopped Rx Day	443
Duration of AE	35 DAYS
Relation to Study Drug by Investigator	REASONABLE POSSIBILITY
Investigator Alternative Etiology	NOT REPORTED
Discontinued Study Drug Due to the Event	NO
SAE Criteria	REQUIRES OR PROLONGS HOSPITALIZATION, LIFE THREATENING

Event #2: Serious Adverse Event, Study Specific Adverse Events of Interest

Event Description	SEPSIS
Preferred term	敗血症
AE Onset Date / Rx Day	[redacted]20[redacted] / 409
Age at AE Onset	2[redacted]

Laboratory Testing

NOT REPORTED

Microbiology

[redacted]20[redacted] (RX DAY 430): BLOOD NPTST029-BLOOD CULTURE: NEGATIVE;
[redacted]20[redacted] (RX DAY 434): BLOOD NPTST029-BLOOD CULTURE: NEGATIVE

SAE Supplemental Procedure

[redacted]20[redacted] (RX DAY 417): COMPUTED TOMOGRAPHY OF THE TOTAL ABDOMEN: SMALL AMOUNT OF INTRACAVITARY FLUID; [redacted]20[redacted] (RX DAY 428): COMPUTED TOMOGRAPHY ANGIOGRAPHY (CT-ANGIOGRAPHY) OF THE CHEST: ABSENCE OF SIGNS OF PTE + BILATERAL PLEURAL EFFUSION + MODERATE PERICARDIAL EFFUSION + CARDIOMEGALY; [redacted]20[redacted] (RX DAY 435): TRANSTHORACIC ECHOCARDIOGRAM: MILD PERICARDIAL EFFUSION, PRESENCE OF MILD FIBRIN IN PERICARDIUM, PRESERVED FE

AE Stopped Rx Day	443

Duration of AE	35 DAYS
Relation to Study Drug by Investigator	REASONABLE POSSIBILITY
Investigator Alternative Etiology	NOT REPORTED
Discontinued Study Drug Due to the Event	NO
SAE Criteria	REQUIRES OR PROLONGS HOSPITALIZATION, LIFE THREATENING

Generated: [redacted]
Program Source Code: [redacted]

Investigator No.: [redacted]

Subject Number: [redacted]

Protocol Number: M15-554

治験責任医師からの報告。本被験者はブラジルの 2[redacted] 歳女性であり，ABT-494（ウパダシチニブ）の治験で盲検化された治験薬が投与され，肺炎及び敗血症の事象を発現した。

Event 1～2 の臨床経過：
関連する病歴は多発性関節炎，ヒト T リンパ球向性ウイルスキャリア，乾癬プラーク，乾癬性関節炎，高血圧，非喫煙者及び非飲酒者であった。

被験者は，最初の 24 週間，本治験の盲検プラセボ対照期に組み入れられていた。20[redacted] 年 [redacted] 月 [redacted] 日，ウパダシチニブの盲検投与が開始された。

20[redacted] 年 [redacted] 月 [redacted] 日，被験者は肺炎及び敗血症を発現した。20[redacted] 年 [redacted] 月 [redacted] 日，肺炎及び敗血症は消失した。

20[redacted] 年 [redacted] 月 [redacted] 日，被験者は肺炎とそれに伴う発熱，疲労（tiredness），疲労（fatigue），胸痛及び小関節と中関節の対称性多発性関節炎のため入院した。被験者の呼吸状態は白血球像の悪化（詳細不明）とともに悪化を続け，肺病巣を伴う敗血症のため ICU に入室する必要があった。被験者の白血球数及び呼吸状態は改善せず，リウマチ科にコンサルテーションしたところ，メチルプレドニゾロン 125 mg の連日静脈内投与の開始を提案された（リウマチ疾患再燃の可能性）。被験者の呼吸状態と白血球像は顕著に改善した（詳細不明）。20[redacted] 年 [redacted] 月 [redacted] 日，CT 血管造影で両側胸水，中等度の心嚢液貯留及び心拡大が認められた。20[redacted] 年 [redacted] 月 [redacted] 日，血液培養は陰性であった。被験者の状態は改善し続け，経口 prednisone に移行し一般病棟に移った。20[redacted] 年 [redacted] 月 [redacted] 日，被験者は退院した。

投与された薬剤は，メロペネム，バンコマイシン，メチルプレドニゾロン，ranitidina，エノキサパリンナトリウム及び tazocin であった。

The patient's past medications include: ETANERCEPT for PSORIATIC ARTHRITIS (20[redacted] - 20[redacted]) ABATACEPT for PSORIATIC ARTHRITIS (20[redacted] - [redacted] [redacted] 20[redacted]) Causality for UPADACITINIB (Blinded)

---

1) Pneumonia (10035664) (Pneumonia (10035664)) [v.23.0] [10035664]

Causality as per reporter (Drug/Vaccine): Reasonable possibility

Causality as per Mfr. (Drug/Vaccine): Reasonable possibility

Dechallenge: Yes

Rechallenge: rechallenge was done, reaction did not recur

2) Sepsis (10040047) (Sepsis (10040047)) [v.23.0] [10040047]

Causality as per reporter (Drug/Vaccine): Reasonable possibility

Causality as per Mfr. (Drug/Vaccine): Reasonable possibility

Dechallenge: Yes

Rechallenge: rechallenge was done, reaction did not recur

Alternative Etiology for UPADACITINIB (Blinded)

Event of PNEUMONIA

- Investigator: Not applicable

- AbbVie: Not applicable

Event of SEPSIS

- Investigator: Not applicable

- AbbVie: Not applicable

Relevant Laboratory & Other Diagnostic Tests

[redacted] **20[redacted] BLOOD CULTURE:** negative

[redacted] **20[redacted] BLOOD CULTURE:** negative

[redacted] **20[redacted] BODY WEIGHT:** 122.2 KG

[redacted] **20[redacted] CHEST X-RAY (WEEK 56):** Normal

[redacted] **20[redacted] CT ABDOMEN:** small amount of intracavitary fluid

[redacted] **20[redacted] CT ANGIOGRAPHY:** chest: absence of signs of PTE; + bilateral pleural effusion + moderate pericardial effusion + cardiomegaly

[redacted] **20[redacted] TRANSTHORACIC ECHOCARDIOGRAPHY:** mild pericardial effusion, presce of mild fibrin in pericardium, preserved FE

被験者番号 [redacted] (Investigator [redacted])

Reason for Narrative

Adverse Event Preferred Term(s)	Serious Adverse Event	Adverse Event Leading to Discontinuation of Study Drug	Death	Event of Interest
良性副甲状腺腫瘍	X			

Treatment Group	Age at Study Start	Sex	Race
ABT-494 15 mg QD	4[redacted]	FEMALE	WHITE

Medical History	Onset Year
OTHER: PSORIASIS VULGARIS	20[redacted]
OTHER: HYPERCALCEMIA	20[redacted]

Prior Procedures	Procedure Year
Not reported.	

Tobacco Use	Status	Number/Day	Number of Years	Year Stopped
CHEWING TOBACCO	UNKNOWN			
CIGARETTES	CURRENT	1 PACK	22	
CIGARS	UNKNOWN			
E-CIGARETTES	UNKNOWN			
PIPES	UNKNOWN			

Alcohol Use	Status	Number/Day
ALCOHOL	CURRENT	Less than 2

Study Drug Administration

Study Drug	Dose/Units	Route	Frequency	First Dose Date/Day	Last Dose Date/Day	Duration (Days)
ABT-494	15MG	ORAL	QD	[redacted]20[redacted] / 1	[redacted]20[redacted] / 162	162
ABT-494	15MG	ORAL	QD	[redacted]20[redacted] / 163	[redacted]20[redacted] / 392	230
ABT-494	15MG	ORAL	QD	[redacted]20[redacted] / 393	/	

Previous Therapy - Prior to baseline/enrollment

Medication Name (WHO Drug)	Dose/Units	Frequency	Start Year-Month / RX Day
BCG Vaccine	NOT REPORTED	NOT REPORTED	Y-M: 19[redacted]
IBUPROFEN	400 mg	QID	Y-M: 20[redacted]-
HYDROCORTISONE	1 OTHER: APPLICATION	BID	Y-M: 20[redacted]-
METHOTREXATE	15 mg	EVERY WEEK	Y-M: 20[redacted]-
FOLIC ACID	10 mg	EVERY WEEK	Y-M: 20[redacted]-
KETOPROFEN	100 mg	BID	Y-M: 20[redacted]-
NIMESULIDE	100 mg	BID	Y-M: 20[redacted]-
SECUKINUMAB	150 mg	OTHER: ONCE PER MONTH	Y-M: 20[redacted]-
METHOTREXATE	20 mg	EVERY WEEK	Y-M: 20[redacted]- / -89
FOLIC ACID	10 mg	EVERY WEEK	Y-M: 20[redacted]- / -86
INTRAUTERINE CONTRACEPTIVE DEVICE	1 OTHER: APPLICATION	OTHER: UNKNOWN	Y-M: 20[redacted]- / -29

Other Medications - Medications taken within 30 days prior to each narrative event until AE stopped or end of study

Medication Name (WHO Drug)	Dose/Units	Frequency	Start Year-Month / RX Day	Stop Year-Month / RX Day
METHOTREXATE	20 mg	EVERY WEEK	Y-M: 20[redacted]- / -89	Not reported.
FOLIC ACID	10 mg	EVERY WEEK	Y-M: 20[redacted]- / -86	Not reported.
INTRAUTERINE CONTRACEPTIVE DEVICE	1 OTHER: APPLICATION	OTHER: UNKNOWN	Y-M: 20[redacted]- / -29	Not reported.

Event #1: Serious Adverse Event

Event Description RIGHT PARATHYROID ADENOMA
Preferred term 良性副甲状腺腫瘍
AE Onset Date / Rx Day [redacted]20[redacted] / 239
Age at AE Onset 4[redacted]
Laboratory Testing
NOT REPORTED
Microbiology
NOT REPORTED
SAE Supplemental Procedure
NOT REPORTED
AE Stopped Rx Day NOT REPORTED

Duration of AE	NOT REPORTED
Relation to Study Drug by Investigator	NO REASONABLE POSSIBILITY
Investigator Alternative Etiology	INCREASED ACTIVITY OF THE RADIOPHARMACEUTICAL IN RIGHT SIDE OF THE THYROID
Discontinued Study Drug Due to the Event	NO
SAE Criteria	REQUIRES OR PROLONGS HOSPITALIZATION

Generated: [redacted]
Program Source Code: [redacted]

Investigator No.: [redacted]

Subject Number: [redacted]

Protocol Number: M15-554
治験責任医師からの報告。本被験者はチェコ共和国の 4[redacted] 歳女性であり，ABT-494（ウパダシチニブ）の治験で盲検化された治験薬が投与され，右副甲状腺腺腫の事象を発現した。

Event 1 の臨床経過：
関連する病歴は尋常性乾癬，乾癬性関節炎，現喫煙者（1 日 1 箱を 22 年間）及び現飲酒者（1 日 2 杯未満）であった。

被験者は，最初の 24 週間，本治験の盲検プラセボ対照期に組み入れられていた。20[redacted] 年 [redacted] 月 [redacted] 日，ABT-494 の盲検投与が開始された。

20[redacted] 年 [redacted] 月 [redacted] 日，被験者は右副甲状腺腺腫を発現した。20[redacted] 年 [redacted] 月 [redacted] 日，右副甲状腺腺腫は消失した。

20[redacted] 年 [redacted] 月 [redacted] 日，被験者は「MIBI」により確認された甲状腺右側の放射性医薬品の活性亢進のために入院した。20[redacted] 年 [redacted] 月 [redacted] 日，被験者は低侵襲の副甲状腺摘出術を受け，右副甲状腺腺腫が確認された。術後に反回神経不全麻痺が生じたが，20[redacted] 年 [redacted] 月 [redacted] 日に消失した。

投与された薬剤は，novalgin であった。

The patient's past medications include:

IBALGIN for PSORIATIC ARTHRITIS ([redacted] 20[redacted] - [redacted] 20[redacted])

LOCOID LIPOCREAM for PSORIASIS ([redacted] 20[redacted] - [redacted] 20[redacted])

METHOTREXATE for PSORIATIC ARTHRITIS ([redacted] 20[redacted] - [redacted] 20[redacted])

KETONAL for PSORIATIC ARTHRITIS ([redacted] 20[redacted] - [redacted] 20[redacted])

AULIN for PSORIATIC ARTHRITIS ([redacted] 20[redacted] - [redacted] 20[redacted])

SECUKINUMAB for PSORIATIC ARTHRITIS ([redacted] 20[redacted] - [redacted] 20[redacted])

Causality for UPADACITINIB (Blinded)

---

1) Parathyroid adenoma (10033940) (Parathyroid tumour benign (10033964)) [v.23.0] [10033940]

Causality as per reporter (Drug/Vaccine): No reasonable possibility

Causality as per Mfr. (Drug/Vaccine): No reasonable possibility

Dechallenge: Yes

Rechallenge: rechallenge was done, reaction did not recur

Alternative Etiology for UPADACITINIB (Blinded)

Event of RIGHT PARATHYROID ADENOMA

- Investigator: Increased activity of the radiopharmaceutical in right side of the thyroid.

- AbbVie: The etiology for parathyroid adenoma remains unknown for most patients. Additional risk factor includes subject's gender, women are affected 3 times a often as men.

Relevant Laboratory & Other Diagnostic Tests

[redacted] 20[redacted] **CALCIUM:** 2.68 MMOL/L (normal 2.1 to 2.55)

[redacted] 20[redacted] **CALCIUM:** 2.33 MMOL/L (normal 2.1 to 2.55)

[redacted] 20[redacted] **CHEST X-RAY:** Screening: Normal

[redacted] 20[redacted] **MIBI SCINTIGRAPHY:** Not reported

[redacted] 20[redacted] **PTH:** 114.5 ng/L (normal 15 to 65)

[redacted] 20[redacted] **PTH:** 19.11 ng/L (normal 15 to 65)

[redacted] 20[redacted] **PTH:** 32.51 ng/L (normal 15 to 65)

被験者番号 [redacted] (Investigator [redacted])

Reason for Narrative

Adverse Event Preferred Term(s)	Serious Adverse Event	Adverse Event Leading to Discontinuation of Study Drug	Death	Event of Interest
心不全	X			

Treatment Group	Age at Study Start	Sex	Race
Placebo/ABT-494 15 mg QD	6[redacted]	FEMALE	WHITE

Medical History	Onset Year
OTHER: FRACTURE OF LEFT KNEE	19[redacted]
OTHER: PLAQUE PSORIASIS	19
OTHER: COMMOTIO CEREBRI	19
OTHER: FRACTURE OF LEFT INDEX FINGER	20
OTHER: VERTEBRAL ALGIC SYNDROME	20
DEPRESSION: ANXIOSIS DEPRESSIVE DISORDER	20
OTHER: VARICES OF LOWER EXTREMITIES	20
OTHER: VERTIGO BLOOD VESSEL ETIOLOGY	20
OTHER: STRANGULATORY ILEUS	20
OTHER: CHOLECYSTECTOMY	20
OTHER: ERYTHEMA NODOSUM ON BOTH FORARM	20
HYPERTENSION	20

Prior Procedures	Procedure Year
SURGERY: APENDECTOMY	19[redacted]
SURGERY: OVARECTOMY OF RIGHT SIDE	19
SURGERY: OVARECTOMY OF LEFT SIDE	19
SURGERY: ADNEXECTOMY BILATERAL	19
SURGERY: HYSTERECTOMY	19

Tobacco Use	Status	Number/Day	Number of Years	Year Stopped
CHEWING TOBACCO	NEVER			
CIGARETTES	CURRENT	0.5 PACK	37	
CIGARS	NEVER			
E-CIGARETTES	NEVER			
PIPES	NEVER			

Alcohol Use	Status	Number/Day
ALCOHOL	NEVER	

Study Drug Administration

Study Drug	Dose/Units	Route	Frequency	First Dose Date/Day	Last Dose Date/Day	Duration (Days)
PLACEBO		ORAL	QD	[redacted]20[redacted] / 1	[redacted]20[redacted] / 168	168
ABT-494	15MG	ORAL	QD	[redacted]20[redacted] / 169	[redacted]20[redacted] / 392	224
ABT-494	15MG	ORAL	QD	[redacted]20[redacted] / 393	/	

Previous Therapy - Prior to baseline/enrollment

Medication Name (WHO Drug)	Dose/Units	Frequency	Start Year-Month / RX Day
BCG Vaccine	NOT REPORTED	NOT REPORTED	Y-M: 19[redacted]
ESCITALOPRAM	10 mg	QD	Y-M: 20[redacted]
IBUPROFEN	600 mg	QD	Y-M: 20[redacted]-[redacted]
COLECALCIFEROL	1000 IU	QD	Y-M: 20[redacted]
FOLIC ACID	10 mg	EVERY WEEK	Y-M: 20[redacted]-[redacted]
METHOTREXATE	20 mg	EVERY WEEK	Y-M: 20[redacted]-[redacted]
INFLIXIMAB	186 mg	OTHER: ONCE PER SIX WEEKS	Y-M: 20[redacted]-[redacted]
RILMENIDINE	1 mg	BID	Y-M: 20[redacted]-[redacted] / -208
FOLIC ACID	10 mg	EVERY WEEK	Y-M: 20[redacted]-[redacted] / -161
METHOTREXATE	20 mg	EVERY WEEK	Y-M: 20[redacted]-[redacted] / -161

Other Medications - Medications taken within 30 days prior to each narrative event until AE stopped or end of study

Medication Name (WHO Drug)	Dose/Units	Frequency	Start Year-Month / RX Day	Stop Year-Month / RX Day
ESCITALOPRAM	10 mg	QD	Y-M: 20[redacted]	Not reported.
COLECALCIFEROL	1000 IU	QD	Y-M: 20[redacted]	Not reported.
RILMENIDINE	1 mg	BID	Y-M: 20[redacted]-[redacted] / -208	Y-M: 20[redacted]-[redacted] / 221
FOLIC ACID	10 mg	EVERY WEEK	Y-M: 20[redacted]-[redacted] / -161	Not reported.
METHOTREXATE	20 mg	EVERY WEEK	Y-M: 20[redacted]-[redacted] / -161	Not reported.
ATORVASTATIN	80 mg	QD	Y-M: 20[redacted]-[redacted] / 222	Not reported.
BISOPROLOL	2.5 mg	QD	Y-M: 20[redacted]-[redacted] / 222	Not reported.
PANTOPRAZOLE	40 mg	QD	Y-M: 20[redacted]-[redacted] / 222	Not reported.

PERINDOPRIL	2.5 mg	QD	Y-M: 20[redacted]- [redacted] / 222	Y-M: 20[redacted]- [redacted] / 246
ISOSORBIDE DINITRATE	1 OTHER: APPLICATION	OTHER: ONCWE	Y-M: 20[redacted]- [redacted] / 230	Y-M: 20[redacted]- [redacted] / 230
METAMIZOLE	500 mg	PRN	Y-M: 20[redacted]- [redacted] / 230	Y-M: 20[redacted]- [redacted] / 233
FUROSEMIDE	20 mg	QD	Y-M: 20[redacted]- [redacted] / 230	Y-M: 20[redacted]- [redacted] / 234
CLOPIDOGREL	75 mg	QD	Y-M: 20[redacted]- [redacted] / 230	Y-M: 20[redacted]- [redacted] / 236
PAYNOCIL	1 OTHER: TABLET	QD	Y-M: 20[redacted]- [redacted] / 230	Y-M: 20[redacted]- [redacted] / 246

Event #1: Serious Adverse Event

Event Description	PRIMOMANIFESTATION OF HEART FAILURE
Preferred term	心不全
AE Onset Date / Rx Day	[redacted]20[redacted] / 230
Age at AE Onset	6[redacted]

Laboratory Testing

NOT REPORTED

Microbiology

NOT REPORTED

SAE Supplemental Procedure

[redacted]20[redacted] (RX DAY 230): CHEST X-RAY: WITHOUT INFILTRATION OR CONGESTION; ELECTROCARDIOGRAPHY: NONSPECIFIC POLARIZATION CHANGES SEPTALLY, WITHOUT DEVELOPMENT EVEN AFTER EXERCISE; X-RAY OF CERVICAL SPINE: WITHOUT STRUCTURAL CHANGES, OSTEOCHONDROSIS OF DISC C5/6 AND DISC C6/7, SPONDYLOTIC CHANGES; X-RAY OF THORATIC SPINE: WITHOUT STRUCTURAL CHANGES, SPONDYLOTIC CHANGES WITH A PEAK IN THE LOWER HALF; [redacted]20[redacted] (RX DAY 231): ECHOCARDIOGRAPHY: LIGHTER HYPOKINESIS OFSEPTUM, EF 47%;
[redacted]20[redacted] (RX DAY 232): BICYCLE ERGOMETRY: NOT COMPLETED FOR DYSPNOEA AND MUSCLE FATIGUE; [redacted]20[redacted] (RX DAY 236): CORONAROGRAPHY: CORONARY ARTERIES WITHOUT STENOSIS; ELECTROCARDIOGRAPHY: WITHOUT PATHOLOGY

AE Stopped Rx Day	233
Duration of AE	4 DAYS
Relation to Study Drug by Investigator	NO REASONABLE POSSIBILITY
Investigator Alternative Etiology	VERTEBROALGIC SYNDROME
Discontinued Study Drug Due to the Event	NO
SAE Criteria	REQUIRES OR PROLONGS HOSPITALIZATION

Generated: [redacted]
Program Source Code: [redacted]

Investigator No.: [redacted]

Subject Number: [redacted]

Protocol Number: M15-554

治験責任医師からの報告。本被験者はチェコ共和国の 6[redacted] 歳女性であり，ABT-494（ウパダシチニブ）の治験で盲検化された治験薬が投与され，グレード 3 の心不全初回発症の事象を発現した。

Event 1 の臨床経過：
関連する病歴は局面型乾癬，vertebral algic syndrome，乾癬性関節炎，高血圧，現喫煙者（1 日 0.5 箱を 37 年間）及び父親が心筋梗塞のため 6[redacted] 歳で死亡した家族歴であった。

20[redacted] 年 [redacted] 月 [redacted] 日，被験者は心不全初回発症を発現した。20[redacted] 年 [redacted] 月 [redacted] 日，心不全初回発症は消失した。

20[redacted] 年 [redacted] 月 [redacted] 日，被験者は胸痛並びに腹部，背部，肩への放散痛のために入院した。入院時病歴及び診察によると，被験者には高血圧，高脂血症及び椎骨疼痛症候群があった。主診断は心不全初回発症と特定された。心電図検査では，労作後でも進行を伴わない非特異的な分極変化が認められた。胸部 X 線検査で浸潤やうっ血は認められなかった。脊椎の X 線検査で構造の変化は認められなかった。20[redacted] 年 [redacted] 月 [redacted] 日，心エコー検査で中隔の運動低下が軽度認められ，駆出率は 47%であった。被験者は狭心症の治療とともに椎骨疼痛症候群の悪化に対し鎮痛療法を受けた。20[redacted] 年 [redacted] 月 [redacted] 日，自転車エルゴメトリーが行われたが，被験者の呼吸困難及び疲労のため評価が完了しなかった。治験責任医師によると，高脂血症，狭心症，冠動脈のアテローム性動脈硬化症及び椎骨疼痛症候群の悪化が，継続中の非重篤な有害事象と考えらえた。20[redacted] 年 [redacted] 月 [redacted] 日，被験者は疼痛も発熱もなく良好な状態で退院した。

20[redacted] 年 [redacted] 月 [redacted] 日，冠動脈造影検査が行われたが，冠動脈に狭窄は認められなかった。治験責任医師によると，冠動脈の病因は除外され，筋骨格系の病因が患者の障害の原因と考えられた。事象の発現中，治験薬投与は中断されなかった。被験者の直近の状態は良好であった。

投与された薬剤は，furon，novalgin，trombex，ヘパリン，godasal 及び isoket であった。

The patient's past medications include:

IBALGIN for VERTEBROALGIC SYNDROME ([redacted] 20[redacted] - [redacted] 20[redacted])

REMICADE for PSORIATIC ARTHRITIS ([redacted] [redacted] 20[redacted] - [redacted] [redacted] 20[redacted])

Causality for UPADACITINIB (Blinded)

---

1) Heart failure (10019279) (Cardiac failure (10007554)) [v.22.1] [10019279]

Causaliy as per reporter (Drug/Vaccine): No reasonable possibility

Causality as per Mfr. (Drug/Vaccine): No reasonable possibility

Dechallenge: Not Applicable

Alternative Etiology for UPADACITINIB (Blinded)

Event of PRIMOMANIFESTATION OF HEART FAILURE

- Investigator: Vertebroalgic Syndrome

- AbbVie: Risk factors include pre-existing hypertension, current smoking (0.5 ppd for the last 35 years) and family history of cardiovascular disease.

Relevant Laboratory & Other Diagnostic Tests

[redacted] **20[redacted] BICYCLE ERGOMETRY:** NOT COMPLETED FOR DYSPNOEA AND MUSCLE FATIGUE

[redacted] **20[redacted] BLOOD PRESSURE:** 125/80mmhg

[redacted] **20[redacted] BODY TEMPERATURE:** 36.5 Degrees C

[redacted] **20[redacted] CHEST X-RAY:** WITHOUT INFILTRATION OR CONGESTION

[redacted] **20[redacted] CORONAROGRAPHY:** CORONARY ARTERIES WITHOUT STENOSIS

[redacted] **20[redacted] ECHOCARDIOGRAPHY:** LIGHTER HYPOKINESIS OFSEPTUM, EF 47%

[redacted] **20[redacted] ELECTROCARDIOGRAPHY:** NONSPECIFIC POLARIZATION CHANGES SEPTALLY, WITHOUT DEVELOPMENT EVEN AFTER EXERCISE

[redacted] **20[redacted] ELECTROCARDIOGRAPHY:** WITHOUT PATHOLOGY

[redacted] **20[redacted] HCT:** 0.383 no units

[redacted] **20[redacted] HEART RATE:** 90 bpm

[redacted] **20[redacted] HGB:** 129 G/L

[redacted] **20[redacted] PLT:** 344 X10**9/L

[redacted] **20[redacted] RESPIRATORY RATE:** 14 rpm

[redacted] **20[redacted] WBC:** 5.83 X10**9/L

[redacted] **20[redacted] X-RAY OF CERVICAL SPINE:** WITHOUT STRUCTURAL CHANGES, OSTEOCHONDROSIS OF DISC C5/6 AND DISC C6/7, SPONDYLOTIC CHANGES

[redacted] **X-RAY OF THORATIC SPINE:** WITHOUT STRUCTURAL CHANGES, SPONDYLOTIC CHANGES WITH A PEAK IN THE LOWER HALF

被験者番号 [redacted] (Investigator [redacted])

Reason for Narrative

Adverse Event Preferred Term(s)	Serious Adverse Event	Adverse Event Leading to Discontinuation of Study Drug	Death	Event of Interest
心不全	X	X		X

Treatment Group	Age at Study Start	Sex	Race
Placebo/ABT-494 30 mg QD	5[redacted]	MALE	WHITE

Medical History	Onset Year
OTHER: FRACTURE OF THE LEFT PATELLA	19[redacted]
OTHER: RIGHT METATARSAL BONE FRACTURE	19
HYPERTENSION	20
OTHER: PLAQUE PSORIASIS	20
DIABETES MELLITUS	20
HYPERLIPIDEMIA	20
OTHER: LEFT SCAPHOID FRACTURE	20
OBESITY	20
OTHER: IMPAIRED GLUCOSE TOLERANCE	20
OTHER: UMBILICAL HERNIA	20
OTHER: SCLEROSIS ARCUS AORTAE	20

Prior Procedures	Procedure Year
SURGERY: APPENDECTOMY	19[redacted]
SURGERY: COMMUNITED OF THE LEFT PATELLA FRACTURE	19
SURGERY: INGUINAL HERNIA OF LEFT SIDE	20

Tobacco Use	Status	Number/Day	Number of Years	Year Stopped
CHEWING TOBACCO	NEVER			
CIGARETTES	FORMER	0.25 PACK	15	19[redacted]
CIGARS	NEVER			
E-CIGARETTES	NEVER			
PIPES	NEVER			

Alcohol Use	Status	Number/Day
ALCOHOL	CURRENT	Less than 2

Study Drug Administration

Study Drug	Dose/Units	Route	Frequency	First Dose Date/Day	Last Dose Date/Day	Duration (Days)
PLACEBO		ORAL	QD	[redacted] / 1	[redacted] / 169	169
ABT-494	30MG	ORAL	QD	[redacted] / 170	[redacted] / 392	223
ABT-494	30MG	ORAL	QD	[redacted] / 393	[redacted] / 423	31

Previous Therapy - Prior to baseline/enrollment

Medication Name (WHO Drug)	Dose/Units	Frequency	Start Year-Month / RX Day
BCG Vaccine	NOT REPORTED	NOT REPORTED	Y-M: 19[redacted]
BISOPROLOL	5 mg	QD	Y-M: 20[redacted]
METFORMIN	850 mg	QD	Y-M: 20[redacted]
RILMENIDINE	1 mg	BID	Y-M: 20[redacted]
NIMESULIDE	100 mg	BID	Y-M: 20[redacted]
METHOTREXATE	15 mg	EVERY WEEK	Y-M: 20[redacted]
FOLIC ACID	10 mg	EVERY WEEK	Y-M: 20[redacted]
AMLODIPINE BESILATE W/INDAPAMIDE/PE	1 OTHER: TABLETS	QD	Y-M: 20[redacted]
SECUKINUMAB	150 mg	OTHER: MONTHLY	Y-M: 20[redacted]

Other Medications - Medications taken within 30 days prior to each narrative event until AE stopped or end of study

Medication Name (WHO Drug)	Dose/Units	Frequency	Start Year-Month / RX Day	Stop Year-Month / RX Day
BISOPROLOL	5 mg	QD	Y-M: 20[redacted]	Y-M: 20[redacted] / 424
METFORMIN	850 mg	QD	Y-M: 20[redacted]	Y-M: 20[redacted] / 395
RILMENIDINE	1 mg	BID	Y-M: 20[redacted]	Y-M: 20[redacted] / 395
NIMESULIDE	100 mg	BID	Y-M: 20[redacted]	ONGOING
AMLODIPINE BESILATE W/INDAPAMIDE/PE	1 OTHER: TABLETS	QD	Y-M: 20[redacted]	Y-M: 20[redacted] / 424
CICLESONIDE	160 ug	QD	Y-M: 20[redacted] / 276	ONGOING
FORMOTEROL	12 ug	BID	Y-M: 20[redacted] / 276	ONGOING
IPRATROPIUM	0.02 mg	PRN	Y-M: 20[redacted] / 276	ONGOING

METFORMIN	1000 mg	QD	Y-M: 20[redacted]- [redacted] / 396	ONGOING
RILMENIDINE	1 mg	QD	Y-M: 20[redacted]- [redacted] / 396	ONGOING
PREGABALIN	150 mg	QD	Y-M: 20[redacted]- [redacted] / 396	Y-M: 20[redacted]- [redacted] / 419
ZOFILIP	1 OTHER: TABLET	QD	Y-M: 20[redacted]- [redacted] / 396	Y-M: 20[redacted]- [redacted] / 419

Event #3: Serious Adverse Event, AE Leading to Discontinuation of Study Drug, Study Specific Adverse Events of Interest, Positively Adjudicated Events

Event Description	HEART FAILURE
Preferred term	心不全
AE Onset Date / Rx Day	[redacted]20[redacted] / 417
Age at AE Onset	5[redacted]
Laboratory Testing	
NOT REPORTED	
Microbiology	
NOT REPORTED	
SAE Supplemental Procedure	
NOT REPORTED	
AE Stopped Rx Day	425 (8 DAYS AFTER LAST TREATMENT)
Duration of AE	9 DAYS
Relation to Study Drug by Investigator	NO REASONABLE POSSIBILITY
Investigator Alternative Etiology	DILATED CARDIOMYOPATHY
Discontinued Study Drug Due to the Event	YES
SAE Criteria	REQUIRES OR PROLONGS HOSPITALIZATION

Generated: [redacted]
Program Source Code: [redacted]

Investigator No.: [redacted]

Subject Number: [redacted]

Protocol Number: M15-554

治験責任医師からの報告。本被験者はチェコ共和国の 5[redacted] 歳男性であり，ABT-494（ウパダシチニブ）の治験で盲検化された治験薬が投与され，心不全の事象を発現した。

Event 3 の臨床経過：
関連する病歴は元紙巻タバコ喫煙者（1 日 0.25 箱を 15 年間，19[redacted] 年に禁煙），高血圧，局面型乾癬，糖尿病，高脂血症，耐糖能障害，肥満，乾癬性関節炎，大動脈弓硬化及び現飲酒者（1 日 2 杯未満）であった。

被験者は，最初の 24 週間，本治験の盲検プラセボ対照期に組み入れられていた。20[redacted] 年 [redacted] 月 [redacted] 日，ウパダシチニブの盲検投与が開始された。

20[redacted] 年 [redacted] 月 [redacted] 日，被験者は心不全を発現した。20[redacted] 年 [redacted] 月 [redacted] 日，心不全は消失した。

20[redacted] 年 [redacted] 月 [redacted] 日，被験者は日常生活で呼吸困難を含む軽度の症状及び軽微な制限を発現した。20[redacted] 年 [redacted] 月 [redacted] 日，被験者は心不全のために入院した。息切れの症状はあったが，胸痛はなかった。本事象に関連する危険因子として肥満，高血圧，高脂血症，慢性閉塞性肺疾患が報告された。胸部 X 線検査で心拡大が認められ，心電図検査で脱分極変化が認められた。被験者はフロセミド及び血栓症予防薬を投与され，高血圧治療が変更された。症状は鎮静化した。20[redacted] 年 [redacted] 月 [redacted] 日，被験者は退院した。本事象により治験薬の投与が完全に中止された。心不全の原因は肺高血圧症（非重篤）及び慢性閉塞性肺疾患（非重篤）である可能性が高いと考えられると報告された。20[redacted] 年 [redacted] 月 [redacted] 日，冠動脈造影検査が行われた：拡張型心筋症（非重篤）と診断され，虚血による心不全の可能性は低いとされた。拡張型心筋症が被験者の心不全の原因として確認された。

20[redacted] 年 [redacted] 月 [redacted] 日，被験者の呼吸状態は改善したが，息切れは特に階段を昇る際に持続していることが示されている。72 時間のホルター心電図モニタリングの結果，初期調律 64-105 bpm（平均 53）の洞調律で，心房頻脈が散発するが早期発作は伴わないことが示された。

投与された薬剤は，anopyrin，furon，kalnormin，ヒドロコルチゾン，syntophyllin，フロセミド，クレキサン，trombex 及び生理食塩液であった。

Causality for UPADACITINIB (Blinded)

---

1) Heart failure (10019279) (Cardiac failure (10007554)) [v.23.0] [10019279]

Causality as per reporter (Drug/Vaccine): No reasonable possibility

Causality as per Mfr. (Drug/Vaccine): No reasonable possibility

Dechallenge: Yes

Rechallenge: No rechallenge was done, recurrence is not applicable

Alternative Etiology for UPADACITINIB (Blinded)

Event of HEART FAILURE

- Investigator: Dilated cardiomyopathy.

- AbbVie: Risk factors include pre-existing hypertension, obesity, diabetes mellitus and chronic obstructive pulmonary disease.

Relevant Laboratory & Other Diagnostic Tests

Unknown date 72-HOUR ECG HOLTER MONITORING: Sinus rhythm as the primary rhythm of 64-105 bpm (mean 53), sporadic and not fast paroxysms of atrial tachycardia.

Unknown date 72-HOUR ECG HOLTER MONITORING: ([redacted]): Sporadic atrial tachycardia.

[redacted] **BLOOD PRESSURE:** 140/90 mmHh

[redacted] **BODY TEMPERATURE:** 36.5 Degrees C

[redacted] **BODY WEIGHT:** 153.6 KG

[redacted] **C-REACTIVE PROTEIN:** 8.0 MG/L (normal 0 to 5)

[redacted] **C-REACTIVE PROTEIN:** 7.2 MG/L (normal 0 to 5)

[redacted] **C-REACTIVE PROTEIN:** 2.0 MG/L (normal 0 to 5)

[redacted] **CHEST X-RAY:** Heart shadow dilation, sclerosis arcus aorta

[redacted] **CORONAROGRAPHY:** Conclusion: Coronary arteries without stenosis, remodeled left ventricle, LVEF 38%, Recommendation: ischemic etiology of heart failure is unlikely. Dilated cardiomyopathy was confirmed as the etiology of the heart failure.

[redacted] **ECHOCARDIOGRAPHY:** hypokinesis of the basis of the lateral wall with LVEF 46%, mitral regurgitation (non-serious), tricuspid regurgitation (non-serious)

[redacted] **ELECTROCARDIOGRAPHY:** Repolarization changes on the lower wall and ventrally, 1x ventricular extrasystoles

[redacted] **ELECTROCARDIOGRAPHY:** Sinus tachycardia, left anterior hemiblock, poster lateral repolarization changes

[redacted] **ELECTROCARDIOGRAPHY:** Diffuse repolarization changes

[redacted] **PERFUSION LUNG SCAN:** Physiological scan, pulmonary embolism excluded

[redacted] **PRO BNP:** 10325 NG/L (normal 0 to 227)

[redacted] **PT INR:** 1.1 RATIO (normal 0.8 to 1.2)

[redacted] **PT INR:** 1.09 RATIO (normal 0.8 to 1.2)

[redacted] **PULSE:** 108 /min

[redacted] **20[redacted] RESPIRATORY RATE:** 14 /min

[redacted] **20[redacted] TROPONIN T:** 0.113 no unit

[redacted] **20[redacted] TROPONIN T:** 0.105 no unit

[redacted] **20[redacted] ULTRASOUND OF ABDOMEN:** Hepatic steatosis, hepatomegaly, otherwise without pathology

被験者番号 [redacted] (Investigator [redacted])

Reason for Narrative

Adverse Event Preferred Term(s)	Serious Adverse Event	Adverse Event Leading to Discontinuation of Study Drug	Death	Event of Interest
甲状腺腫	X			

Treatment Group	Age at Study Start	Sex	Race
ABT-494 30 mg QD	3[redacted]	FEMALE	WHITE

Medical History	Onset Year
OTHER: PLAQUE PSORIASIS	20[redacted]

Prior Procedures	Procedure Year
Not reported.	

Tobacco Use	Status	Number/Day	Number of Years	Year Stopped
CHEWING TOBACCO	NEVER			
CIGARETTES	CURRENT	0.5 PACK	15	
CIGARS	NEVER			
E-CIGARETTES	NEVER			
PIPES	NEVER			

Alcohol Use	Status	Number/Day
ALCOHOL	NEVER	

Study Drug Administration

Study Drug	Dose/Units	Route	Frequency	First Dose Date/Day	Last Dose Date/Day	Duration (Days)
ABT-494	30MG	ORAL	QD	[redacted]20[redacted] / 1	[redacted]20[redacted] / 168	168
ABT-494	30MG	ORAL	QD	[redacted]20[redacted] / 169	[redacted]20[redacted] / 392	224
ABT-494	30MG	ORAL	QD	[redacted]20[redacted] / 393	/	

Previous Therapy - Prior to baseline/enrollment

Medication Name (WHO Drug)	Dose/Units	Frequency	Start Year-Month / RX Day
FOLIC ACID	10 mg	EVERY WEEK	Y-M: 20[redacted]
METHOTREXATE	20 mg	EVERY WEEK	Y-M: 20[redacted]
OMEPRAZOLE	20 mg	QD	Y-M: 20[redacted]
SECUKINUMAB	150 mg	OTHER: ONCE MONTHLY	Y-M: 20[redacted]
FEMODENE	0,030/0,075 mg	QD	Y-M: 20[redacted] / -144
CALCIUM CARBONATE	600 mg	QD	Y-M: 20[redacted] / -115
METHYLPREDNISOLONE	4 mg	BID	Y-M: 20[redacted] / -108
ETANERCEPT	50 mg	EVERY WEEK	Y-M: 20[redacted] / -36
IBUPROFEN	400 mg	BID	Y-M: 20[redacted] / -36

Other Medications - Medications taken within 30 days prior to each narrative event until AE stopped or end of study

Medication Name (WHO Drug)	Dose/Units	Frequency	Start Year-Month / RX Day	Stop Year-Month / RX Day
FOLIC ACID	10 mg	EVERY WEEK	Y-M: 20[redacted]	Not reported.
METHOTREXATE	20 mg	EVERY WEEK	Y-M: 20[redacted]	Not reported.
FEMODENE	0,030/0,075 mg	QD	Y-M: 20[redacted] / -144	Not reported.
CALCIUM CARBONATE	600 mg	QD	Y-M: 20[redacted] / -115	Not reported.
METHYLPREDNISOLONE	4 mg	BID	Y-M: 20[redacted] / -108	Not reported.
IBUPROFEN	400 mg	BID	Y-M: 20[redacted] / -36	Not reported.
PANTOPRAZOLE	40 mg	BID	Y-M: 20[redacted] / 113	Not reported.
ITOPRIDE	50 mg	TID	Y-M: 20[redacted] / 169	Not reported.
ALPRAZOLAM	0,25 mg	BID	Y-M: 20[redacted] / 195	Not reported.
COLECALCIFEROL	15 gtt	EVERY WEEK	Y-M: 20[redacted] / 287	Not reported.
LEVOTHYROXINE	100 ug	QD	Y-M: 20[redacted] / 287	Y-M: 20[redacted] / 372

Event #1: Serious Adverse Event

Event Description	STRUMA NODOSA-ENLARGED THYROID GLAND
Preferred term	甲状腺腫

AE Onset Date / Rx Day [redacted]20[redacted] / 238
Age at AE Onset 3[redacted]
Laboratory Testing
NOT REPORTED
Microbiology
NOT REPORTED
SAE Supplemental Procedure
[redacted]20[redacted] (RX DAY 279): SURGERY - STRUMECTOMY: RESOLVED; [redacted]20[redacted] (RX DAY 287): HISTOLOGICAL EXAMINATION: ONCOCYTIC ADENOMA IN THE RIGHT LOBE
AE Stopped Rx Day 287
Duration of AE 50 DAYS
Relation to Study Drug by Investigator NO REASONABLE POSSIBILITY
Investigator Alternative Etiology UNKNOWN
Discontinued Study Drug Due to the Event NO
SAE Criteria REQUIRES OR PROLONGS HOSPITALIZATION

Generated: [redacted]
Program Source Code: [redacted]

Investigator No.: [redacted]

Subject Number: [redacted]

Protocol Number: M15-554

治験責任医師からの報告。本被験者はチェコ共和国の 3[redacted] 歳女性であり，ABT-494（ウパダシチニブ）の治験で盲検化された治験薬が投与され，結節性甲状腺腫-甲状腺肥大の事象を発現した。

Event 1 の臨床経過：

関連する病歴は乾癬性関節炎，現紙巻タバコ喫煙者（1 日 0.5 箱を 15 年間）及び非飲酒者であった。

被験者は，最初の 24 週間，本治験の盲検プラセボ対照期に組み入れられていた。20[redacted] 年 [redacted] 月 [redacted] 日，ABT-494 の盲検投与が開始された。

20[redacted] 年 [redacted] 月 [redacted] 日，被験者は結節性甲状腺腫-甲状腺肥大を発現した。20[redacted] 年 [redacted] 月 [redacted] 日，結節性甲状腺腫-甲状腺肥大は消失した。

20[redacted] 年 [redacted] 月 [redacted] 日，被験者は結節性甲状腺腫を発現した。その他の合併症や異常はなかった。20[redacted] 年 [redacted] 月 [redacted] 日，被験者は嚥下困難で入院した。20[redacted] 年 [redacted] 月 [redacted] 日，甲状腺全摘術が行われた。術後合併症はなく，外科切開部位は順調に治癒していた。20[redacted] 年 [redacted] 月 [redacted] 日，被験者は退

院した。20[redacted] 年 [redacted] 月 [redacted] 日，診察が行われ，外科切開部位は問題なく治癒したと判断された。

The patient's past medications include:

SECUKINUMAB for PSORIATIC ARTHRITIS ([redacted] 20[redacted] - [redacted] 20[redacted])

ETANERCEPT for PSORIATIC ARTHRITIS ([redacted] 20[redacted] - [redacted] 20[redacted])

NOVALGIN for GASTROENTERITIS ([redacted] 20[redacted] - [redacted] 20[redacted])

Causality for ABT-494 (Blinded)

---

1) Struma nodosa (10080173) (Goitre (10018498)) [v.22.1] [10080173]

Causality as per reporter (Drug/Vaccine): No reasonable possibility

Causality as per Mfr. (Drug/Vaccine): No reasonable possibility

Dechallenge: Yes

Rechallenge: rechallenge was done, reaction did not recur

Alternative Etiology for ABT-494 (Blinded)

Event of STRUMA NODOSA-ENLARGED THYROID GLAND

- Investigator: UNKNOWN

- AbbVie: EVENT IS COMMON IN THE GENERAL POPULATION. ADDITIONAL RISK FACTOR INCLUDES FEMALE GENDER.

Relevant Laboratory & Other Diagnostic Tests

[redacted] 20[redacted] **HISTOLOGY:** ONCOCYTIC ADENOMA IN THE RIGHT LOBE

被験者番号 [redacted] (Investigator [redacted])

Reason for Narrative

Adverse Event Preferred Term(s)	Serious Adverse Event	Adverse Event Leading to Discontinuation of Study Drug	Death	Event of Interest
心筋梗塞	X			

Treatment Group	Age at Study Start	Sex	Race
ABT-494 15 mg QD	5[redacted]	FEMALE	WHITE

Medical History	Onset Year
OTHER: PLAQUE PSORIASIS	19[redacted]
CHOLELITHIASIS: CHOLECYSTECTOMY	19[redacted]
HYPERTENSION	20[redacted]
OTHER: GASTRITIS CHRONICA	20[redacted]
OSTEOPOROSIS	20[redacted]

Prior Procedures	Procedure Year
SURGERY: APENDECTOMY	19[redacted]
SURGERY: HYSTERECTOMY DUE TO MYOMA UTERI	20[redacted]

Tobacco Use	Status	Number/Day	Number of Years	Year Stopped
CHEWING TOBACCO	NEVER			
CIGARETTES	CURRENT	0.5 PACK	20	
CIGARS	NEVER			
E-CIGARETTES	NEVER			
PIPES	NEVER			

Alcohol Use	Status	Number/Day
ALCOHOL	CURRENT	Less than 2

Study Drug Administration

Study Drug	Dose/Units	Route	Frequency	First Dose Date/Day	Last Dose Date/Day	Duration (Days)
ABT-494	15MG	ORAL	QD	[redacted]20[redacted] / 1	[redacted]20[redacted] / 168	168
ABT-494	15MG	ORAL	QD	[redacted]20[redacted] / 169	[redacted]20[redacted] / 392	224
ABT-494	15MG	ORAL	QD	[redacted]20[redacted] / 393	/	

Previous Therapy - Prior to baseline/enrollment

Medication Name (WHO Drug)	Dose/Units	Frequency	Start Year-Month / RX Day
SULFASALAZINE	1 g	BID	Y-M: 20[redacted]
ATENOLOL	50 mg	BID	Y-M: 20[redacted]
OMEPRAZOLE	20 mg	QD	Y-M: 20[redacted]
CELECOXIB	100 mg	OTHER: 3 TIMES A WEEK	Y-M: 20[redacted]
FOLIC ACID	10 mg	EVERY WEEK	Y-M: 20[redacted]
METHOTREXATE	10 mg	EVERY WEEK	Y-M: 20[redacted]
COLECALCIFEROL	15 gtt	EVERY WEEK	Y-M: 20[redacted]
CALCIUM CARBONATE	600 mg	QD	Y-M: 20[redacted]
SECUKINUMAB	150 mg	OTHER: MONTHLY	Y-M: 20[redacted]

Other Medications - Medications taken within 30 days prior to each narrative event until AE stopped or end of study

Medication Name (WHO Drug)	Dose/Units	Frequency	Start Year-Month / RX Day	Stop Year-Month / RX Day
ATENOLOL	50 mg	BID	Y-M: 20[redacted]	Not reported.
OMEPRAZOLE	20 mg	QD	Y-M: 20[redacted]	Not reported.
FOLIC ACID	10 mg	EVERY WEEK	Y-M: 20[redacted]	Not reported.
METHOTREXATE	10 mg	EVERY WEEK	Y-M: 20[redacted]	Not reported.
COLECALCIFEROL	15 gtt	EVERY WEEK	Y-M: 20[redacted]	Not reported.
CALCIUM CARBONATE	600 mg	QD	Y-M: 20[redacted]	Not reported.
GLYCERYL TRINITRATE	0,4 mg	PRN	Y-M: 20[redacted] / 253	Not reported.
CLOPIDOGREL	75 mg	QD	Y-M: 20[redacted] / 253	Y-M: 20[redacted] / 267

Event #1: Serious Adverse Event

Event Description APICAL MYOCARDIAL INFARCTION

Preferred term 心筋梗塞

AE Onset Date / Rx Day [redacted]20[redacted] / 248

Age at AE Onset 5[redacted]

Laboratory Testing

[redacted]20[redacted] (RX DAY 254): Aspartate Aminotransferase: 44 [6 - 37] U/L; NPTST094-GGT: 0.87 [0.1 - 0.5] ukat/L

Microbiology

NOT REPORTED

SAE Supplemental Procedure

[redacted]20[redacted] (RX DAY 253): ECG: ABNORMAL, BUT MI NOT PROVEN; [redacted]20[redacted] (RX DAY 254): ECHOCARDIOGRAPHY: WITHOUT PATHOLOGY; [redacted]20[redacted] (RX DAY 255): CHEST X-RAY: NORMAL FINDING-WITHOUT PATHOLOGY; ERGOMETRY: WITHOUT PATHOLOGY-NO KES AND SVES ACTIVITY; [redacted]20[redacted] (RX DAY 267): CORONAROGRAPHY: NORMAL

AE Stopped Rx Day 267

Duration of AE 20 DAYS

Relation to Study Drug by Investigator NO REASONABLE POSSIBILITY
Investigator Alternative Etiology HYPERTENSION
Discontinued Study Drug Due to the Event NO
SAE Criteria REQUIRES OR PROLONGS HOSPITALIZATION, OTHER MEDICALLY IMPORTANT SERIOUS EVENT

Generated: [redacted]
Program Source Code: [redacted]

Investigator No.: [redacted]

Subject Number: [redacted]

Protocol Number: M15-554

治験責任医師からの報告。本被験者はチェコ共和国の 5[redacted] 歳女性であり，ABT-494（ウパダシチニブ）の治験で盲検化された治験薬が投与され，心尖部心筋梗塞の事象を発現した。

Event 1 の臨床経過：

関連する病歴は高血圧，乾癬性関節炎，現喫煙者（1 日 0.5 箱を 20 年間）及び現飲酒者（1 日 2 杯未満）であった。

試験の盲検を解除。

被験者は，最初の 24 週間，本治験の盲検プラセボ対照期に組み入れられていた。20[redacted] 年 [redacted] 月 [redacted] 日，ABT-494 の盲検投与が開始された。

20[redacted] 年 [redacted] 月 [redacted] 日，被験者は心尖部心筋梗塞を発現した。20[redacted] 年 [redacted] 月 [redacted] 日，心尖部心筋梗塞は消失した。

20[redacted] 年 [redacted] 月 [redacted] 日，被験者は，胸骨圧迫感，発汗及び呼吸悪化のため入院した。心臓マーカー測定，心電図検査，エコー検査及びコロノグラフィは行われなかった。20[redacted] 年 [redacted] 月 [redacted] 日，被験者は退院した。

投与された薬剤は，nitromint 及び trombex であった。

Causality for UPADACITINIB (Blinded)

---

1) Apical myocardial infarction (10059869) (Myocardial infarction (10028596)) [v.22.1] [10059869]

Causality as per reporter (Drug/Vaccine): No reasonable possibility

Causality as per Mfr. (Drug/Vaccine): No reasonable possibility

Dechallenge: Yes

Rechallenge: rechallenge was done, reaction did not recur

Alternative Etiology for UPADACITINIB (Blinded)

Event of APICAL MYOCARDIAL INFARCTION

- Investigator: Hypertension.

- AbbVie: Risk factors include pre-existing hypertension and current and extensive tobacco use.

Relevant Laboratory & Other Diagnostic Tests

[redacted] **20[redacted] AST:** 0.73 ukat/L (normal 0.1 to 0.62)

[redacted] **20[redacted] CHEST X-RAY:** Normal finding-without pathology

[redacted] **20[redacted] CORONOGRAPHY:** Normal

[redacted] **20[redacted] ECG:** ABNORMAL, BUT MI NOT PROVEN

[redacted] **20[redacted] ECHOCARDIOGRAPHY:** WITHOUT PATHOLOGY

[redacted] **20[redacted] ERGOMETRY:** Without pathology-no KES and SVES activity

[redacted] **20[redacted] GGT:** 0.87 ukat/L (normal 0.1 to 0.5)

被験者番号 [redacted] (Investigator [redacted])

Reason for Narrative

Adverse Event Preferred Term(s)	Serious Adverse Event	Adverse Event Leading to Discontinuation of Study Drug	Death	Event of Interest
細気管支炎	X			X
肺感染	X	X		X

Treatment Group	Age at Study Start	Sex	Race
Placebo/ABT-494 15 mg QD	6[redacted]	FEMALE	WHITE

Medical History	Onset Year
OTHER: HEAD PLAQUE OF PSORIASIS	20[redacted]
DEPRESSION: FATHER'S DEATH	20[redacted]
EMPHYSEMA/CHRONIC OBSTRUCTIVE PULMONARY DISEASE	20[redacted]
HYPERTENSION	20[redacted]
OTHER: POST-MENAUPOSAL	20[redacted]

Prior Procedures	Procedure Year
Not reported.	

Tobacco Use	Status	Number/Day	Number of Years	Year Stopped
CHEWING TOBACCO	NEVER			
CIGARETTES	CURRENT	1.5 PACK	30	
CIGARS	NEVER			
E-CIGARETTES	NEVER			
PIPES	NEVER			

Alcohol Use	Status	Number/Day
ALCOHOL	CURRENT	Less than 2

Study Drug Administration

Study Drug	Dose/Units	Route	Frequency	First Dose Date/Day	Last Dose Date/Day	Duration (Days)
PLACEBO		ORAL	QD	[redacted]20[redacted] / 1	[redacted]20[redacted] / 172	172
ABT-494	15MG	ORAL	QD	[redacted]20[redacted] / 173	[redacted]20[redacted] / 365	193

Previous Therapy - Prior to baseline/enrollment

Medication Name (WHO Drug)	Dose/Units	Frequency	Start Year-Month / RX Day
BCG Vaccine	NOT REPORTED	NOT REPORTED	Y-M: 19[redacted]
CELECOXIB	200 mg	BID	Y-M: 20[redacted]
METHOTREXATE	15 mg	EVERY WEEK	Y-M: 20[redacted]
GOLIMUMAB	NK mg	NOT REPORTED	Y-M: 20[redacted]
OXYCODONE	20 mg	BID	Y-M: 20[redacted]
OXYCODONE	40 mg	BID	Y-M: 20[redacted]
OXYCODONE	5 mg	OTHER: IF NEEDED, IF PAIN	Y-M: 20[redacted]
PANADEINE CO	600 / 50 mg	TID	Y-M: 20[redacted]
DILTIAZEM	200 mg	QD	Y-M: 20[redacted]
PREDNISONE	5 mg	QD	Y-M: 20[redacted]
ZOFENOPRIL	15 mg	QD	Y-M: 20[redacted]
TIOTROPIUM	2.5 ug	BID	Y-M: 20[redacted]
VENLAFAXINE	75 mg	QD	Y-M: 20[redacted]
BEKFORM	200/6 OTHER: MG/DOSE	NOT REPORTED	Y-M: 20[redacted]

Other Medications - Medications taken within 30 days prior to each narrative event until AE stopped or end of study

Medication Name (WHO Drug)	Dose/Units	Frequency	Start Year-Month / RX Day	Stop Year-Month / RX Day
CELECOXIB	200 mg	BID	Y-M: 20[redacted]	Y-M: 20[redacted] / 198
OXYCODONE	20 mg	BID	Y-M: 20[redacted]	ONGOING
OXYCODONE	40 mg	BID	Y-M: 20[redacted]	ONGOING
OXYCODONE	5 mg	OTHER: IF NEEDED, IF PAIN	Y-M: 20[redacted]	ONGOING
PANADEINE CO	600 / 50 mg	TID	Y-M: 20[redacted]	ONGOING
DILTIAZEM	200 mg	QD	Y-M: 20[redacted]	ONGOING
ZOFENOPRIL	15 mg	QD	Y-M: 20[redacted]	ONGOING
TIOTROPIUM	2.5 ug	BID	Y-M: 20[redacted]	ONGOING
VENLAFAXINE	75 mg	QD	Y-M: 20[redacted]	ONGOING
BEKFORM	200/6 OTHER: MG/DOSE		Y-M: 20[redacted]	ONGOING
PARACETAMOL	1000 mg	TID	Y-M: 20[redacted] / 94	ONGOING
PREDNISONE	10 mg	QD	Y-M: 20[redacted] / 112	ONGOING
CEFTRIAXONE	1 g	QD	Y-M: 20[redacted] / 198	Y-M: 20[redacted] / 203
SPIRAMYCIN	1.5 MIU	TID	Y-M: 20[redacted] / 198	Y-M: 20[redacted] / 203

LANSOPRAZOLE	15 mg	QD	Y-M: 20[redacted] / 203	ONGOING
LEVOFLOXACIN	500 mg	BID	Y-M: 20[redacted] / 203	Y-M: 20[redacted] / 206
DILTIAZEM	200 mg	QD	Y-M: 20[redacted] / 203	Y-M: 20[redacted] / 345
AUGMENTIN	1 g	BID	Y-M: 20[redacted] / 345	Y-M: 20[redacted] / 352
AUGMENTIN	1 g	QD	Y-M: 20[redacted] / 366	Y-M: 20[redacted] / 367
CEFTRIAXONE	2 g	QD	Y-M: 20[redacted] / 366	Y-M: 20[redacted] / 368
SPIRAMYCIN	1.5 MIU	TID	Y-M: 20[redacted] / 366	Y-M: 20[redacted] / 368

Event #1: Serious Adverse Event, Study Specific Adverse Events of Interest

Event Description	INFECTIOUS BRONCHIOLITIS
Preferred term	細気管支炎
AE Onset Date / Rx Day	[redacted]20[redacted] / 191
Age at AE Onset	6[redacted]

Laboratory Testing

[redacted]20[redacted] (RX DAY 201): Leukocytes: 10.4 [4 - 10] 10^9/L; NPTST038-C-REACTIVE PROTEIN: 42.4 [0.3 - 5] mg/L; NPTST157-NT-PROBNP: 1328 [5 - 125] ng/L; [redacted]20[redacted] (RX DAY 211): Leukocytes: 14.5 [4 - 10] 10^9/L

Microbiology

[redacted]20[redacted] (RX DAY 198): URINE NPTST071-CYTOBACTERIOLOGICAL EXAMINATION: NEGATIVE; [redacted]20[redacted] (RX DAY 199): SPUTUM NPTST162-PCR OF RESPIRATOTY PATHOGENES: NEGATIVE; [redacted]20[redacted] (RX DAY 200): SPUTUM NPTST070-CYTOBACTERIOLOGICAL EXAMINATION: NEGATIVE

SAE Supplemental Procedure

[redacted]20[redacted] (RX DAY 198): CT ANGIOGRAPHY: BLURRED MICRONODULAR APPEARANCE THAT MAY SUGGEST AN INFECTIOUS ORIGIN; ELECTROCARDIOGRAM: SINUS TACHYCARDIA, LEFT AND RIGHT ATRIAL HYPERTROPHY; OXYGEN THERAPY: NOT APPLICABLE; TEMPERATURE: 36.6? CELSIUS

AE Stopped Rx Day	203
Duration of AE	13 DAYS
Relation to Study Drug by Investigator	REASONABLE POSSIBILITY
Investigator Alternative Etiology	NOT REPORTED
Discontinued Study Drug Due to the Event	NO
SAE Criteria	REQUIRES OR PROLONGS HOSPITALIZATION, OTHER MEDICALLY IMPORTANT SERIOUS EVENT

Event #2: Serious Adverse Event, AE Leading to Discontinuation of Study Drug, Study Specific Adverse Events of Interest

Event Description	PULMONARY INFECTION
Preferred term	肺感染
AE Onset Date / Rx Day	[redacted]20[redacted] / 345
Age at AE Onset	6[redacted]
Laboratory Testing	
NOT REPORTED	
Microbiology	
[redacted]20[redacted] (RX DAY 366): BLOOD NPTST029-BLOOD CULTURE: NEGATIVE-NEGATIVE; URINE NPTST069-CYTOBACTERIOLIGICAL URINE EXAM: POSITIVE-PRESENCE OF LEUKOCYTES; [redacted]20[redacted] (RX DAY 370): SPUTUM NPTST070-CYTOBACTERIOLOGICAL EXAMINATION: NEGATIVE-OROPHARYNGEAL COMMENSAL FLORA	
SAE Supplemental Procedure	
[redacted]20[redacted] (RX DAY 366): CHEST XRAYS: UNKNOWN; ELECTROCARDIOGRAM: TACHYCARDIA	
AE Stopped Rx Day	373 (8 DAYS AFTER LAST TREATMENT)
Duration of AE	29 DAYS
Relation to Study Drug by Investigator	REASONABLE POSSIBILITY
Investigator Alternative Etiology	NOT REPORTED
Discontinued Study Drug Due to the Event	YES
SAE Criteria	REQUIRES OR PROLONGS HOSPITALIZATION

Generated: [redacted]
Program Source Code: [redacted]

Investigator No.: [redacted]

Subject Number: [redacted]

Protocol Number: M15-554

治験責任医師からの報告。本被験者はフランスの 6[redacted] 歳女性であり，ABT-494（ウパダシチニブ）の治験で盲検化された治験薬が投与され，感染性細気管支炎の事象を発現した。

Event 1 の臨床経過：

関連する病歴は乾癬性関節炎，慢性閉塞性肺疾患，高血圧，現喫煙者（1 日 1.5 箱を 30 年間）及び現飲酒者（1 日 2 杯未満）であった。

被験者は，最初の 24 週間，本治験の盲検プラセボ対照期に組み入れられていた。20[redacted] 年 [redacted] 月 [redacted] 日，ABT-494 の盲検投与が開始された。

20[redacted] 年 [redacted] 月 [redacted] 日，被験者は感染性細気管支炎を発現した。20[redacted] 年 [redacted] 月 [redacted] 日，感染性細気管支炎は消失した。

以前（20[redacted] 年 [redacted] 月 [redacted] 日），被験者は発熱及び咳嗽を伴う肺感染（非重篤）を発現していた。

20[redacted] 年 [redacted] 月 [redacted] 日，被験者は熱性呼吸困難のため入院した。被験者は，気管支うっ血，「大量発汗」，低酸素血症及び呼吸困難といった徴候・症状を呈していた。心血管系の診察で，軽度の胸部不快感と，気管支閉塞の徴候が認められた。右心不全の徴候はなかった。肺の診察で，被験者は 2 リットル未満の酸素補給下で発話時に呼吸困難を呈した。感染性の検体（ECBC，ECBU，各種呼吸器病原体の PCR）はすべて陰性であった。両肺で広範性の低音性連続性ラ音，両肺野で歯擦音が聴取された。抗菌剤，酸素補給及び ventolin エアロゾルによる治療が行われた。治療効果は良好で，呼吸困難及び発熱は治療開始から 24 時間後に消失した。20[redacted] 年 [redacted] 月 [redacted] 日，被験者は退院した。

投与された薬剤は，rovamycine，rocephine，酸素補給，レボフロキサシン，ベンラファキシン及び ventolin エアロゾルであった。

The patient's past medications include:

METHOTREXATE for PSORIATIC ARTHRITIS (20[redacted] - 20[redacted])

SIMPONI for PSORIATIC ARTHRITIS (20[redacted] - 20[redacted])

CORTANCYL for PSORIATIC ARTHRITIS (20[redacted] - [redacted] [redacted] 20[redacted], Started [redacted] [redacted] 20[redacted])

AMOXICILLIN for PULMONARY INFECTION ([redacted] [redacted] 20[redacted] - [redacted] [redacted] 20[redacted])

CEFTRIAXONE for BRONCHIOLITIS ([redacted] [redacted] 20[redacted] - [redacted] [redacted] 20[redacted])

Causality for UPADACITINIB (Blinded)

---

1) Bronchiolitis (10006448) (Bronchiolitis (10006448)) [v.22.0] [10006448]

Causality as per reporter (Drug/Vaccine): Reasonable possibility

Causality as per Mfr. (Drug/Vaccine): No reasonable possibility

Dechallenge: Yes

Rechallenge: rechallenge was done, outcome unknown

Alternative Etiology for UPADACITINIB (Blinded)

Event of INFECTIOUS BRONCHIOLITIS

- Investigator: Not Applicable.

- AbbVie: RISK FACTORS INCLUDE SUBJECT'S AGE, CURRENT SMOKING STATUS OF 1.5 PPD FOR 30 YEARS AND PRE-EXISTING CHRONIC OBSTRUCTIVE PULMONARY DISEASE.

Relevant Laboratory & Other Diagnostic Tests

[redacted] **20[redacted] BODY TEMPERATURE:** 36.6 Degrees C

[redacted] **20[redacted] C-REACTIVE PROTEIN:** 42.4 MG/L (normal 0.3 to 5.0)

[redacted] **20[redacted] CT ANGIOGRAPHY:** Blurred micronodular appearance that may suggest an infectious origin.

[redacted] **20[redacted] ECHOCARDIOGRAM:** Regular sinus tachycardia, left and right atrial hypertrophy. thoracic distention with accentuation of the bronchial pattern. conclusion : Infectious bronchiolitis without documented germs.

[redacted] **20[redacted] NT-PROBNP:** 1328 5-125 ng/l

Unknown date PULMONARY EXAMINATION: Dyspneic to speech under 2L of oxygen. Bilateral and symmetrical vesicular murmur decreased on both fields with diffuse ronchis and sibilants.

Unknown date RESPIRATORY PATHOGENS: ECBC, ECBU, and Respiratory PCR all negative.

[redacted] **20[redacted] SPO2:** 54.1 % (normal 94 to 100)

[redacted] **20[redacted] WHITE BLOOD CELLS:** 10.4 X10**9/L (normal 4 to 10)

[redacted] **20[redacted] WHITE BLOOD CELLS:** 14.5 X10**9/L (normal 4 to 10)
Investigator No.: [redacted]

Subject Number: [redacted]

Protocol Number: M15-554

治験責任医師からの報告。本被験者はフランスの 6[redacted] 歳女性であり，ABT-494（ウパダシチニブ）の治験で盲検化された治験薬が投与され，肺感染の事象を発現した。

Event 2 の臨床経過：

関連する病歴は頭部尋常性乾癬，乾癬性関節炎，うつ病，肺気腫／慢性閉塞性肺疾患，高血圧，現紙巻タバコ喫煙者（1 日 1.5 箱を 30 年間）及び現飲酒者（1 日 2 杯未満）であった。

20[redacted] 年 [redacted] 月 [redacted] 日，被験者は肺感染を発現した。20[redacted] 年 [redacted] 月 [redacted] 日，肺感染は消失した。

20[redacted] 年 [redacted] 月 [redacted] 日，被験者は，呼吸困難，頻脈及び低酸素血症の徴候・症状で担当医を受診し，オーグメンチン 7 日分を処方された。症状が悪化し，被験者は 20[redacted] 年 [redacted] 月 [redacted] 日に入院した。20[redacted] 年 [redacted] 月 [redacted] 日，被験者は退院した。

本事象により治験薬の投与が完全に中止された。

投与された薬剤は，セフトリアキソン，rovamycin，ロセフィン及びオーグメンチンであった。

The patient's past medications include:

CELEBREX for PSORIATIC ARTHRITIS (20[redacted] - [redacted] 20[redacted])

METHOTREXATE for PSORIATIC ARTHRITIS (20[redacted] - 20[redacted])

SIMPONI for PSORIATIC ARTHRITIS (20[redacted] - [redacted] 20[redacted])

CORTANCYL for PSORIATIC ARTHRITIS (20[redacted] - [redacted] 20[redacted])

MONURIL for URINARY INFECTION ([redacted] 20[redacted] - [redacted] 20[redacted])

CEFTRIAXONE for INFECTIOUS BRONCHIOLITIS ([redacted] 20[redacted] - [redacted] 20[redacted])

ROCEPHINE for INFECTIOUS BRONCHOLITIS ([redacted] 20[redacted] - [redacted] 20[redacted])

ROVAMYCINE for INFECTIOUS BRONCHOLITIS ([redacted] 20[redacted] - [redacted] 20[redacted])

LEVOFLOXACINE for INFECTIOUS BRONCHIOLITIS ([redacted] 20[redacted] - [redacted] 20[redacted])

Causality for UPADACITINIB (Blinded)

---

1) Lung infection (10061229) (Lung infection (10061229)) [v.22.0] [10061229]

Causality as per reporter (Drug/Vaccine): Reasonable possibility

Causality as per Mfr. (Drug/Vaccine): No reasonable possibility

Dechallenge: Yes

Rechallenge: No rechallenge was done, recurrence is not applicable

Alternative Etiology for UPADACITINIB (Blinded)

Event of PULMONARY INFECTION

- Investigator: Not applicable

- AbbVie: Event more likely related to pre-existing emphysema/chronic obstructive pulmonary disease and current extensive smoking history of 1.5 packs per day for 30 years.

Relevant Laboratory & Other Diagnostic Tests

[redacted] **20[redacted] BLOOD CULTURE:** negative

[redacted] **20[redacted] CHEST X-RAY:** Normal

[redacted] **20[redacted] CHEST XRAY:** unknown

[redacted] **20[redacted] CYTOBACTERIOLIGICAL URINE EXAM:** positive- presence of leukocytes

[redacted] **20[redacted] CYTOBACTERIOLOGICAL EXAM OF SPUTUM:** negative-oropharyngeal commensal flora

[redacted] **20[redacted] ELECTROCARDIOGRAM:** tachycardia

被験者番号 [redacted] (Investigator [redacted])

Reason for Narrative

Adverse Event Preferred Term(s)	Serious Adverse Event	Adverse Event Leading to Discontinuation of Study Drug	Death	Event of Interest
急速進行性変形性関節症	X	X		

Treatment Group	Age at Study Start	Sex	Race
ABT-494 15 mg QD	7[redacted]	FEMALE	WHITE

Medical History	Onset Year
ANEMIA: ANEMIA	NOT REPORTED
OSTEOARTHRITIS: BILATERAL OSTEOARTHRITIS OF HIP	NOT REPORTED
OTHER: NAUSEA	NOT REPORTED
TUBERCULOSIS: ACTIVE TB	19[redacted]
OTHER: PLAQUE OF PSORIASIS	19[redacted]
DRUG ALLERGIES/REACTIONS: PENICILINE ALLERGY	19[redacted]
OTHER: INTESTINAL PAIN	19[redacted]
HYPERTENSION	20[redacted]
OTHER: CORONARY SPASM	20[redacted]
EMPHYSEMA/CHRONIC OBSTRUCTIVE PULMONARY DISEASE	20[redacted]
OSTEOARTHRITIS: SHOULDERS	20[redacted]
DEPRESSION: CONTROLLED WITH MEDICATION	20[redacted]
HYPERLIPIDEMIA: HYPERCHOLESTEROLEMIA	20[redacted]
DRUG ALLERGIES/REACTIONS: PRISTINAMYCINE ALLERGY	20[redacted]
GASTROESOPHAGEAL REFLUX DISEASE	20[redacted]
DRUG ALLERGIES/REACTIONS: PROPOFOL ALLERGY	20[redacted]
KIDNEY DISORDER: CHRONIC RENAL FAILURE	20[redacted]
OTHER: SIGMOIDITIS	20[redacted]

Prior Procedures	Procedure Year
SURGERY: APPENDICECTOMY	19[redacted]
SURGERY: CHOLECYSTECTOMY	19[redacted]
SURGERY: TUBOPLASTY	19[redacted]
SURGERY: C-SECTION	19[redacted]
SURGERY: AMYGDALECTOMY	19[redacted]
SURGERY: HYSTERECTOMY DUE TO OVARIAN CYST	19[redacted]
SURGERY: OVARIECTOMY DUE TO OVARIAN CYST	19[redacted]
SURGERY: SYNOVECTOMY	20[redacted]
SURGERY: SURGERY OF RIGHT SHOULDER TENDONS	20[redacted]
SURGERY: SURGERY OF LEFT SHOULDER TENDONS	20[redacted]

Tobacco Use	Status	Number/Day	Number of Years	Year Stopped
CHEWING TOBACCO	NEVER			
CIGARETTES	NEVER			
CIGARS	NEVER			
E-CIGARETTES	NEVER			
PIPES	NEVER			

Alcohol Use	Status	Number/Day
ALCOHOL	CURRENT	Less than 2

Study Drug Administration

Study Drug	Dose/Units	Route	Frequency	First Dose Date/Day	Last Dose Date/Day	Duration (Days)
ABT-494	15MG	ORAL	QD	[redacted]20[redacted] / 1	[redacted]20[redacted] / 148	148

Previous Therapy - Prior to baseline/enrollment

Medication Name (WHO Drug)	Dose/Units	Frequency	Start Year-Month / RX Day
ESTRADIOL	0.06 %	QD	Y-M: 19[redacted]
AMLODIPINE	10 mg	QD	Y-M: 20[redacted]
VALSARTAN	80 mg	QD	Y-M: 20[redacted]
PREDNISONE	5 mg	QD	Y-M: 20[redacted]
ULTRACET	37.5/325 mg	PRN	Y-M: 20[redacted]
TRIMEBUTINE	200 mg	QD	Y-M: 20[redacted]
ATORVASTATIN	40 mg	QD	Y-M: 20[redacted]
HEPATITIS B IMMUNIZATION	NOT REPORTED	NOT REPORTED	Y-M: 20[redacted]
ESOMEPRAZOLE	20 mg	QD	Y-M: 20[redacted]
IVABRADINE	5 mg	BID	Y-M: 20[redacted]
ADALIMUMAB	40 mg	EVERY 2 WEEKS	Y-M: 20[redacted]
ETANERCEPT	50 mg	EVERY WEEK	Y-M: 20[redacted]
AMITRIPTYLINE	20 gtt	QD	Y-M: 20[redacted]
VENLAFAXINE	75 mg	TID	Y-M: 20[redacted]

NEFOPAM	20 mg	PRN	Y-M: 20[redacted]
GLYCERYL TRINITRATE	10 mg	QD	Y-M: 20[redacted] / -305
CERTOLIZUMAB PEGOL	200 mg	EVERY 2 WEEKS	Y-M: 20[redacted] / -152
HERPES ZOSTER IMMUNIZATION	NOT REPORTED	NOT REPORTED	Y-M: 20[redacted] / -28
VARICELLA ZOSTER VACCINE	0.65 mL	OTHER: ONCE	Y-M: 20[redacted] / -28

Other Medications - Medications taken within 30 days prior to each narrative event until AE stopped or end of study

Medication Name (WHO Drug)	Dose/Units	Frequency	Start Year-Month / RX Day	Stop Year-Month / RX Day
ESTRADIOL	0.06 %	QD	Y-M: 19[redacted]	ONGOING
AMLODIPINE	10 mg	QD	Y-M: 20[redacted]	ONGOING
VALSARTAN	80 mg	QD	Y-M: 20[redacted]	ONGOING
PREDNISONE	5 mg	QD	Y-M: 20[redacted]	ONGOING
ULTRACET	37.5/325 mg	PRN	Y-M: 20[redacted]	ONGOING
ATORVASTATIN	40 mg	QD	Y-M: 20[redacted]	ONGOING
ESOMEPRAZOLE	20 mg	QD	Y-M: 20[redacted]	ONGOING
IVABRADINE	5 mg	BID	Y-M: 20[redacted]	ONGOING
AMITRIPTYLINE	20 gtt	QD	Y-M: 20[redacted]	ONGOING
VENLAFAXINE	75 mg	TID	Y-M: 20[redacted]	ONGOING
NEFOPAM	20 mg	PRN	Y-M: 20[redacted]	ONGOING
GLYCERYL TRINITRATE	10 mg	QD	Y-M: 20[redacted] / -305	ONGOING
VALACICLOVIR	500 mg	QD	Y-M: 20[redacted] / 24	ONGOING
DOMPERIDONE	10 mg	PRN	Y-M: 20[redacted] / 50	Y-M: 20[redacted] / 57
TRIAMCINOLONE	40 mg	OTHER: ONCE	Y-M: 20[redacted] / 82	Y-M: 20[redacted] / 82
FLUTICASONE	125 ug	BID	Y-M: 20[redacted] / 87	Y-M: 20[redacted] / 90
LIDOCAINE	UNKNOWN mg	OTHER: ONCE	Y-M: 20[redacted] / 92	Y-M: 20[redacted] / 92
CYANOCOBALAMIN			Y-M: 20[redacted] / 127	ONGOING
FOLIC ACID	5 mg	QD	Y-M: 20[redacted] / 127	ONGOING
IRON	80 mg	QD	Y-M: 20[redacted] / 127	ONGOING
ERYTHROPOIETIN HUMAN	40000 IU	EVERY WEEK	Y-M: 20[redacted] / 133	Y-M: 20[redacted] / 156
PREDNISONE	5 mg	QD	Y-M: 20[redacted] / 134	Y-M: 20[redacted] / 148
BLOOD AND RELATED PRODUCTS		OTHER: ONCE	Y-M: 20[redacted] / 152	Y-M: 20[redacted] / 182
IRON		OTHER: ONCE	Y-M: 20[redacted] / 152	Y-M: 20[redacted] / 182

Event #1: Serious Adverse Event, AE Leading to Discontinuation of Study Drug

Event Description	RAPID DESTRUCTIVE OSTEOARTHRITIS OF THE HIP
Preferred term	急速進行性変形性関節症
AE Onset Date / Rx Day	[redacted]20[redacted] / 82
Age at AE Onset	7[redacted]

Laboratory Testing

[redacted]20[redacted] (RX DAY 99): NPTST056-CRP: 8 [0 - 5] mg/L; [redacted]20[redacted] (RX DAY 141): Hemoglobin: 90 [118 - 150] g/L

Microbiology

NOT REPORTED

SAE Supplemental Procedure

[redacted]20[redacted] (RX DAY 92): ASPIRATION OF THE HIP AND INJECTION OF LIDOCAINE: BLANK ASPIRATION; [redacted]20[redacted] (RX DAY 98): X-RAY OF HIP: INCREASING OF NARROWING OF COXOFEMORAL JOINT; [redacted]20[redacted] (RX DAY 161): HIP PROSTHESIS SURGERY: HIP REPLACEMENT

AE Stopped Rx Day	163 (15 DAYS AFTER LAST TREATMENT)
Duration of AE	82 DAYS
Relation to Study Drug by Investigator	REASONABLE POSSIBILITY
Investigator Alternative Etiology	NOT REPORTED
Discontinued Study Drug Due to the Event	YES
SAE Criteria	REQUIRES OR PROLONGS HOSPITALIZATION, OTHER MEDICALLY IMPORTANT SERIOUS EVENT

Generated: [redacted]
Program Source Code: [redacted]

Investigator No.: [redacted]

Subject Number: [redacted]

Protocol Number: M15-554

治験責任医師からの報告。本被験者はフランスの7[redacted]歳女性であり，ABT-494（ウパダシチニブ）の治験で盲検化された治験薬が投与され，股関節の急速破壊型変形性関節症の事象を発現した。

Event 1 の臨床経過：

関連する病歴は乾癬性関節炎，滑膜切除，右肩腱手術，左肩腱の手術，変形性肩関節症，非喫煙者，現飲酒者（1 日 2 杯未満），両股関節の変形性関節症及び貧血であった。

20[redacted]年[redacted]月[redacted]日，被験者は股関節の急速破壊型変形性関節症を発現した。20[redacted]年[redacted]月[redacted]日，股関節の急速破壊型変形性関節症は消失した。

20[redacted]年[redacted]月[redacted]日，リドカイン注が投与され，股関節吸引術が行われた。関節液は吸引されなかった。

20[redacted]年[redacted]月[redacted]日，被験者は左股関節痛及び歩行困難で入院した。治験薬の投与は入院中に休止された。診察の際，被験者は，この 3 週間，機械的な鼡径部痛が続いているとした。X 線検査及び股関節のスキャン検査が行われ，急速破壊型変形性関節症が認められた。急激な進展は見られなかったため，「浸潤」ではなかった。被験者は松葉杖が必要であった。20[redacted]年[redacted]月[redacted]日，被験者は退院した。

治験薬投与再開後，股関節痛が再発した。

20[redacted]年[redacted]月[redacted]日，本事象により治験薬の投与が完全に中止された。

20[redacted]年[redacted]月[redacted]日，人工股関節置換術が行われた。

投与された薬剤は hexatrione であった。

The patient's past medications include:

HUMIRA for PSORIATIC ARTHRITIS ([redacted] 20[redacted] - [redacted] 20[redacted])

PROPOFOL for UNKNOWN INDICATION

PRISTINAMYCINE for UNKNOWN INDICATION

PENICILINE for UNKNOWN INDICATION

Causality for ABT-494 (Blinded)

---

1) Rapidly destructive coxarthrosis (10067459) (Rapidly progressive osteoarthritis (10075201)) [v.22.0] [10067459]

Causality as per reporter (Drug/Vaccine): Reasonable possibility

Causality as per Mfr. (Drug/Vaccine): No reasonable possibility

Dechallenge: Yes

Rechallenge: rechallenge was done, reaction recurred

Alternative Etiology for ABT-494 (Blinded)

Event of RAPID DESTRUCTIVE OSTEOARTHRITIS OF THE HIP

- Investigator: Not applicable.

- AbbVie: Event more likely related to pre-existing bilateral osteoarthritis of hip, age, and pre-existing psoriatic arthritis.

Relevant Laboratory & Other Diagnostic Tests

[redacted] **ASPIRATION OF THE HIP:** Did not have any fluid.

[redacted] **CRP:** 8 MG/L (normal 0 to 5)

[redacted] **HEMOGLOBIN:** 9.0 G/DL (normal 11.8 to 15)

[redacted] **HIP SCAN:** rapid destructive osteoarthritis

[redacted] **X-RAY OF HIP:** Increasing of narrowing of coxofemoral joint

被験者番号 [redacted] (Investigator [redacted])

Reason for Narrative

Adverse Event Preferred Term(s)	Serious Adverse Event	Adverse Event Leading to Discontinuation of Study Drug	Death	Event of Interest
異所性妊娠	X	X		

Treatment Group	Age at Study Start	Sex	Race
ABT-494 30 mg QD	4[redacted]	FEMALE	WHITE

Medical History	Onset Year
OTHER: PLAQUE PSORIASIS	19[redacted]
OTHER: LATENT TB	20[redacted]

Prior Procedures	Procedure Year
SURGERY: COLECISTECTOMY	20[redacted]
SURGERY: CAESAREAN SECTION	20[redacted]
SURGERY: CAESAREAN SECTION	20[redacted]

Tobacco Use	Status	Number/Day	Number of Years	Year Stopped
CHEWING TOBACCO	NEVER			
CIGARETTES	NEVER			
CIGARS	NEVER			
E-CIGARETTES	NEVER			
PIPES	NEVER			

Alcohol Use	Status	Number/Day
ALCOHOL	NEVER	

Study Drug Administration

Study Drug	Dose/Units	Route	Frequency	First Dose Date/Day	Last Dose Date/Day	Duration (Days)
ABT-494	30MG	ORAL	QD	[redacted]20[redacted] / 1	[redacted]20[redacted] / 56	56

Previous Therapy - Prior to baseline/enrollment

Medication Name (WHO Drug)	Dose/Units	Frequency	Start Year-Month / RX Day
BCG Vaccine	NOT REPORTED	NOT REPORTED	Y-M: 19[redacted]
ISONIAZID	300 mg	QD	Y-M: 20[redacted]
ADALIMUMAB	40 mg	EVERY 2 WEEKS	Y-M: 20[redacted]
FOLIC ACID	5 mg	EVERY WEEK	Y-M: 20[redacted]
METHOTREXATE	20 mg	EVERY WEEK	Y-M: 20[redacted]
PARACETAMOL	1000 mg	QD	Y-M: 20[redacted]
INTRAUTERINE CONTRACEPTIVE DEVICE	NA OTHER: NA	OTHER: NA	Y-M: 20[redacted]

Other Medications - Medications taken within 30 days prior to each narrative event until AE stopped or end of study

Medication Name (WHO Drug)	Dose/Units	Frequency	Start Year-Month / RX Day	Stop Year-Month / RX Day
FOLIC ACID	5 mg	EVERY WEEK	Y-M: 20[redacted]	Not reported.
METHOTREXATE	20 mg	EVERY WEEK	Y-M: 20[redacted]	Not reported.
PARACETAMOL	1000 mg	QD	Y-M: 20[redacted]	Not reported.
INTRAUTERINE CONTRACEPTIVE DEVICE	NA OTHER: NA	OTHER: NA	Y-M: 20[redacted]	Y-M: 20[redacted] / 113
CIPROFLOXACIN	500 mg/kg	BID	Y-M: 20[redacted] / 55	Y-M: 20[redacted] / 60
LEFLUNOMIDE	20 mg	QD	Y-M: 20[redacted] / 90	Not reported.

Event #1: Serious Adverse Event, AE Leading to Discontinuation of Study Drug

Event Description ECTOPIC PREGNANCY

Preferred term 異所性妊娠

AE Onset Date / Rx Day [redacted]20[redacted] / 57 (1 DAY AFTER LAST TREATMENT)

Age at AE Onset 4[redacted]

Laboratory Testing

[redacted]20[redacted] (RX DAY 57): NPTST191-SERUM BETA HCG: 6837 [5 - 24.9] uIU/mL; [redacted]20[redacted] (RX DAY 78): NPTST028-BETA HCG: 350.7 [5 - 24.9] uIU/mL

Microbiology

NOT REPORTED

SAE Supplemental Procedure

[redacted]20[redacted] (RX DAY 41): TRANSVAGINAL ECHOGRAPHIE: RETENTION ABORTION (6-7 WEEKS); [redacted]20[redacted] (RX DAY 72): ULTRASOUND: CONFIRMED RETENTION ABORTION

AE Stopped Rx Day 90 (34 DAYS AFTER LAST TREATMENT)

Duration of AE 34 DAYS

Relation to Study Drug by Investigator NO REASONABLE POSSIBILITY

Investigator Alternative Etiology IUD

Discontinued Study Drug Due to the Event YES

SAE Criteria OTHER MEDICALLY IMPORTANT SERIOUS EVENT

Generated: [redacted]
Program Source Code: [redacted]

Investigator No.: [redacted]

Subject Number: [redacted]

Protocol Number: M15-554

治験責任医師からの報告。本被験者はチリの 4[redacted] 歳女性であり，ABT-494（ウパダシチニブ）の治験で盲検化された治験薬が投与され，異所性妊娠及び妊娠時の薬物曝露（非重篤）の事象を発現した。

Event 1 の臨床経過：

関連する病歴は局面型乾癬，潜伏性結核，乾癬性関節炎，胆嚢切除術，帝王切開 2 回，子宮内器具，非喫煙者及び非飲酒者であった。

被験者は妊娠時の薬物曝露を発現した（日付不明）。20[redacted] 年 [redacted] 月 [redacted] 日，被験者は異所性妊娠を発現した。20[redacted] 年 [redacted] 月 [redacted] 日，異所性妊娠は消失した。

最終月経期（LMP）は 20[redacted] 年 [redacted] 月（日付不明）であった。被験者は避妊法として IUD を使用していた。20[redacted] 年 [redacted] 月 [redacted] 日，被験者は尿路感染症（非重篤）と診断された。20[redacted] 年 [redacted] 月 [redacted] 日，尿妊娠検査で妊娠が確認された。出産予定日（EDD）は 20[redacted] 年 [redacted] 月（日付不明）であった。胎児は，妊娠前及び妊娠第 1 期に母親が ABT-494 を使用したことから ABT-494 に（子宮内）曝露した。20[redacted] 年 [redacted] 月 [redacted] 日，被験者は異所性妊娠と診断された。本事象により治験薬の投与は中止された。被験者は自然流産した（日付不明）。

The patient's past medications include:

HUMIRA for PSORIATIC ARTHRITIS ([redacted] 20[redacted] - [redacted] 20[redacted])

ACETAMINOPHEN for COMMON COLD ([redacted] [redacted] 20[redacted] - [redacted] [redacted] 20[redacted])

Causality for ABT-494 (Blinded)

---

1) Ectopic pregnancy (10014166) (Ectopic pregnancy (10014166)) [v.22.0] [10014166]

Causality as per reporter (Drug/Vaccine): No reasonable possibility

Causality as per Mfr. (Drug/Vaccine): No reasonable possibility

Dechallenge: No

2) Drug exposure during pregnancy (10049193) (Exposure during pregnancy (10073513)) [v.22.0] [10049193]

Causality as per reporter (Drug/Vaccine): No reasonable possibility

Causality as per Mfr. (Drug/Vaccine): No reasonable possibility

Dechallenge: Not Applicable

Alternative Etiology for ABT-494 (Blinded)

Event of ECTOPIC PREGNANCY

- Investigator: IUD.

- AbbVie: Event is more likely related to concomitant use of an IUD for contraception, history of 2 prior caesarean sections and subject's age.

Event of DRUG EXPOSURE DURING PREGNANCY

- Investigator: Not reported.

- AbbVie: Special situation of maternal use of active pharmaceutical ingredient.

Relevant Laboratory & Other Diagnostic Tests

[redacted] **20[redacted] BETA HCG:** 350.7 uIU/mL (normal 5.0 to 24.9)

[redacted] **20[redacted] SERUM BETA HCG:** 6837 uIU/mL (normal 5.0 to 24.9)

[redacted] **20[redacted] TRANSVAGINAL ULTRASOUND:** Retention abortion (6-7 WEEKS)

[redacted] **20[redacted] URINE PREGNANCY TEST:** negative

[redacted] **20[redacted] URINE PREGNANCY TEST:** positive